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Deborah Olmstead Setter 
IMMUNOREGULATION OF THE CENTRAL RESPONSE TO 
PERIPHERAL NERVE INJURY: 
MOTONEURON SURVIVAL AND RELEVANCE TO ALS 
Facial nerve axotomy (FNA) in immunodeficient mice causes significantly more 
facial motoneuron (FMN) loss relative to wild type (WT), indicating that the immune 
system is neuroprotective. Further studies reveal that both CD4+ T cells and interleukin-
10 (IL-10) act centrally to promote neuronal survival after injury. This study first 
investigated the roles of IL-10 and CD4+ T cells in neuroprotection after axotomy.  
CD4+ T cell-mediated neuroprotection requires centrally-produced IL-10, but the 
source of IL-10 is unknown. Using FNA on IL-10 reporter mice, immunohistochemistry 
was employed to identify the IL-10 source. Unexpectedly, axotomy induced astrocyte 
production of IL-10. To test if microglia- or astrocyte-specific IL-10 is needed for 
neuroprotection, cell-specific conditional knockout mice were generated. Neither 
knockout scenario affected FMN survival after FNA, suggesting that coordinated IL-10 
production by both glia contributes to neuroprotection. 
The effect of immune status on the post-FNA molecular response was studied to 
characterize CD4+ T cell-mediated neuroprotection. In the recombinase-activating gene-
2 knockout (RAG-2-/-) mouse model of immunodeficiency, glial microenvironment 
responses were significantly impaired. Reconstitution with CD4+ T cells restored glial 
activation to normal levels. Motoneuron regeneration responses remained unaffected by 
immune status. These findings indicate that CD4+ T cell-mediated neuroprotection after 
injury occurs indirectly via microenvironment regulation. 
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Immunodysregulation is evident in amyotrophic lateral sclerosis (ALS), and FMN 
survival after FNA is worse in the mutant superoxide dismutase (mSOD1) mouse model 
of ALS. Further experiments reveal that mSOD1 CD4+ T cells are neuroprotective in 
RAG-2-/- mice, whereas mSOD1 whole splenocytes (WS) are not. The third aim 
examined if the mSOD1 WS environment inhibits mSOD1 CD4+ T cell glial regulation 
after axotomy. Unexpectedly, both treatments were equally effective in promoting glial 
activation. Instead, mSOD1 WS treatment induced a motoneuron-specific death 
mechanism prevalent in ALS.  
In conclusion, the peripheral immune system regulates the central glial 
microenvironment utilizing IL-10 to promote neuronal survival after axotomy. 
Astrocytes, specifically, may be responsible for transducing peripheral immune signals 
into microenvironment regulation. Additionally, the immune system in ALS may directly 
participate in disease pathology.  
Kathryn J. Jones, Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
Approximately 20 million people in the United States suffer an impaired quality 
of life due to peripheral nerve injury or disease-induced peripheral neuropathy (Noble et 
al., 1998; Campbell, 2008; Ciaramitaro et al, 2010; Brannagan, 2012). Veterans, 
especially those who have served in the Middle East, have a higher incidence of 
traumatic peripheral nerve injury because body armor technology improvements have 
increased survivability of formerly lethal traumatic events (Campbell, 2008). Although 
the peripheral nervous system has robust regenerative capabilities, functional recovery 
after peripheral nerve injury is frequently suboptimal and presents a significant clinical 
problem (Campbell, 2008; Houdek & Shin, 2015). Therefore, studying factors that 
enhance peripheral nerve regeneration may reveal new therapeutic strategies that will 
improve functional outcomes and quality of life for patients with peripheral nerve injury 
and neuropathy.  
Using the facial nerve axotomy (FNA) model, our laboratory discovered that the 
adaptive arm of the immune system is necessary for both preserving facial motoneuron 
(FMN) survival and promoting axon regeneration to target musculature (Serpe et al., 
1999; Beahrs et al., 2010). Restoration of the immune system by adoptively transferring 
whole splenocytes into immunodeficient mice prior to FNA rescues FMN survival. This 
neuroprotection is specifically mediated by CD4+ T cells belonging to the interleukin-4-
producing T helper 2 (Th2) subclass, which is associated with tissue repair and 
regeneration processes (Byram et al., 2003; Serpe et al., 2003; Wainwright et al., 2008; 
Kwon et al., 2014; Sadtler et al., 2016). The generation of neuroprotective CD4+ T cells 
requires two instances of antigen presentation, first by peripheral antigen presenting cells, 
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then by microglia in the central nervous system (Byram et al., 2004). In addition, reactive 
astrocytes produce chemokines that further attract T cells to the injured facial motor 
nucleus (Wainwright et al., 2009b; Wainwright et al., 2009c). Centrally-derived 
interleukin-10 (IL-10), an anti-inflammatory cytokine, is also necessary for CD4+ T cell-
mediate neuroprotection (Xin et al., 2011). On the molecular level, motoneurons 
upregulate regeneration-associated gene expression, and robust glial activation occurs 
(Mesnard et al., 2010). Altogether, an orchestrated series of events is involved in CD4+ T 
cell-mediated neuroprotection, and this study seeks to further elucidate the mechanisms 
behind this process.  
A form of peripheral neuropathy also occurs in amyotrophic lateral sclerosis 
(ALS), a fatal motoneuron (MN) disease. In ALS, disease pathology first results in loss 
of the neuromuscular junction, and subsequent axonal die-back leads to death of the MN 
cell body. Peripheral nerve transection mimics this target disconnection-induced MN 
death. When FNA is superimposed on the mutant superoxide dismutase 1 (mSOD1) 
mouse model of ALS, significantly greater FMN loss is observed relative to wild type 
(WT) (Mesnard et al., 2011). On the gene expression level, the MN regeneration response 
is intact, but glial activation is dysregulated, and promotion of a MN-specific cell death 
pathway is also evident (Mesnard et al., 2011; Haulcomb et al., 2014). Significant 
abnormalities in the immune system are observed in both ALS patients and the mSOD1 
mouse model, leading our research group to suspect that immunodysregulation in ALS 
may contribute to disease pathology. To test this hypothesis, immunodeficient animals 
received adoptive transfer of either mSOD1 whole splenocytes (WS) or isolated mSOD1 
CD4+ T cells and then were subjected to FNA. While neuroprotection was observed in 
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mSOD1 CD4+ T cell recipients, this rescue was not observed in mSOD1 WS recipients 
(Mesnard-Hoaglin et al., 2014). This finding suggests that a factor within the mSOD1 
whole splenocyte milieu inhibits the neuroprotective effects of mSOD1 CD4+ T cells. A 
closer study of immune-mediated neuroprotection is warranted to determine how the 
mSOD1 immune system blocks CD4+ T cell neuroprotection, with the ultimate goal of 
finding a factor that can therapeutically manipulated to treat motoneuron disease.  
To accomplish this goal, it is necessary to first gain a better understanding of both 
whole splenocyte and CD4+ T cell immune-mediated neuroprotection mechanisms 
within a normally functioning system, and then to use this information to characterize 
abnormalities within the ALS immune system. It is also necessary to identify the cellular 
source and kinetics of IL-10 production after FNA, as neuroprotection requires centrally-
produced IL-10. The central hypothesis of this work is that after nerve injury, activated 
CD4+ T cells induce microglia to produce IL-10, which orchestrates the generation of an 
anti-inflammatory, pro-repair microenvironment that ultimately promotes FMN survival, 
and these events are inhibited within the ALS peripheral immune system environment.  
This hypothesis was tested by the following aims:  
Aim 1: Determine the source of neuroprotective IL-10 in the axotomized 
facial motor nucleus. The hypothesis for this aim is that microglia are the source of 
neuroprotective IL-10 after FNA. To test this hypothesis, a reporter mouse stain was used 
to identify histologically which cell types within the FMN produce IL-10, and cre/lox 
mouse strains were used to knockdown IL-10 production in a cell-specific manner. The 
histological analysis concluded that axotomy induced IL-10 expression in astrocytes, and 
neurons constitutively produce IL-10. IL-10 knockdown in microglia or astrocytes had no 
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detrimental effects on FMN survival after FNA. These findings suggest that 
neuroprotective IL-10 production after FNA comes from either a combined glial effort or 
neurons.  
Aim 2: Characterize gene expression profile changes after facial nerve 
axotomy in immunodeficient and WT CD4+ T cell-reconstituted mice. The 
hypothesis for this aim is that immunodeficiency will result in a dysregulated glial 
microenvironment response to FNA, and adoptive transfer of WT CD4+ T cells will 
restore microenvironment responses to normal levels. qPCR analysis of the laser-
captured facial motor nucleus after FNA from both immunodeficient and CD4+ T cell-
reconstituted mice was performed. Overall, astrocyte, microglia, and inflammatory 
cytokine production after FNA was significantly impaired in immunodeficient mice, and 
adoptive transfer of CD4+ T cells rescued these responses to normal levels. These results 
lead us to conclude that CD4+ T cell-mediated neuroprotection occurs indirectly via 
regulation of the glial response to injury, not by direct actions on the motoneurons.  
Aim 3: Analyze gene expression profile changes after facial nerve axotomy in 
mice immunoreconstituted with mSOD1 whole splenocytes or mSOD1 CD4+ T cells. 
The hypothesis for this aim is that adoptive transfer of mSOD1 WS will result in a 
dysregulated glial microenvironment response to FNA, and adoptive transfer of mSOD1 
CD4+ T cells will result in regulation of glial microenvironment responses to normal 
levels. After adoptive transfer of lymphocytes and FNA, qPCR of the facial motor 
nucleus from the treatment groups was performed to compare gene expression profiles, 
similar to Aim 2. A WT WS recipient group was added as an additional control. Both 
mSOD1 WS and mSOD1 CD4+ T cell recipient groups exhibited comparable 
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microenvironment regulation responses, however, the mSOD1 WS treatment resulted in 
significantly greater expression of a MN-specific cell death pathway. These results 
suggest that the lack of neuroprotection by mSOD1 WS could be due to induction of MN 
death mechanisms or an alternative glial activation phenotype that is neurotoxic.  
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CHAPTER 2: LITERATURE REVIEW 
2.1. Peripheral nerve injury 
The nervous system is divided into central and peripheral components, with the 
central nervous system (CNS) including the brain, cerebellum, and spinal cord, and the 
peripheral nervous system (PNS) including the nerves and ganglia. Nerves can convey 
autonomic, sensory, and motor information to and from the CNS. MN within the CNS are 
specifically responsible for controlling skeletal muscle contractions.  
MN can be subdivided into upper and lower motoneurons (UMN and LMN, 
respectively). UMN reside in the motor cortex of the brain and their axonal projections 
synapse on the dendrites and soma of LMN in the brainstem and spinal cord. The axons 
of LMN exit the CNS and are bundled into the cranial or spinal nerves of the PNS as they 
follow course to their target musculature.  
Cutting of axons (“axotomy”) can occur in both the CNS and PNS, and different 
injury responses are observed after axotomy in these two environments. Following CNS 
axotomy, such as in spinal cord injury, a suppressive microenvironment prevents axon 
regeneration and reconnection to target. Oligodendrocytes contribute to this suppression 
by secreting myelin-associated inhibitors of axonal growth. Additionally, astrocytes 
generate a glial scar composed of chondroitin sulfate proteoglycans that is a barrier to 
axonal growth (Huebner & Strittmatter, 2009). For these reasons, there is little functional 
recovery after CNS trauma. Conversely, the PNS has a robust regeneration response to 
axotomy. Wallerian degeneration, a process by which Schwann cells and peripheral 
monocytes clear the distal axonal debris, creates a conduit for the growing daughter axon. 
Robust activation of regeneration-associated genes is also observed after peripheral nerve 
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injury, not CNS injury (Bomze et al., 2001; Huebner & Strittmatter, 2009). Therefore, 
studying PNS regeneration processes will facilitate discovery of novel therapeutic 
strategies for patients suffering from nerve injury.  
Full regeneration after a peripheral nerve injury depends on the survival of the 
cell body, regrowth of the axon, and reconnection to target. Axotomies can be classified 
by the severity of the damage administered, ranging from a crush injury (axonotmesis), 
after which full recovery is detected in a matter of days, to a complete transection injury 
(neurotmesis), in which no functional recovery is observed (Seddon, 1942; Sunderland, 
1951). For the purposes of this study, a neurotmesis-grade axotomy was used. This model 
was selected because it elicits the greatest amount of MN death, facilitating study of 
factors that promote or inhibit MN survival after injury.  
 
2.2. Facial nerve axotomy model 
The mouse facial motor nucleus (FMNuc) is located in the ventral pons and is 
comprised of six subnuclei that form a horseshoe-like shape (Ashwell, 1982). Axon 
projections from FMN wrap dorsomedially around the abducens nucleus (forming a 
structure called the “genu”) before ventrolaterally exiting the brainstem as the facial 
nerve rostral to the facial motor nucleus. The facial nerve courses through the internal 
acoustic meatus and tympanic bulla bone, within which, the nerve to the stapedius muscle 
branches off, and the remainder of the nerve exits the stylomastoid foramen. The facial 
nerve then divides into its major branches: temporal, zygomatic, buccal, marginal 
mandibular, cervical, and posterior auricular. These branches innervate the facial, 
auricular, and platysma muscles of the head and neck.  
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The superficial nature and ease of access to the facial nerve as it exits the 
stylomastoid foramen permits selective injury to the nerve with minimal damage to 
adjacent tissues. Additionally, examination of the FMN responses is simplified given that 
they are grouped in the FMNuc. Unlike the spinal cord, interneurons and γ-MN do not 
reside in the FMNuc, and this distinction allows for exclusive study of α-MN responses. 
Because of the highly symmetrical nature of the nervous system and lack of crosstalk 
between the right and left FMNuc, the uninjured FMNuc can be used as a paired internal 
control for experiments (Isokawa-Akesson & Komisaruk, 1987; Hurley, 2003). 
Monocytes do not infiltrate into the FMNuc following FNA, and the blood-brain barrier 
(BBB) remains intact, resulting in a sterile nerve injury (Raivich et al., 1998; Hurley, 
2003; Bottcher et al., 2013). Therefore, the resulting responses of the FMN and the 
surrounding microenvironment are purely consequential to the FNA.  
Following FNA, paralysis of vibrissae and loss of the eye blink reflex is 
immediately observed. With a facial nerve crush (axonotmesis) injury, complete recovery 
is observed in approximately 10 days post-operation (dpo) (Serpe et al., 2002). With a 
complete facial nerve transection, no functional recovery is observed, even at 6 months 
post injury (unpublished data from our laboratory).  
Additionally, the rodent model of peripheral nerve injury reproduces the human 
response to nerve injury. These similarities allow for translation of findings from mouse 
and rat models to human clinical trials (Campbell, 2008; Wang et al., 2013; Gordon & 
Borschel, 2016). Regarding facial nerve injury specifically, autopsy examination of the 
human FMNuc three months post injury reveals morphological changes also observed in 
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rodent models, validating the use of mouse FNA as a translational scientific technique 
(Graeber et al., 1993).  
 
2.3. Changes in the facial motor nucleus after facial nerve axotomy  
Comprehensive reviews exist detailing the changes in the FMNuc after FNA 
(Lieberman, 1971; Grafstein, 1975; Moran & Graeber, 2004). Findings most relevant to 
this dissertation are described in this introductory section.  
 
2.3.1. Motoneuron response 
After the axon is severed, the soma of the MN undergoes significant changes in 
morphology and function as it transitions from a homeostatic to a regenerative 
phenotype. One of the most distinct manifestations of this transition is chromatolysis, a 
phenomenon first described by Franz Nissl in 1894. Nissl discovered that basic dyes 
(e.g., thionin) stain neuronal cytoplasm, and he described the thionin-bound structures in 
neurons as “Nissl substance.” Nissl substance was later discovered to be rough 
endoplasmic reticulum (RER), and the thionin was binding to the acidic ribosomal RNA 
studding RER membranes. Neurons have abundant RER within their cytoplasm because 
they manufacture significantly more protein than other cell types in the brain. Following 
axotomy, labeling of basophilic structures diminishes, resulting in “chromatolysis” 
(Greek: chroma- color, lysis- loosen). Electron microscopy reveals that chromatolysis 
results from the neuronal RER converting from long, parallel cisternae to disordered, 
short segments within the cytoplasm, disrupting the color resolution of the thionin stain 
(Torvik & Skjorten, 1971).  
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In addition to chromatolysis, the nucleus and nucleolus both swell and migrate 
eccentrically after FNA (Cammermeyer, 1963; Lieberman, 1971; Guntinas-Lichius et al., 
1997). This increased nuclear and nucleolar size results from increased demand placed on 
the MN to generate necessary cytoskeletal proteins for constructing the regrowing axon. 
Specifically, actin, tubulin, and growth-associated protein (Gap-43) mRNA and protein 
synthesis are increased (Lieberman, 1971; Tetzlaff et al., 1988a; Bisby & Tetzlaff, 1992). 
Conversely, neurofilament production decreases after axotomy, likely due to its role in 
radial, not longitudinal axon growth (Lieberman, 1971; Tetzlaff et al., 1988a; Bisby & 
Tetzlaff, 1992). Acetylcholine esterase expression is decreased after axotomy as well, 
corresponding with the shift in neuronal phenotype away from signal transmission and 
towards regeneration (Lieberman, 1971).  
The exact trigger for the MN cell body response to axotomy is not known; 
however, evidence suggests that depolarization of the MN cell membrane immediately 
after axotomy leads to a change in membrane potential that lasts for hours after injury 
(Cragg, 1970; Berdan et al., 1993). Other theories propose that loss of action potentials, 
depletion of retrogradely transported materials, or loss of peripheral trophic factors may 
induce MN changes (Cragg, 1970; Grafstein, 1975; Olsson et al., 1978).  
To summarize, the motoneuron responds to the severing of its axon by 
undergoing a dramatic change in its phenotype from homeostatic signal transduction to a 
pro-regenerative program with the goal of restoring axonal reconnection to target 
musculature. Accompanying this phenotypic shift is morphological restructuring of its 
organelles to meet the increased demand for cytoskeletal protein synthesis.  
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2.3.2. Microglia response 
Following peripheral nerve injury, microglia proliferate and their morphology 
changes from a small cell body with long, branching processes to a swollen cell body 
with shortened processes (Graeber et al., 1988; Almolda et al., 2014). Expression of 
complement 3 receptor (C3R; also known as Mac-1, CD11b, and OX-42) and Iba1 both 
increase and are useful markers of microglia activation (Ito et al., 1998; Byram et al., 
2004). Time-lapse video of FMNuc-containing brainstem slices from neonatal rats at 6-9 
dpo reveal microglia migrating along neuronal processes and forming pseudopod and 
lamellopod processes after FNA (Schiefer et al., 1999) . These findings indicate that 
microglia respond to axotomy by changing their morphology, motility, and expression of 
activation markers.  
 
2.3.3. Astrocyte response 
In response to axotomy, astrocytes switch from a protoplasmic, GFAP-negative 
(glial fibrillary acidic protein) phenotype to a fibrous, GFAP-positive phenotype (Tetzlaff 
et al., 1988b). Astrocyte activation is proportional to the severity of the nerve injury 
administered, demonstrating their sensitivity to the damage inflicted to the MN (Laskawi 
& Wolff, 1996). The mouse background strain can alter the astrocyte response to injury, 
the exact mechanisms of which are unknown (Lidman et al., 2002). 
 
2.3.4. Synaptic stripping 
The synaptic inputs on LMN from UMN are ensheathed by astrocytes to maintain 
the synaptic connection (Castellano et al., 2016). After axotomy, these synaptic inputs are 
 12 
displaced by microglia in a process called “synaptic stripping” (Blinzinger & Kreutzberg, 
1968). Removal of afferent inputs benefits the MN by allowing it to devote its energy 
towards regeneration and away from signal processing (Jinno & Yamada, 2011; 
Castellano et al., 2016). Additionally, removal of excitatory inputs prevent excitoxicity 
(Mentis et al., 1993). Later studies discovered that microglia displaced these synapses in 
the early phase after axotomy, and between 2-3 weeks post-operation (wpo), astrocytes 
processes replace the microglia in surrounding the MN soma (Moran & Graeber, 2004).  
To initiate synaptic stripping, purines released by the injured MN bind to purine 
receptors on microglia processes, inducing the microglia to wrap around the MN and aid 
in separation of synaptic contacts. Microglia sense the types and levels of purines 
released by the injured MN, and this information initiates pro- or anti-phagocytic 
responses (Castellano et al., 2016). Interferon-recognition factor 8 (IRF8) is also a key 
signaling protein for microglia wrapping around axotomized FMN (Masuda et al., 2012; 
Xie et al., 2014). In summary, synaptic stripping is an important process for promoting 
MN survival after axotomy and occurs as a result of glia reacting to injury signals from 
the axotomized MN.  
 
2.4. The immune system and facial nerve axotomy 
2.4.1. Consequences of immunodeficiency 
To determine if the immune system was beneficial or harmful after nerve injury, 
FNA was performed on severe combined immunodeficient (scid) mice and FMN survival 
was quantified at 28 dpo. Scid mice possess a mutation that blocks the maturation of B 
and T cells, resulting in loss of the adaptive arm of the immune system. More FMN die 
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after FNA in scid mice relative to WT mice, suggesting that the adaptive arm of the 
immune system serves a neuroprotective role after FNA. This hypothesis is confirmed 
when adoptive transfer of WT whole splenocytes into scid mice prior to FNA rescued 
FMN survival after axotomy to WT levels (Serpe et al., 1999; Serpe et al., 2000). These 
findings were reaffirmed in the recombinase activating gene-2 knockout (RAG-2-/-) 
mouse, in which B and T cells fail to mature, resulting in a lack of the adaptive arm of the 
immune system (Serpe et al., 2003). Immunodeficiency also slows functional recovery 
after facial nerve crush (Serpe et al., 2002; Beahrs et al., 2010). Administration of 
dexamethasone, a corticosteroid that decreases the number of lymphocytes in the blood, 
also results in delayed functional recovery and greater neuronal death after FNA 
(Lieberman et al., 2011). 
To identify which immune cell in the adaptive arm of the immune system was 
neuroprotective, FMN survival after FNA was examined in immune cell knockout mice. 
In mice deficient in CD4+ T cells, significant FMN loss after FNA occurred. In contrast, 
mice deficient in CD8+ T cells or B cells had FMN survival comparable to WT after 
FNA, signifying that only CD4+ T cells are relevant to immune-mediated 
neuroprotection. These results were verified by adoptive transfer of CD4+ T cells into 
either CD4-/- or RAG-2-/- mice, and FMN survival was rescued to WT levels, whereas 
adoptive transfer of CD8+ T or B cells had no effect on FMN survival (Serpe et al., 
2003). As new lymphocyte subtypes were discovered, their role in FMN survival after 
injury was also assessed. Thus far, natural killer cells and regulatory CD4+CD25+ T cells 
have been ruled out of having neuroprotective effects for injured motoneurons (Byram et 
al., 2003; DeBoy et al., 2006a).  
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2.4.2. T cells and neuroprotection 
For T cells to execute neuroprotective actions, they require both peripheral and 
central antigen presentation via major histocompatibility complex class II (MHCII) 
expressed on antigen-presenting cells (APCs) (Byram et al., 2004). Activated T cells 
capable of recognizing only ovalbumin by their T cell receptors are not neuroprotective, 
indicating that antigen-specific activation of T cells is necessary (Byram et al., 2006). 
After axotomy, antigens from the injured FMN drain into cervical lymph nodes, and 
APCs in the lymph node activate naïve T cells. These activated T cells circulate and re-
encounter target antigen expressed on MHCII in the CNS, inducing a secondary 
activation that results in effector T cell activity. Microglia are the predominant expressers 
of MHCII in the CNS and activate T cells with high efficiency relative to astrocytes and 
other CNS APCs (Male et al., 1987; Pryce et al., 1989; Aloisi et al., 1998; Aloisi et al., 
1999; Hurley, 2003).  
All CD4+ T cell subsets expand in the draining cervical lymph nodes after FNA, 
peaking in number at 7 dpo, then declining at 9 dpo as the cells migrate into the 
peripheral blood (Xin et al., 2008). This timecourse is supported by evidence of T cell 
infiltration into the injured FMNuc peaking at 14 dpo (Raivich et al., 1998; Ankeny & 
Popovich, 2007; Ha et al., 2007b). To identify which T cell subset was specifically 
responsible for neuroprotection, signal transducer and activator of transcription (STAT) 
and interleukin knockout experiments were performed. These experiments revealed that 
IL-4 and STAT-6, which promote T cell differentiation towards the Th2 subset, are 
necessary for neuroprotection.  
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Facial nerve re-injury experiments provide additional evidence for CD4+ T cell-
mediated neuroprotection. An augmented T cell-infiltration response and accelerated 
functional recovery are observed in animals receiving a second FNA ten weeks following 
their first FNA. This finding suggests that immune memory from the first FNA leads to a 
stronger immune response when the injury reoccurs (Ha et al., 2007b; Ha et al., 2008).  
 
2.4.3. IL-10 and other cytokines relevant to neuroprotection 
Astrocytes, microglia, and neurons express multiple cytokines and their receptors 
at homeostasis and after injury, and ongoing studies continue to assess the role these 
proteins play in neuroprotection.  
IL-10 is an anti-inflammatory cytokine that promotes neuroprotection after CNS 
injury (Kiyota et al., 2012; Joniec-Maciejak et al., 2014; Gravel et al., 2016; Zhou et al., 
2016). IL-10 deficiency results in greater FMN loss after FNA. WT CD4+ T cells do not 
rescue FMN survival after FNA in IL-10-/- mice, indicating that neuroprotective IL-10 
does not derive from CD4+ T cells. Furthermore, IL-10-/- CD4+ T cells are capable of 
neuroprotection in RAG-2-/- mice, ruling out the adaptive arm of the immune system as 
the IL-10 source (Xin et al., 2011). IL-10 is incapable of crossing the BBB, therefore, 
neuroprotective IL-10 must derive from the CNS parenchyma (Kastin et al., 2003). IL-10 
mRNA and protein levels remain unchanged after FNA in WT mice. In RAG-2-/- mice, 
however, there is a decrease in IL-10 protein levels at 7 dpo, suggesting that the immune 
system maintains IL-10 expression after FNA (Xin et al., 2011). IL-10 receptor (IL-10R) 
is constitutively expressed by neurons, and axotomy induces IL-10R expression 
exclusively on astrocytes. There was no detectable IL-10R expression on microglia 
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before or after axotomy. The expression of IL-10R on neurons after FNA is unknown 
because conventional MN markers, such as choline acetyltransferase, are not expressed 
by injured MN (Xin et al., 2011). In a transgenic mouse with astrocytic overexpression of 
IL-10, FMN survival after FNA is increased. Few changes are observed between WT and 
transgenic IL-10 overproducing mice, except for differential expression of phagocytosis-
related proteins in microglia after axotomy (Villacampa et al., 2015). To summarize, IL-
10 is an important factor in CD4+ T cell-mediated neuroprotection.  
Cytokine expression microarrays of the FMNuc at 7 days post-FNA reveals that 
Th2-related cytokines are strongly induced, whereas Th1-associated cytokines are 
undetectable. Of these cytokines, CCL11 expression is the most highly expressed, and its 
expression peaks at 14 dpo (Wainwright et al., 2009c). A colocalization study identified 
that FMN express CCL11 constitutively in the uninjured FMNuc. After axotomy, 
neuronal expression is no longer detectable, and astrocyte expression of CCL11 is 
induced. At 30 dpo, when the post-axotomy responses return to baseline levels, neuronal 
CCL11 expression is regained and astrocyte expression of CCL11 is not detectable 
(Wainwright et al., 2009a). CCL11 binds multiples chemokine receptors (CCR), one of 
which is CCR3 on T cells. CCR3-/- mice have increased FMN loss after FNA, and 
adoptive transfer of CCR3-/- CD4+ T cells into RAG-2-/- mice does not restore FMN 
survival (Wainwright et al., 2009b). Collectively, these studies indicate that axotomy 
induces astrocytic production of CCL11 which recruits T cells to the injured FMN.  
Tumor necrosis factor-alpha (TNFα) is a pro-inflammatory cytokine that has both 
neuroprotective and neurotoxic effects in the CNS after injury (Terrado et al., 2000; Liu 
et al., 2017). TNFα mRNA expression has been described in both early (1-2 dpo) and late 
 17 
(14 dpo) timepoints post-FNA (Raivich et al., 1998; Streit et al., 1998; Streit et al., 2000). 
Neutralization of TNFα by overexpression of soluble TNFR1 modestly increases FMN 
survival after injury (Terrado et al., 2000). TNFα has two receptors, TNFR1 and TNFR2, 
and they have differential effects on the cellular response. FNA was performed on 
transgenic mice in which either TNFR1 or TNFR2 was knocked out to determine which 
receptor was relevant for FMN survival after FNA. No changes in FMN survival or 
microglia activation were observed in these two mouse models. When both TNFR1 and 
TNFR2 are simultaneously knocked out, FMN survival is significantly increased 
(Raivich, 2002). This combined deletion of TNFR1&2 also results in a significant 
decrease in MHCI expression by microglia (Bohatschek et al., 2004a). MHCI is an 
important antigen presenting protein for cells and also is necessary for the pruning of 
synapses during neurodevelopment (Corriveau et al., 1998; Huh et al., 2000). In addition, 
decreased expression of microglial B7.2, a costimulatory molecule for antigen 
presentation, is observed in TNFR1&2-/- mice (Bohatschek et al., 2004b). Microglia 
antigen presentation may play an important role in the synaptic stripping process after 
axotomy. These data collectively suggest that TNFα is a significant regulator of microglia 
activity after axotomy, and inhibition of these processes promotes FMN survival.  
IL-6 is a pleotropic cytokine with immunoregulatory effects that can promote 
inflammation or tissue repair (Almolda et al., 2014). mRNA expression is increased 
within 24 hours post-operation (hpo), and expression of IL-6 receptors (IL-6R) is induced 
on both astrocytes and neurons after FNA (Klein et al., 1997). Evidence suggests that IL-
6 is primarily produced by axotomized FMN (Streit et al., 2000). Knocking out IL-6 
prevents axotomy-induced expression of GFAP by astrocytes, a process mediated by IL-6 
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activation of STAT-3 (Klein et al., 1997; Tyzack et al., 2014). Loss of IL-6 also reduces 
microglia proliferation after FNA, most likely due to loss of astrocyte production of 
macrophage colony stimulating factor (MCSF) (Klein et al., 1997). MCSF acts on 
microglia to induce proliferation and facilitate microglia wrapping around injured FMN 
(Raivich et al., 1994; Kalla et al., 2001). When adult and neonatal rat responses to FNA 
are compared, there is significantly less FMN survival in neonatal rats. A lack of IL-6 
expression is also observed in neonatal rats after FNA, whereas adult rats have robust IL-
6 expression after axotomy (Streit et al., 2000). In an FNA study in which astrocytes 
constitutively overexpress IL-6, a small increase in FMN death is observed, and the 
microglia activation response to FNA is significantly altered. Specifically, expression of 
CD11b peaks at an earlier timepoint post-FNA, and decreased microglia apposition 
around axotomized FMN is observed (Almolda et al., 2014). These data collectively 
suggest that a “Goldilocks zone” exists for IL-6 after FNA, outside of which both 
insufficient and excessive IL-6 can result in neuronal death. To summarize the role of IL-
6 in the post-axotomy response, IL-6 expression by neurons after injury stimulates 
surrounding astrocytes to adopt a pro-regenerative phenotype that promotes proliferation 
and perineuronal apposition of microglia via MCSF.  
Pituitary adenylate cyclase-activating polypeptide (PACAP) can act as a 
neuroimmune modulator, and its expression by MN is strongly induced as early as 6 hpo 
(Zhou et al., 1999; Mesnard et al., 2010; Mesnard et al., 2011). Although knocking out 
PACAP does not impact FMN survival, it does result in significant increases in cytokine 
expression and microglia activation, suggesting that PACAP regulates the glial 
microenvironment response to FNA (Armstrong et al., 2008). PACAP promotes 
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microglia production of Th2-differentiation signaling chemokines, specifically C-C motif 
chemokine ligand 11 (CCL11) (Wainwright et al., 2008). PACAP gene expression 
increases after injury in the FMNuc. 
 
2.4.4. Molecular response of cells within the facial motor nucleus to axotomy 
When FMN loss after FNA is quantified for each subnucleus of the FMNuc, the 
ventromedial (VM) subnucleus has the most FMN death, and the ventrolateral (VL) 
subnucleus has virtually no FMN death. In RAG-2-/- mice, there is no disproportionate 
effect of immunodeficiency on the distribution of FMN death across the FMNuc, and 
adoptive transfer of CD4+ T cells does not affect this either (Canh et al., 2006). These 
findings suggest that a factor within the VM and VL subnuclei determines neuronal fate 
after injury.  
Using laser-capture microdissection, the VM and VL subnuclei were isolated for 
gene expression analysis to identify what factors promote neuronal survival or death. 
Unexpectedly, the VL subnucleus had a comparable motoneuron regeneration response. 
Conversely, significant differences in proinflammatory gene expression and glial 
activation were observed. When neurons and neuropil were laser-captured separately, the 
proinflammatory gene expression was only detectable in neuropil samples. Together, 
these findings indicate that the differences in inflammatory responses in the 
microenvironment, not neuroregenerative responses, are responsible for mediating 
neuronal survival after injury.  
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2.5. Introduction to ALS 
ALS is a lethal paralytic disease characterized by progressive loss of motor 
function with sensory and cognitive sparing (Wijesekera & Leigh, 2009). The prevalence 
of ALS in the United States is 3.9/100,000 people (Mehta et al., 2014). Males are slightly 
more affected, and smoking and military service are risk factors associated with ALS 
(Bryan et al., 2016). Approximately 5-10% of ALS cases are linked to familial heritable 
gene defects (fALS), and the remaining 90% of cases are classified as spontaneous ALS 
(sALS) (Calvo et al., 2014). ALS etiology remains unknown, and over 20 genes have 
been associated with fALS, with a wide range of physiological impacts. These 
discoveries have led to generation of the cell autonomous and non-cell autonomous 
theories of MN death in ALS. According to the cell autonomous theory, genetic mutation 
disrupt vital processes within MN that ultimately leads to MN death. These disruptions 
can cause MN death via multiple pathways, and theories include excitotoxicity, 
endoplasmic reticulum stress, protein degradation pathway stress, oxidative stress, 
mitochondrial dysfunction, altered axonal transport, and synaptic vesicle defects (Ilieva et 
al., 2009; Pandya et al., 2013). Almost all therapies targeting these abnormalities have 
failed to improve prognosis, with the exception of riluzole (Turner et al., 2001; Orrell, 
2010; Pandya et al., 2013). Riluzole alleviates glutamate-mediated excitotoxicity and 
extends patient survival by an average of 2-3 months (Meissner et al., 2010). 
The non-cell autonomous theory is that ALS genetic mutations negatively affect 
the microenvironment surrounding the MN, thereby inducing MN death. 
Neuroinflammatory damage, BBB leakiness, and extracellular accumulations of mSOD1 
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are all contributors to disease pathology, and many research groups are examining these 
factors as causative agents for disease (Ilieva et al., 2009; Pandya et al., 2013).  
In humans, it is nearly impossible to identify determinants of MN death in ALS 
because ALS is a clinical disease, meaning that the diagnosis is based on motor deficit 
progression with all other possible diseases ruled out. Given the hardiness of the CNS 
motor systems, significant motoneuron death must occur before clinical abnormalities are 
detected. An additional obstacle in studying ALS is that tissue acquired from a living 
patient is restricted to either peripheral blood or cerebrospinal fluid (CSF), given that 
nervous system tissue collection is only permitted at autopsy. Altogether, assessing the 
sequence of events that leads to MN death in ALS is largely limited to use of rodent 
models and iPSCs.  
 
2.6. mSOD1 mouse model of ALS 
Mutations in SOD1 are the most common genetic cause of ALS (Cirulli et al., 
2015). SOD1 is a protein that has been highly conserved throughout evolution and is 
ubiquitously expressed. SOD1 comprises 1-2% of total soluble protein in the CNS. The 
primary function of SOD1 is to convert superoxide to hydrogen peroxide (Bunton-
Stasyshyn et al., 2015). Knocking out SOD does not result in motoneuron disease (MND) 
symptoms in mice, suggesting that loss-of-function deficits are not causative for ALS. 
Instead, studies suggest that either a toxic gain-of-function or prion-like behavior of 
misfolded SOD protein contribute to MND.  
The first mouse model of ALS that recapitulated the human disease was published 
in 1994 (Gurney et al., 1994). When the human mutated SOD1G93A (mSOD1) gene is 
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inserted into a B6/SJL mouse, motor deficits can be observed at 120 days of age (doa). 
The motor deficits first manifest in hindlimb muscles, then progress to forelimbs, and 
animal death occurs between 150-160 doa. In this mouse model, the first detectable 
pathology of ALS is the loss of neuromuscular junctions (NMJs) in the hindlimb muscles 
at 47 doa. At roughly 80 doa, axon loss is evident in the ventral roots, and at 100 doa, 
MN death is first detected in the lumbar spinal cord, suggesting a progressive die-back of 
the MN (Gurney et al., 1994; Fischer et al., 2004). This axonal die-back suggests that 
some disease factor induces target disconnection, which, in turn, leads to MN death 
(Dadon-Nachum et al., 2011).  
 
2.6.1. Motoneuron-specific mSOD1 and MND 
With the discovery of SOD1 mutations causing MND, the next question was 
whether the mSOD1 mutation isolated to MN alone would induce MN death. 
Surprisingly, in two mouse models where mSOD1 was expressed solely in MN, no motor 
deficits or MN pathology were observed, even with doubling of the expression of 
mSOD1 in MN (Pramatarova et al., 2001; Lino et al., 2002). A later study was successful 
in recapitulating MND with a Thy1/mSOD1 mouse model, primarily because this genetic 
model produced about 5-fold more mSOD1 than previously reported models (Jaarsma et 
al., 2008). Interestingly, the average endstage of disease in this mouse model is between 
600-700 doa, suggesting that MN are highly resilient to toxicity from SOD1 mutations. 
This MN resilience supports the non-cell autonomous hypothesis for ALS.   
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2.6.2. Microglia-specific mSOD1 and MND 
To identify if microglia played a role in mSOD1 MND, a CD11b-
cre/mSOD1G37R-flox mouse model was employed. When mSOD1 expression is knocked 
down in microglia, survival is increased by approximately 100 days relative to control 
(Boillee et al., 2006). This dramatic effect suggests that mSOD1 expression in microglia 
significantly contributes to disease progression and MN death. Further characterization of 
microglia activation in mSOD1 rats determined that in the early presymptomatic phase, 
monocytes infiltrate the sciatic nerve, while in the late presymptomatic phase, myeloid 
activation is evident in the spinal cord. This suggests that myeloid cell activation acts in 
parallel with axonal die-back, but it is unknown if this is causative or reactionary (Graber 
et al., 2010).  
Microglia-mediated neurotoxicity could be consequential to an alteration in the 
cell’s phenotypic polarization after injury or disease. Activated microglia can be roughly 
divided into M1 and M2 phenotypes, characterized by expression of either pro-
inflammatory markers, such as TNFα and inducible nitric oxide synthase (iNOS), and 
pro-repair markers, such as arginase 1 (Arg1) and IL-10, respectively. Assessment of M1 
and M2 markers in mSOD1 mouse spinal cord at multiple timepoints reveals that both 
cell types increase throughout disease. A significantly higher proportion of activated 
microglia are Arg1+ than iNOS+, indicating that the majority of microglia are behaving 
in an M2 pro-repair, anti-inflammatory fashion (Lewis et al., 2014). Inhibition of 
microglia proliferation or downstream cytokine signaling via janus kinase 2 (JAK2) 
confers no therapeutic benefit to mSOD1 mice (Tada et al., 2014; Martinez-Muriana et 
 24 
al., 2016). However, this inhibition strategy affects both M1 and M2 microglia, which 
could cancel out any neuroprotective effects. 
To better understand the inflammatory reaction in mSOD1 mice, a nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB)/GFP (green fluorescent protein) 
reporter mouse was crossed with the mSOD1 mouse. NF-κB/GFP was most highly 
expressed in microglia. Time-lapse videos of MN and microglia co-culture systems 
reveal that mSOD1 microglia phagocytize both synapses and MN, leading to increased 
MN death. Inhibiting NF-κB in microglia, not astrocytes, results in significant increases 
in MN survival in co-culture experiments. NF-κB inhibition in mSOD1 mice also extends 
survival. Conversely, reducing inhibition of NF-κB results in increased inflammatory 
cytokine expression and accelerated disease progression, further linking microglia-
mediated neuroinflammation and MN death (Frakes et al., 2014). In summary, a growing 
body of evidence suggests that SOD1 mutations in microglia result in a proinflammatory, 
hyperphagocytic microglia response that is toxic to MN (Brites & Vaz, 2014).  
 
2.6.3. Astrocyte-specific mSOD1 and MND 
In vitro experiments in which mouse mSOD1 astrocytes are co-cultured with 
normal MN reveal that these astrocytes are highly neurotoxic, suggesting that astrocytes 
also contribute to non-cell autonomous pathways of MN death (Di Giorgio et al., 2007). 
Silencing mSOD1 in astrocytes restores MN survival to WT levels (Haidet-Phillips et al., 
2011). The use of astrocytes derived from induced pluripotent stem cells (iPSCs) from 
human fALS and sALS patients yield similar results (Haidet-Phillips et al., 2011). When 
the cre/lox system is used to knockdown mSOD1 in astrocytes in mSOD1 mice, animal 
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survival is increased by about 60 days, further supporting this hypothesis. Human ALS 
iPSC astrocytes injected into the spinal cord of scid mice can engraft into the CNS, and 
over time motor deficits are observed comparable to mSOD1 mouse deficits (Chen et al., 
2015a). In summary, mSOD1 in astrocytes also have demonstrable neurotoxic effects on 
MN.  
 
2.7. Immune dysregulation in human patients with ALS 
The role of the immune system at endstage in ALS has been characterized from 
analysis of autopsy tissue. In diseased CNS tissue, potent glial activation is observed 
surrounding MN cell bodies in the CNS. Increased microglia activation correlates with 
rapidity of disease progression (Brettschneider et al., 2012). Assessment of innate 
immune activators also reveals significant increases in expression of toll-like receptors 
(TLR) and their accompanying downstream mediators (Casula et al., 2011). Additionally, 
complement (C) proteins, C1q and C3d, accumulate in deposits within the spinal cord 
(Sta et al., 2011). A study analyzing the immune response in ALS muscle tissue also 
found complement proteins on motor end plates, especially C1q and the membrane attack 
complex (MAC) (Bahia El Idrissi et al., 2016). This evidence of immune activation at 
both the peripheral terminal and central soma of the MN suggests that the immune system 
plays a role in ALS disease pathology.  
To characterize inflammatory and immune changes before death in ALS patients, 
measures of cytokines and white blood cell counts have been reported in multiple studies. 
The majority of these studies yield conflicting results, most likely a result of their small 
sample size (8-20 patients) and the heterogeneity of this disease (sALS v fALS, 
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variability of disease progression rate, gender, age, etc.) (Holmoy et al., 2006; Kuhle et 
al., 2009; Saleh et al., 2009; Hovden et al., 2013; Ehrhart et al., 2015). For these reasons, 
I choose to restrict my assessment of immune system alterations in ALS to the highest 
powered clinical publications. In the Chen et al. 2014 publication, peripheral blood 
samples were collected from 284 patients with ALS. This study identified that both men 
and women with ALS had significantly decreased proportions of CD4+ T cells relative to 
controls, as well as increased circulating immune complexes (Chen et al., 2014). In 
women, significantly higher C3 levels were also detected in peripheral blood. In Lu et al. 
2016, plasma cytokine levels were measured in 98 ALS patients at regular intervals for 
up to 4 years. This study identified significantly higher levels of 11 inflammatory 
markers in peripheral blood, including TNFα, pro-inflammatory interleukins (IL-1β and 
IL-2), and anti-inflammatory interleukins (IL-4 and IL-10). IL-6 was the only cytokine to 
increase with disease progression (Lu et al., 2016).  
T cells may play a special role in ALS disease. Published case studies describe 
MND-like symptoms in patients infected with human immunodeficiency virus (HIV), an 
infection that selectively kills CD4+ T cells. With anti-retroviral therapy, these symptoms 
are eliminated, suggesting a connection between T cells and MN function (Moulignier et 
al., 2001; Alfahad & Nath, 2013). There have also been reports of ALS development in 
patients with myasthenia gravis, an autoimmune disease in which antibodies target 
acetylcholine receptors, leading to elimination of NMJs. These cases further imply an 
involvement of aberrant immune system activity in ALS disease pathology (Staff & 
Appel, 2016).  
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Overall, these studies reveal a dysregulated immune profile in patients with ALS. 
The involvement of the immune system links the axonal die back and non-cell 
autonomous theories of ALS etiology because the immune system is an important 
presence in both the PNS and CNS. Multiple clinical trials using immunosuppression 
have failed to benefit ALS patients (Kelemen et al., 1983; Brown et al., 1986; Werdelin 
et al., 1990; Drachman et al., 1994). One explanation for these failures is that 
administering treatment at such an advanced disease stage could be too little, too late. An 
alternative explanation is that the immune system has both a neuroprotective and a 
neurodegenerative role. Eliminating the entire immune system could result in 
neurodegeneration because the neuroprotective aspects of the immune system are lost. 
This hypothesis is supported by the work done in our laboratory studying immune-
mediated neuroprotection after axotomy.  
 
2.8. Immune dysregulation in the mSOD1 mouse model of ALS 
Multiple studies have measured immune changes throughout the lifespan of the 
mSOD1G93A mouse model of ALS to identify early alterations that may be causative of 
the disease. The earliest inflammatory changes in mSOD1 spinal cord tissue have been 
described at 40-42 doa, at which increased microglia activation, immunoglobulin G (IgG) 
deposits, and integrin markers have been detected (Alexianu et al., 2001). Additionally, 
TNFα, IL-1R, and CD86 gene expression are increased at this early timepoint. At 63 doa, 
further microglial cytokine expression is observed, suggesting early microglia activation 
occurs in MND (Chen et al., 2004). At symptom onset and disease endstage 
(approximately 80 – 126 doa), potent increases in microglia and astrocyte activation are 
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observed, as well as significant increases in inflammatory cytokine protein and apoptotic 
gene expression (Alexianu et al., 2001; Hensley et al., 2002; Yoshihara et al., 2002; 
Hensley, 2003; Chen et al., 2004). Overall, these data suggest that immune dysregulation 
in ALS begins early in the disease and accumulates throughout the disease process.  
Depending on the mouse background strain, mSOD1G93A motoneuron disease can 
progress slowly (C57 background) or rapidly (SJL background). A comparison study was 
conducted to determine if differential immune responses existed between these two 
groups. The study focused on changes in the sciatic nerve at approximately similar 
disease stages of these two strains. In C57 (slow progression) sciatic nerves, higher levels 
of MHCI, CCL2, and C3 were detected, as well as higher CD8+ T cell infiltration. 
Conversely, in SJL (fast progression) sciatic nerves, much lower immunoactivation was 
detected (Nardo et al., 2016). These data suggest that immune activation and 
inflammatory cytokine production may be neuroprotective and prolong axonal survival, 
whereas deficient immunoactivation results in accelerated axonal loss. This study 
supports the hypothesis for this work that dysregulation in the ALS immune system may 
lead to a loss of neuroprotection, not an augmentation in neurotoxicity.  
 
2.9. T cells in mSOD1 MND 
In the early presymptomatic stage of MND in mSOD1 mice, no changes are 
evident in levels of CD4+ or CD8+ T cells in the peripheral blood (Gravel et al., 2016). 
However, at end-stage, significant lymphopenia and loss of splenic mass and architecture 
is evident (Kuzmenok et al., 2006; Banerjee et al., 2008). To test if lymphopenia 
contributed to mSOD1 disease, adoptive transfer of WT WS to mSOD1 mice was 
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performed, and no therapeutic benefits were observed (Banerjee et al., 2008). In contrast, 
regular treatment of mSOD1 mice with WT CD4+ T cells prior to and throughout 
disease, either enriched for regulatory T cells (CD4+CD25+; Tregs) or effector T cells 
(CD4+CD25-; Teffs) revealed that Tregs delayed symptom onset and Teffs increased 
disease latency (Banerjee et al., 2008).  
Despite the overall lymphopenia, CD4+ and CD8+ T cells accumulate in the 
mSOD1 spinal cord with disease progression. To further examine if T cells were 
neuroprotective or neurotoxic, a T cell receptor (TCR) knockout was crossed with the 
mSOD1 mouse model, and accelerated disease progression and death was observed in 
these mice (Chiu et al., 2008). This finding is further confirmed with a similar phenotype 
observed in both mSOD1/RAG-1-/- mice and mSOD1/CD4-/- transgenic mice (Beers et 
al., 2008). Altogether, these findings support the hypothesis that CD4+ T cells promote 
MN survival and delay disease progression in mSOD1 MND.  
To test if increasing CD4+ T cell numbers could confer neuroprotection, 
castration was performed on male mSOD1 mice. Castration results in an increased 
thymus size and increase in circulating CD4+ T cells; however, this increase in T cells 
only increased survival by an average of 9 days. Decreased microglia activation was 
observed in the spinal cord, suggesting that T cell modulation of microglia responses may 
be neuroprotective (Sheean et al., 2015).  
 
2.10. FNA and mSOD1 MND 
One drawback of studying disease progression in the mSOD1 mouse model is that 
there is no exact timing for disease onset. Even in animals with identical genotypes, 
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significant differences in disease progression can be observed (Gurney et al., 1994; 
Haulcomb et al., 2014) MN are also heterogeneously affected by this disease, with some 
MN dying very early, and some living for the remainder of the animal’s lifespan (Fischer 
et al., 2004). In addition, some MN maintain connection target musculature to endstage 
(Gurney et al., 1994). To circumvent this problem, FNA can be superimposed onto the 
mSOD1 mouse model to induce target disconnection of all FMN at the exact same time. 
Because axotomy simulates the target-disconnection pathology in ALS, essentially all 
FMN are experiencing the disease pathology simultaneously. To minimize confounding 
injury with mSOD1 disease processes, the axotomy is induced at 56 doa, a timepoint 
much earlier than when mSOD1 MND affects FMN survival (136 doa). This timepoint 
for axotomy was also selected to ensure that the immune system has completely matured 
in these animals.  
When FNA is performed on mSOD1 mice at 56 doa, significantly greater FMN 
loss is observed in mSOD1 mice at 28 dpo (84 doa). To confirm that the mSOD1 MND 
was not confounding the axotomy-induced death, FMN were quantified on the uninjured 
side and the numbers were equivalent to uninjured WT FMN counts (Mesnard et al., 
2011). In addition to greater MN death, functional recovery from facial nerve crush is 
also delayed in mSOD1 mice relative to WT. It should be emphasized here that recovery 
still occurs in mSOD1 mice, suggesting that the regenerative program within injured MN 
is still functional (Mesnard et al., 2013). Gene expression profile analysis after facial 
nerve transection further confirms that the MN regenerative phenotype after axotomy 
remains comparable to WT, using markers such as Gap-43 and βII-tubulin. In addition, 
there is deficient activation of the glial response after axotomy. In the uninjured FMN, 
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mRNA levels of astrocyte and microglia activation genes are increased relative to WT, 
indicating some baseline glial activation occurring due to the mSOD1 MND. In addition, 
baseline expression of inflammatory cytokines Tnfα and Ifnγ (interferon γ) is increased 
and continues to rise with axotomy (Mesnard et al., 2011; Haulcomb et al., 2014).  
A closer examination of cell death pathways in the axotomized mSOD1 FMNuc 
reveals a high prevalence of both Fas and neuronal nitric oxide synthase (nNos) 
expression after FNA (Haulcomb et al., 2014). Conversely, no differences were detected 
in TNFR1 mediated cell death, which is surprising given the significant increase in TNFα 
detected in mSOD1 CNS tissue. Other mSOD1 studies of Fas/nNos death have 
determined than MN with multiple different mSOD1 mutations are hypersensitive to 
Fas/nNos mediated cell death as compared with trophic deprivation or excitotoxic 
stimulation (Raoul et al., 2002). This difference is specific for mSOD1 MN and is not 
observed in WT MN. A closer examination reveals that nitric oxide (NO) triggers MN to 
express Fas ligand (FasL), which may be responsible for potentiating MN death via 
Fas/nNos pathways.  
Because both RAG-2-/- mice and mSOD1 mice suffer similar MN death after 
FNA, and because immune dysregulation is observed in mSOD1 mice, a study from our 
laboratory was conducted to assess if mSOD1 splenocytes could confer neuroprotection. 
Adoptive transfer of mSOD1 WS does not rescue FMN survival after FNA in RAG-2-/- 
mice. With this finding, the next hypothesis was that mSOD1 CD4+ T cells were 
ineffective in promoting FMN survival. This hypothesis was disproven when adoptive 
transfer of isolated mSOD1 CD4+ T cells into RAG-2-/- mice resulted in FMN survival 
after FNA comparable to WT. To identify if immunotherapy could improve FMN 
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survival after FNA, mSOD1 mice were injected with either WT WS, WT CD4+ T cells, 
WT CD4+ depleted splenocytes, or axotomy-activated WT CD4+ T cells. The mSOD1 
mice that received WT WS had a significant increase in FMN survival, but the other cell 
transfers were incapable of rescuing FMN survival, suggesting that the additive benefit of 
both WT splenocytes and CD4+ T cells could overcome the inhibition of the 
neuroprotection within the mSOD1 mouse milieu (Mesnard-Hoaglin et al., 2014). These 
findings suggest that a factor within the mSOD1 WS suppresses CD4+ T cell mediated 
neuroprotection and form the basis for the work described in this dissertation. 
 
2.11. Aim 1: Determine the source of neuroprotective IL-10 in the axotomized facial 
motor nucleus 
Based on the Xin et al. 2011 study, IL-10 is necessary for CD4+ T cell mediated 
neuroprotection, although it does not derive from CD4+ T cells. IL-10-/- CD4+ T cells 
still rescue FMN survival in RAG-2-/- mice, indicating that the neuroprotective IL-10 
does not derive from the adaptive arm of the immune system. Finally, IL-10 cannot cross 
the BBB, therefore leading us to conclude that neuroprotective IL-10 derives from the 
CNS parenchyma (Kastin et al., 2003). To fully understand the mechanisms of CD4+ T 
cell-mediated neuroprotection, it is necessary to learn the source and kinetics of IL-10 
production after FNA.  
The hypothesis for this aim is that CD4+ T cells, after initial activation in the 
peripheral immune system, migrate to the CNS and interact with MHCII+ microglia. This 
results in a secondary activation of T cells and expression of IL-4, which shifts the 
phenotype of microglia towards M2 microglia that produce neuroprotective IL-10.  
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2.12. Aim 2: Characterize gene expression profile changes after facial nerve 
axotomy in immunodeficient and WT CD4+ T cell-reconstituted mice 
There is a gap in the literature regarding how the adaptive arm of the immune 
system exerts neuroprotective effects in the facial motor nucleus after axotomy. To 
address this, the gene expression profile in immunodeficient RAG-2-/- mice will be 
compared to WT at multiple post-axotomy timepoints. In addition, the gene expression 
profile of RAG-2-/- mice with adoptive transfer of WT CD4+ T cells will be performed to 
characterize the neuroprotective effects of CD4+ T cells. Four aspects of the injury 
response will be assessed: MN regeneration, glial activation, inflammation, and cell death 
receptor pathways. The hypothesis for this aim is that immunodeficiency will impair the 
glial microenvironment response to FNA, leading to increased FMN death, and CD4+ T 
cells will regulate these cellular responses to normal levels.  
 
2.13. Aim 3: Analyze gene expression profile changes after facial nerve axotomy in 
mice immunoreconstituted with mSOD1 whole splenocytes or mSOD1 CD4+ T cells 
To our surprise, mSOD1 CD4+ T cells are capable of neuroprotection, whereas 
mSOD1 WS are not. This finding suggests that an inhibitory factor within the mSOD1 
WS environment impairs CD4+ T cell mediated neuroprotection. To better understand 
the mechanism behind this, gene expression analysis will be performed to examine the 
same genes as in Aim 2. As an additional control, a RAG-2-/- + WT WS group will be 
added for comparison with the mSOD1 WS recipient animals. The hypothesis for Aim 3 
is that the RAG-2-/- + mSOD1 WS group gene expression profile will be comparable to 
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the RAG-2-/- profile with impaired glial microenvironment responses, and the mSOD1 
CD4+ T cell treatment group will be comparable to the WT CD4+ T cell group. This 
hypothesis is based on the assumption that the mSOD1 WS will block the glial 
microenvironment regulation by CD4+ T cells within the whole splenocyte milieu. 
However, when the mSOD1 CD4+ T cells are removed from the suppressive 
environment, they will function comparably to WT CD4+ T cells.  
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CHAPTER 3: MATERIALS AND METHODS 
3.1. Animals used in this study 
For this study, the following mouse strains were purchased from The Jackson 
Laboratory (Bar Harbor, ME): C57BL/6J (WT, 000664), B6(Cg)-Rag2tm1.1Cgn/J 
(RAG-2-/-, 008449), B6.Cg-Tg(SOD1G93A)1Gur/J (mSOD1, 004435), and B6(Cg)-
Il10tm1.1Karp/J (IL-10/GFP, 014530). All purchased mice were obtained at 6 or 7 weeks of 
age and allowed acclimate for 1 week prior to any manipulation. Female mice were 
exclusively used for experiments because male mice cannot be co-housed after surgery 
due to their aggressive nature. The male fighting behavior causes damage to the surgical 
site, leading to infections that can confound experimental results. 
For the IL-10 conditional knockout mice, IL-10 floxed mice were generously 
provided from Dr. Gang Huang’s laboratory at Cincinnati Children’s Hospital (Roers et 
al., 2004). GFAP-cre mice and CX3CR1-cre (CX3C receptor 1) mice were purchased 
from the Jackson Laboratory (Strains: B6.Cg-Tg(GFAP-cre/ERT2)505Fmv/J, 012849; 
B.6.129P2(Cg)-Cx3cr1tm2.1(cre/ERT)Litt/WganJ, 021160). Both cre strains used were 
tamoxifen-inducible. The breeding scheme between the cre and floxed mouse strains 
generated GFAP-cre+/IL-10fl/fl and CX3CR1-cre+/IL-10fl/fl mouse strains. For negative 
controls, cre+/IL-10fl/- and cre-/IL-10fl/fl littermates were used.  
All animal procedures complied with National Institutes of Health guidelines on 
the care and use of laboratory animals and were approved by the Indiana University 
School of Medicine’s Institutional Animal Care and Use Committee. Mice were housed 
in sterilized microisolater cages with a 12 hr light/dark cycle and fed autoclaved food 
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pellets and drinking water ad libitum. The animal facility uses a laminar flow system to 
maintain a pathogen-free environment.  
 
3.2. Genotyping 
Tail snips were collected from mice in the cre/lox breeding scheme, and DNA 
was extracted from them using the Gentra Puregene Mouse Tail Kit (Qiagen, 
Germantown, MD; 158267). PCR was conducted using genomic DNA, forward and 
reverse primers (Table 1), and GE Healthcare illustra™ PuReTaq Ready-To-Go™ PCR 
Beads (Thermo Fisher Scientific, Waltham, MA; 46-001-012). The IL-10 PCR program 
consisted of the following steps: 95°C for 2 min, 40 cycles of 95°C for 30 sec, 60°C for 
45 sec, and 72° C for 45 sec, then 72°C for 5 min. The GFAP-cre and CX3CR1-cre PCR 
programs consisted of the following steps: 94°C for 2 min, then 10 cycles of 94°C for 20 
sec, 65°C for 15 sec (-0.5°C per cycle), and 68°C for 10 sec, then 28 cycles of 94°C for 
15 sec, 60°C for 15 sec, and 72°C for 10 sec, then finished at 72°C for 1 min. Both PCR 
protocols were run on an Eppendorf Model 5333 Mastercycler. The PCR product was run 
on a 2% agarose gel made in TAE buffer at 150 V for 30-40 min, and the gel was imaged 
on the Cell Bioscience FluorChem E imager. 
 
3.3. Induction of cre recombinase 
Tamoxifen (Sigma-Aldrich, St. Louis, MO; T5648) was dissolved in corn oil at a 
concentration of 20 mg/ml by shaking overnight at 37°C in a light-blocking vessel. 75 
mg/kg of tamoxifen was injected intraperitoneally for 5 consecutive days to induce cre. 
Cre induction was maintained by tamoxifen injections twice per week until euthanasia.  
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3.4. Facial nerve axotomy 
Aseptic procedures were followed during the surgery following National Institute 
of Health guidelines. FNA was performed on 8 week old female mice following 
previously established methods (Olmstead et al., 2015). Briefly, mice were anesthetized 
with 2.5% isoflurane in 0.9 L/min oxygen, and sedation was monitored by confirming 
absence of the toe pinch reflex. The area behind the ear was shaved, and the skin was 
sterilized with alternating wipes of betadine and 70% ethanol, repeated three times. Using 
spring scissors, an incision approximately 4 mm in length was made behind the ear 
protuberance. The underlying subcutaneous tissue was bluntly dissected until the facial 
nerve trunk could be observed exiting the stylomastoid foramen. The nerve was 
transected, and the remaining nerve stumps were separated to prevent reconnection. The 
incision was closed with a sterile wound clip, and confirmation of the FNA was 
performed by assessing whisker movement and eye blink reflexes after completion of the 
surgery. Animals were monitored post-operatively for complications for five dpo, and the 
wound clip was removed at 7-10 dpo.  
 
3.5. Isolation and adoptive transfer of whole splenocytes and CD4+ T cells 
Donor mice (1:1 donor:recipient ratio) were euthanized with CO2 inhalation 
followed by cervical dislocation. The spleen was dissected out and placed in a 
gentleMACS C Tube (Miltenyi Biotec, San Diego, CA; 130-093-237) with buffer (1× 
PBS, 0.5% bovine serum albumin, and 2 mM EDTA) and dissociated into a single-cell 
suspension using a gentleMACS Dissociator following the Miltenyi Biotec gentleMACS 
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protocol. The suspension was passed through a 70 µm cell filter into a sterile 50 ml 
conical tube, and centrifuged at 300 x g for 10 min at 4°C.  
For whole splenocyte collection, red blood cell lysis was performed using ACK 
Lysing Buffer (Thermo Fisher Scientific; A1049201) for 4 min at RT. The reaction was 
diluted with 45 ml buffer, then centrifuged at 300 x g for 10 min at 4°C. The pellet was 
resuspended in 1 ml buffer/spleen, filtered, and a cell count was performed. PBS was 
added to the cell suspension to increase the volume to 45 ml, then the mixture was 
centrifuged at 300 x g for 10 min at 4°C. The pellet was resuspended in PBS to make a 5 
x 108 cells/ml concentration of whole splenocytes. Immediately prior to injection, cells 
were passed through a 70 µm cell filter, and 50 x 106 WS in 100 µl of PBS were injected 
into the recipient mouse tail vein.  
CD4+ T cell isolation began with generation of a single-cell suspension of whole 
splenocytes. Red blood cell lysis was not performed to maximize CD4+ T cell yield. The 
whole splenocyte cell pellet was incubated with CD4 (L3T4) MicroBeads (Miltenyi 
Biotec, 130-049-201) per manufacturer protocol, and magnetic separation was performed 
with the Possel_d2 program on an autoMACSTM Pro Separator. A cell count was 
performed, then cells were washed with PBS and centrifuged at 300 x g for 10 min at 
4°C. The pellet was resuspended in PBS to make a 5 x 107 cells/ml concentration of 
CD4+ T cells. Immediately prior to injection, cells were passed through a 70 µm cell 
filter, and 5 x 106 CD4+ T cells in 100 μl of PBS were injected into the recipient mouse 
tail vein.  
CD4+ cell fraction purity was measured using flow cytometry with FITC rat anti-
mouse CD4 antibody (BD Pharmingen, San Jose, CA; 557307). In the WT CD4+ T cell 
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treatment group, 97% of the magnetic-sorted splenocytes were CD4+ (data not shown), in 
accordance with our previously published work (Serpe et al., 2003; Xin et al., 2011). In 
the mSOD1 CD4+ T cell group, cells were manually sorted due to a malfunction of the 
AutoMACS, and 75% of cells in the positive fraction were CD4+ (data not shown).  
 
3.6. Laser-capture microdissection  
Experimental animals were euthanized via CO2 inhalation followed by cervical 
dislocation at 7, 14, 28, and 56 dpo. An unoperated group was also included as a 0 dpo 
control. Brains were rapidly removed and immediately flash frozen in an n-butyl bromide 
(62.5%) and 2-methyl butane (26.5%) biphasic solution chilled on dry ice to -30ºC, then 
stored at -80ºC. The brains were embedded in Optimal Cutting Temperature compound, 
and 25 µm cryostat sections of the entire rostral-caudal extent of the facial nucleus within 
the brainstem were collected on Leica glass polyethylene foil membrane slides 
(Nuhsbaum, McHenry, IL, 11505158) and stored at -80ºC. Tissue staining and laser 
capture microdissection were performed using methods previously described (Mesnard et 
al., 2010). The right (axotomized, Ax) and left (control, C) facial motor nuclei were laser-
captured using a Leica ASLMD, and FMN and surrounding neuropil were collected 
together.  
 
3.7. RNA extraction and reverse transcription 
RNA extraction was performed per the Arcturus PicoPure® RNA Isolation Kit 
protocol (Thermo Fisher Scientific; KIT0204). RNA yield was quantified with a 
NanoDrop 2000 Spectrophotometer. 60 ng of RNA was reverse transcribed into cDNA 
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using the SuperScript® VILO cDNA Synthesis Kit and Master Mix following 
manufacturer instructions (Thermo Fisher Scientific; 11754050). 
 
3.8. qPCR  
qPCR was performed using an Eppendorf Realplex Mastercycler system. The 20 
µl reaction volume contained 1 µl of cDNA, 1 µl of 20× TaqMan® FAM gene expression 
assay (Table 2), 8 µl of 0.002% diethyl pyrocarbonate-treated water, and 10 µl of 
TaqMan Gene Expression Master Mix (Thermo Fisher Scientific; 4369016). The qPCR 
program was as follows: UDG optimization at 50°C for 2 min, AmpliTaq Gold 
Activation at 95°C for 10 min, and then 40 cycles of denaturation at 95°C for 15 sec 
followed by annealing/extension at 60°C for 1 min.  
We have previously established percent-changes in mRNA expression after 
axotomy using custom-made primers and SYBR® green reagents (Mesnard et al., 2010; 
Mesnard et al., 2011; Haulcomb et al., 2014). We opted to use the TaqMan assays in 
these experiments because of their enhanced sensitivity and specificity for gene targets 
(Alvarez & Done, 2014). To validate use of the TaqMan assays, side-by-side 
comparisons of results were obtained using the SYBR and TaqMan systems. This 
comparison revealed that both SYBR and TaqMan yielded similar results for all genes of 
interest except Cd68 and Tnfr1. To maintain consistency with previously established 
results, custom primers and TaqMan probes were used for Cd68 (F 5’-
CCCAAATTCAAATCCGAATCC-3’, R 5’-GGTACCGTCACAACCTCC-3’, probe 5’-
AAAGTGAGTGCGTCCCTTGCAGCC-3’) and Tnfr1 (F 5’-
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TGCCATGCAGGGTTCTTTCTG-3’, R 5’-TTTGCAAGCGGAGGAGGTAGG-3’, 
probe 5’-ACCCAATTCAGGGTGGAAGAAAGGT-3’).  
 
3.9. Statistical analysis of qPCR data 
The percent change in mRNA expression between axotomized and control facial 
motor nuclei was calculated using the Pfaffl method, with glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) as the reference gene (Pfaffl, 2001). Relative gene expression of 
Tnfα compared to Gapdh was used to quantify mRNA expression in the axotomized 
facial motor nucleus because there is no detectable expression of Tnfα in the control 
facial motor nucleus. The Grubbs’ test was performed on the calculated values to detect 
and remove outliers (GraphPad QuickCalcs). Statistical significance was calculated in 
SigmaPlot 13.0 using two-way ANOVA (factors: group × postoperative time, for each 
individual gene) followed by Student-Neuman-Keuls post hoc multiple comparisons 
analysis with a significance level of p < 0.05. 
To validate that axotomy does not induce mRNA expression changes in the 
control FMNuc, one-way ANOVA of the relative expression of each gene of interest 
compared to GAPDH within the control FMNuc was performed at each postoperative 
timepoint with p < 0.05. For all genes examined, no statistically significant changes were 
detected (data not shown).  
 
3.10. Fluorescent immunohistochemistry 
At the appropriate timepoint post-FNA, IL-10/GFP reporter animals were 
euthanized and brain tissue was extracted following the protocol in section 3.6. Brains 
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were frozen instead of perfusion-fixed to preserve the GFP signal. After embedding 
brains in Optimal Cutting Temperature compound, 8 µm cryostat sections of the FMNuc 
were collected on Fisherbrand Superfrost Plus Microscope Slides (Thermo Fisher 
Scientific; 12-550-15) and stored in light-tight boxes at -20ºC.  
Prior to staining, sections were circled with an Elite PAP Pen (Diagnostic 
BioSystems, Pleasanton, CA; K039). On-slide fixation was performed with PFA solution 
(filtered 4% paraformaldehyde in PBS, pH 7.4) for 15 min at RT, then washed with PBS 
3 × 5 min in a humidified chamber. Blocking buffer comprised of 10% normal donkey 
serum (EMD Millipore, Billerica, MA; S30), 1% bovine serum albumin (Jackson 
Immunoresearch, West Grove, PA; 001-000-162), and 0.01% Triton X-100 in PBS was 
applied for 1 hr at RT. After the blocking step, primary antibodies diluted in blocking 
buffer were applied to the slide overnight at 4°C (Table 3). On the following day, slides 
were washed with PBS 3 × 5 min in a Coplin jar, then returned to the humidified 
chamber for incubation with secondary antibody diluted in blocking buffer for 1 hr at RT. 
Afterwards, slides were washed with PBS 3 × 5 min in a Coplin jar. Excess fluid was 
wiped from the slide, and 100 µl of DAPI Fluoromount-G (SouthernBioTech, 
Birmingham, AL; 0100-20) was applied before coverslipping. Imaging was performed 
using an Olympus BX-43 equipped with cellSens Entry version 1.9 software. Image 
processing, including subtraction of background and adjustments to histograms, were 
performed in ImageJ version 1.8.0_111.  
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3.11. Perfusion-fixation of animals 
Mice received a lethal overdose of a mixture of 200 mg/kg ketamine and 5 mg/kg 
xylazine administered intraperitoneally. When the animal was deeply anesthetized, a 
catheter was inserted into the right ventricle of the heart, and the left ventricle was 
lanced. 50 ml of PBS then 50 ml of PFA was passed through the animal using a 
mechanical pump on its slowest setting. The brain was dissected out and placed in a 
Falcon tube with PFA for 4 hours on ice. The brain was then moved to a new tube with a 
solution of 30% sucrose in PBS to cryoprotect the tissue. After the tissue had sunk in the 
sucrose solution, it was stored at -80°C until cryosectioning.  
 
3.12. Thionin stain and facial motoneuron counts 
Flash frozen brains were sectioned at 25 µm on a cryostat, and sections containing 
the FMNuc were collected on Superfrost Plus slides. The sections were post-fixed in 4% 
PFA for 15 min, then washed in water for 2 × 5 min. Sections were stained with 1X 
thionin acetate for 10 min, rinsed with water for 30 sec, then dehydrated with a series of 
30 sec washes with 50%, 70%, 95%, and 100% EtOH. Slides were incubated in Hemo-
De clearing agent (Thermo Fisher Scientific; NC0174259) for a minimum of 3 days 
before coverslipping with Permount.  
An uninvolved investigator coded all slide sets to blind investigators to treatment 
groups. The FMNuc was located using a Leica DMRB microscope fitted with a digital 
camera (Microfire Optronics S97808) operated with Neurolucida version 10.31 software. 
The nucleus ambiguus and facial nerve were used to precisely locate the caudal and 
rostral edges of the FMNuc. FMN profiles displaying a clear nucleus and nucleolus were 
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quantified for the entire axotomized and control FMNuc. The Abercrombie correction 
factor [N = (n × T)/(T + D)] was applied, where N is the actual number of cells, n is the 
number of nuclear profiles, T is the thickness of the section (25 µm), and D is the average 
diameter of nuclei (18.8 µm for control, 18.5 µm for axotomized) (Mesnard et al., 2011). 
Mean percentage FMN survival was quantified by dividing the number of axotomized 
FMN by control FMN and multiplying by 100%. A student’s t-test was performed in 
Excel 2013 to compare control and experimental groups with p < 0.05.  
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Target Primer Sequence (5’ → 3’) 
IL-10fl/fl F CCA GCA TAG AGA GCT TGC ATT ACA 
IL-10fl/fl R GAG TCG GTT AGC AGT ATG TTG TCC AG 
GFAP-cre F GCC AGT CTA GCC CAC TCC TT 
GFAP-cre R TCC CTG AAC ATG TCC ATC AG 
GFAP-cre internal positive 
control F 
CTA GGC CAC AGA ATT GAA AGA TCT 
GFAP-cre internal positive 
control R 
GTA GGT GGA AAT TCT AGC ATC ATC C 
CX3CR1-cre common F  AAG ACT CAC GTG GAC CTG CT 
CX3CR1-cre mutant R CGG TTA TTC AAC TTG CAC CA 
CX3CR1-cre wild type R AGG ATG TTG ACT TCC GAG TTG 
Table 1: Forward and reverse primer sequences for PCR. 
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Gene  TaqMan ID RefSeq Accession 
Number  
Gfap Mm01253033_m1 NM_001131020.1, 
NM_010277.3 
Fas Mm01204974_m1 NM_007987.2 
Gap-43 Mm01144975_m1 NM_008083.2 
βII-tubulin (Tubb2a) Mm00809562_s1 NM_009450.2 
nNos (Nos1) Mm00435175_m1 D14552.1 (GenBank) 
Tnfα Mm00443260_g1 NM_013693.3 
Gapdh Mm99999915_g1 NM_001289726.1, 
NM_008084.3 
Arginase 1  Mm00475988_m1 NM_007482.3 
Interferon-γ Mm01168134_m1 NM_008337.3 
Interleukin-10 Mm00439614_m1 NM_010548.2 
Tradd Mm01251031_g1 NM_001033161.2 
Traf2 Mm00801978_m1 NM_001290413.1,  
NM_009422.3 
Fadd Mm00438861_m1 NM_010175.5 
Table 2: Catalog information for qPCR TaqMan assays ordered from Thermo Fisher 
Scientific.  
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CHAPTER 4: RESULTS 
4.1. Aim 1: Determine the source of neuroprotective IL-10 in the axotomized facial 
motor nucleus 
4.1.1. Validation of the IL-10/GFP reporter mouse  
An IL-10/GFP reporter mouse was employed to determine what cell type in the 
CNS parenchyma was responsible for producing neuroprotective IL-10 after FNA. The 
IL-10/GFP mouse was created by Dr. Christopher Karp’s laboratory at Cincinnati 
Children’s Hospital by knocking in an internal ribosome entry site conjugated to the GFP 
gene between the IL-10 stop and poly-A tail sequences. The final mRNA transcript of the 
IL-10 gene allows for translation of both the IL-10 and GFP proteins separately (Madan 
et al., 2009; Sun et al., 2009). 
To confirm the insertion of the GFP protein did not affect the axotomy model, 
FNA was performed on C57Bl/6 (WT) mice and IL-10/GFP reporter mice, and FMN 
survival was quantified at 28 dpo. IL-10/GFP FMN survival levels were not significantly 
different from WT (Figure 1, 84 ± 5% and 84 ± 3%, respectively, p = 0.57). WT FMN 
survival levels were comparable to previously published results (Serpe et al., 1999; 
Mesnard-Hoaglin et al., 2014).  
 
4.1.2. Fluorescent immunohistochemistry of the IL-10/GFP reporter mouse 
With confirmation that the IL-10/GFP FMN survival was comparable to WT, 
fluorescent immunohistochemistry (IHC) was performed to identify which cell types in 
the CNS produce IL-10. The hypothesis for this experiment was that microglia, not 
astrocytes or neurons, are the primary producers of IL-10 after FNA. This hypothesis was 
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based on previous studies in which microglia are described as sources of IL-10, 
especially in contexts where the microglia have adopted the neuroprotective M2 
phenotype (Zhang et al., 2014; Ma et al., 2015; Chu et al., 2016).  
 
4.1.2.1. GFP 
First, a characterization of GFP expression in the uninjured FMNuc was 
performed. Previous results indicate that there exists a baseline expression of IL-10 in the 
FMNuc, and the immunofluorescence in the reporter mouse line confirms this (Xin et al., 
2011). Because the endogenous GFP signal was weak, an anti-GFP antibody was 
employed to amplify the fluorescent signal. GFP was visibly detected in the uninjured 
FMNuc, as well as in the vasculature (data not shown). There were no visible differences 
in GFP expression between the control and axotomized FMNuc. Both punctate and 
neuronal-like forms of GFP were visible in both C and Ax FMNuc (Figures 2 and 3).  
 
4.1.2.2. Microglia 
The Iba1 antibody was used to assess microglia expression of IL-10. Iba1 is a 
microglia marker that was first described in 1996, and has been used in numerous 
neuroscience studies, including FNA studies (Imai et al., 1996; Graeber et al., 1998; Ito et 
al., 1998; Bohatschek et al., 2004a; Almolda et al., 2015). Unfortunately, the Iba1 
antibody was ineffective in labeling microglia on flash-frozen brain tissue. When this 
experiment was conducted on tissue from animals perfusion-fixed with 4% PFA, as 
described in other GFP reporter mouse experiments, the GFP signal in this specific 
animal model was ablated (Zamanian et al., 2012; Frakes et al., 2014; Greenhalgh et al., 
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2016). When tissue was flash-frozen then fixed on the slide for 15 min in cold 4% PFA, 
GFP signal was retained and both NeuN and GFAP antibodies worked effectively, 
however Iba1 failed to label microglia. Alternative antibodies were assessed for their 
ability to label microglia in flash-frozen tissue, however no success was achieved. Future 
directions for this experiment include examining alternative fixation strategies, such as 
2% PFA or paraformaldehyde/lysine/periodate fixation, for their effectiveness in 
preserving GFP signal and retaining microglia antigenicity.  
 
4.1.2.3. Astrocytes 
Next, GFP expression was assessed in astrocytes of the FMNuc. The astrocyte-
specific cell marker used was GFAP, a cytoskeletal protein within astrocytes. Astrocytes 
exist in a protoplasmic state in the uninjured FMNuc that is GFAP-, and after nerve 
injury, their phenotype shifts to a fibrillary phenotype that is strongly GFAP+ (Graeber et 
al., 1988; Hermanson et al., 1995; Laskawi & Wolff, 1996; Klein et al., 1997). In this 
study, the fibrillary phenotype was first detected at 3 dpo, and increased steadily 
throughout the timecourse, with the greatest number of GFAP+ astrocytes detected at 28 
dpo (Figure 2). At 3 and 7 dpo, GFAP+ astrocytes did not colocalize with GFP. At 10 
dpo, both GFAP+/GFP+ and GFAP+/GFP- astrocytes were detected. At 14 and 28 dpo, 
almost all GFAP+ astrocytes were GFP+. The inset from 28 dpo demonstrates that GFP 
labels the cytoplasm and processes of astrocytes. The MN-like morphology stain of GFP 
was still visible throughout the timecourse. Other small cells, likely microglia, were 
detectable as a DAPI nucleus surrounded by GFP that did not colocalize with NeuN or 
GFAP. To summarize, axotomy-activated astrocytes are negative for IL-10 in the early 
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post-axotomy phase, but at the late post-axotomy phase, astrocytes are induced to express 
IL-10.  
 
4.1.2.4. Neurons 
To verify the presence of GFP in the MN, neuronal nuclei (NeuN) 
immunostaining was used to label FMN. NeuN was first described as an exclusive 
neuronal marker in 1992 (Mullen et al., 1992). It was later discovered that NeuN is the 
protein product of the Fox-3 gene, and it is a splicing regulator protein that binds RNA 
that is also a component of the neuronal nuclear matrix (Kim et al., 2009; Dent et al., 
2010). After axotomy, NeuN phosphorylation diminishes antibody binding to the target, 
however this antibody affinity is not completely lost after axotomy (McPhail et al., 2004; 
Duffy et al., 2011; Tyzack et al., 2014; Yeh et al., 2017).  
NeuN staining of uninjured FMN colocalized strongly with the GFP signal, 
demonstrating that FMN are a source of IL-10 in the homeostatic FMNuc (Figure 3). 
After facial nerve injury, NeuN intensity decreased significantly relative to the uninjured 
side from 3-14 dpo, with some recovery of signal at 28 dpo. Although NeuN signal was 
diminished, there was sufficient signal to allow for GFP colocalization to be examined. 
From 3-28 dpo, GFP colocalized with NeuN labeling. The inset image from 7 dpo 
demonstrates this labeling pattern, with GFP visible in the cytoplasm of the FMN, and a 
central clearing for the center of the nucleus. Overall, based on the GFP morphology and 
its colocalization with NeuN and DAPI, MN expression of GFP appears to be constant 
over the postoperative timecourse, with no significant gain or loss of GFP expression 
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detected. These data suggest that FMN are a significant source of IL-10 both before and 
after axotomy, with no significant changes induced by axotomy.  
 
4.1.3. Selective knockdown of IL-10 and effects on FMN survival 
To identify if a cell-specific source of IL-10 is crucial for FMN survival after 
injury, cre/lox mice were generated in which the IL-10 gene was floxed in either GFAP-
cre or CX3CR1-cre mouse strains. Cre activity was induced with tamoxifen, FNA was 
performed, and FMN survival was quantified at 28 dpo. The control animals for this 
experiment were cre-negative or IL-10fl/- littermates that were also treated with tamoxifen 
and received FNA.  
The hypothesis for this experiment was that microglia-derived IL-10 is crucial for 
FMN survival, therefore, CXCR1-cre+/IL-10fl/fl mice were predicted to have significantly 
greater loss of FMN after axotomy compared to littermate controls. Based on this 
hypothesis, we predicted that GFAP-cre+/IL-10fl/fl mice would exhibit FMN survival 
comparable to WT because microglia-derived IL-10 would be unaffected. 
No significant loss of FMN was observed in CXCR1-cre+/IL-10fl/fl mice relative 
to littermate controls (Figure 4A, n = 8, 88 ± 3%, 83 ± 4%, p = 0.30, respectively). 
Similarly, GFAP-cre+/IL-10fl/fl mice FMN survival was not different from littermate 
controls (Figure 4B, n = 3, 81 ± 7%, 85 ± 7%, p = 0.71, respectively) 
Overall, these data suggest that neither microglia- nor astrocyte-specific IL-10 
production is critical for FMN survival after FNA. It is possible that mechanisms exist 
between microglia and astrocytes where one can compensate for the other’s lack of IL-10 
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production to promote FMN survival. Alternatively, the FMN itself may be the source of 
neuroprotective IL-10.  
 
4.2. Aim 2: Characterize gene expression profile changes after facial nerve axotomy 
in immunodeficient and WT CD4+ T cell immunoreconstituted mice 
4.2.1. Motoneuron regeneration response 
4.2.1.1. Gap-43 
Gap-43 is a growth cone protein that is necessary for regenerating the daughter 
axon and reconnecting to target musculature (Bomze et al., 2001; Benowitz & Popovich, 
2011). Measurement of Gap-43 expression after axotomy can be used to assess the MN 
regeneration response (Tetzlaff et al., 1991; Bisby & Tetzlaff, 1992; Mesnard et al., 2010; 
Mesnard et al., 2011; Haulcomb et al., 2014).  
Analysis of Gap-43 expression after FNA comparing WT and RAG-2-/- mice 
revealed a significant effect of group (Figure 5, F1,48 = 6.287, p = 0.016) and 
postoperative time (F4,48 = 101.069, p < 0.001). In the WT group, expression of Gap-43 
was significantly increased relative to control at 7, 14, and 28 dpo, and levels returned to 
baseline at 56 dpo (1083 ± 41%, 1239 ± 128%, 351 ± 38%, respectively; p < 0.05). In the 
RAG-2-/- group, Gap-43 expression was similarly increased relative to control at 7 and 14 
dpo, however, levels were not different from baseline at 28 and 56 dpo (873 ± 77%, 1057 
± 79%, respectively; p < 0.05). There were no statistically significant differences between 
the WT and RAG-2-/- groups at any timepoint. This finding suggests that 
immunodeficiency does not impair the MN regeneration response after axotomy.  
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With adoptive transfer of WT CD4+ T cells, Gap-43 expression differed 
significantly from uninjured control at 7, 14, and 28 dpo, and returned to baseline at 56 
dpo (1342 ± 81%, 1286 ± 92%, 485 ± 79%, respectively; p < 0.05). Gap-43 expression 
was significantly higher in the RAG-2-/- + WT CD4+ group relative to WT at 7 dpo (p = 
0.038). Comparing RAG-2-/- + WT CD4+ group to RAG-2-/- revealed significant 
differences in Gap-43 expression at 7, 14 and 28 dpo (p < 0.001, 0.020, and 0.004, 
respectively). These data indicate that CD4+ T cells modestly enhance the MN 
regeneration response after axotomy.  
 
4.2.1.2. βII-tubulin 
After axotomy, neurons upregulate expression of actin and tubulin cytoskeletal 
protein expression as part of the axonal regeneration program (Tetzlaff et al., 1988a; 
Tetzlaff et al., 1991; Bisby & Tetzlaff, 1992). βII-tubulin has been previously used a 
measurement of the MN regeneration response after axotomy (Mesnard et al., 2010; 
Mesnard et al., 2011).  
Analysis of βII-tubulin expression after FNA comparing WT and RAG-2-/- mice 
revealed a significant effect of postoperative time (Figure 6, F4,43 = 57.625, p < 0.001). In 
the WT group, expression of βII-tubulin was significantly increased relative to control at 
7, 14, and 28 dpo, and levels returned to baseline at 56 dpo (163 ± 12%, 168 ± 19%, 57 ± 
15%, respectively; p < 0.05). In the RAG-2-/- group, βII-tubulin expression was similarly 
increased relative to control at 7, 14 and 28 dpo, then returned to baseline at 56 dpo (160 
± 21%, 178 ± 19%, 43 ± 26%, respectively; p < 0.05). There were no statistically 
significant differences between the WT and RAG-2-/- groups at any timepoint. This 
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finding suggests that immunodeficiency does not alter the MN regeneration response 
after axotomy.  
With adoptive transfer of WT CD4+ T cells, βII-tubulin expression was 
significantly different from uninjured control at 7, 14, and 28 dpo, and returned to 
baseline at 56 dpo (169 ± 13%, 171 ± 14%, 96 ± 14%, respectively; p < 0.05). Comparing 
the RAG-2-/- + WT CD4+ group to WT revealed no significant differences in βII-tubulin 
expression throughout the timecourse. The comparison of the RAG-2-/- + WT CD4+ 
group to RAG-2-/- revealed significant differences in βII-tubulin expression at 28 dpo (p = 
0.026). These data indicate that CD4+ T cells do not significantly regulate the MN 
regeneration response after axotomy. The difference between the immunodeficiency and 
CD4+ T cell recipient groups may be a consequence of the increased FMN survival at 28 
dpo in the CD4+ T cell group, given that βII-tubulin is a MN-specific gene (Zhang et al., 
2014).  
 
4.2.2. Glial activation response 
4.2.2.1. Gfap 
Astrocytes play a key role after FNA, and their response to facial nerve injury has 
been well documented (Tetzlaff et al., 1988b; Hermanson et al., 1995; Laskawi & Wolff, 
1996; Klein et al., 1997). The role of GFAP in astrocyte function is previously described 
in section 4.1.2.3. 
Analysis of Gfap expression after FNA comparing WT and RAG-2-/- mice 
revealed a significant effect of group (Figure 7, F1,44 = 12.978, p < 0.001) and 
postoperative time (F4,44 = 24.101, p < 0.001). In the WT group, expression of Gfap was 
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significantly increased relative to control at 7, 14, 28, and 56 dpo (909 ± 97%, 805 ± 
71%, 644 ± 121%, 307 ± 45%, respectively; p < 0.05). In the RAG-2-/- group, Gfap 
expression was similarly increased relative to control at 7 and 14 dpo, then fell to 
baseline levels at 28 and 56 dpo (782 ± 249%, 480 ± 79%, respectively; p < 0.05). There 
were statistically significant differences between the WT and RAG-2-/- groups at 14 and 
28 dpo (p = 0.029 and 0.003, respectively). This finding suggests that immunodeficiency 
results in a failure to sustain astrocyte activation for the duration of the timecourse.  
With adoptive transfer of WT CD4+ T cells, Gfap expression differed 
significantly from uninjured control at 7, 14, 28, and 56 dpo (646 ± 32%, 911 ± 31% 763 
± 97% 236 ± 79%, respectively; p < 0.05). Comparing the RAG-2-/- + WT CD4+ group to 
WT revealed a significant difference in Gfap expression at 7 dpo (p = 0.011). Comparing 
RAG-2-/- + WT CD4+ group to RAG-2-/- revealed significant differences in Gfap 
expression at 14 and 28 dpo (p < 0.001 for both). These data indicate that CD4+ T cells 
are responsible for regulating astrocyte activation after axotomy. 
  
4.2.2.2. Cd68 
Cluster of differentiation 68 (CD68) is a transmembrane glycoprotein that belongs 
to the lysosomal-associated membrane protein (LAMP) family and is highly expressed in 
myeloid cells (Holness et al., 1993; Holness & Simmons, 1993; Gottfried et al., 2008). 
CD68 rapidly cycles between the cell surface and the endosomal/lysosomal 
compartments, with a majority of CD68 found in the late endosomal compartment 
(Kurushima et al., 2000). CD68 can bind to oxidized low density lipoprotein and 
liposomes, otherwise its function is largely unknown (Ramprasad et al., 1995). In the 
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CNS, CD68 expression is commonly used as a proxy measurement for microglia 
activation (Yoshihara et al., 2002; Chen et al., 2004; Beers et al., 2008).  
Analysis of Cd68 expression after FNA comparing WT and RAG-2-/- groups 
revealed a significant effect of group (Figure 8, F1,55 = 7.342, p = 0.009) and 
postoperative time (F4,55 = 17.366, p < 0.001). In the WT group, axotomy significantly 
increased Cd68 relative to the uninjured control at 7, 14, and 28 dpo, but not at 56 dpo 
(823 ± 109%, 772 ± 117%, 664 ± 78%, respectively; p < 0.05). In the RAG-2-/- group, 
Cd68 expression was also significantly elevated relative to baseline after axotomy at 7 
and 14 dpo, but not at 28 and 56 dpo (541 ± 73%, 654 ± 28%, respectively; p < 0.05). 
There was a statistically significant difference between the WT and RAG-2-/- groups at 28 
dpo (p = 0.036). This finding suggests that immunodeficiency results in dysregulation of 
the microglia activation response in the late phase post-axotomy.  
With adoptive transfer of WT CD4+ T cells, Cd68 expression was significantly 
different from baseline at 7, 14, 28, and 56 dpo (749 ± 93%, 810 ± 62%, 626 ± 104%, 
363 ± 103%, respectively; p < 0.05). There were no statistically significant differences 
between WT and RAG-2-/- + WT CD4+ groups at any timepoint. Comparing RAG-2-/- 
and RAG-2-/- + WT CD4+ groups revealed significant differences in Cd68 expression at 
28 and 56 dpo (p = 0.011, 0.037, respectively). These data suggest that CD4+ T cells 
regulate microglia activation after axotomy.  
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4.2.3. Inflammatory gene expression 
4.2.3.1. Tnfα 
Tnfα is a proinflammatory cytokine that is necessary for microglia expression of 
αXβ2 integrin, MHCI, and B7.2 costimulatory molecule expression after facial nerve 
injury (Raivich, 2002; Bohatschek et al., 2004a; Bohatschek et al., 2004b). Additionally, 
knocking out both TNFR1&2 simultaneously promotes motoneuron survival after facial 
nerve injury, suggesting that TNFα may have dual roles in immune-mediated 
neuroprotection (Raivich, 2002). 
For all groups and timepoints, there was no detectable Tnfα expression in the C 
FMNuc. Therefore, data shown is relative gene expression from the axotomized side 
only.  
Analysis of Tnfα expression after FNA comparing WT and RAG-2-/- groups 
revealed a significant effect of group (Figure 9, F1,26 = 10.004, p = 0.004) and a 
significant interaction between group × postoperative time (F3,26 = 5.166, p = 0.006). In 
the WT group, axotomy significantly increased Tnfα relative to the uninjured control at 7 
and 14 dpo, then returned to baseline levels at 28 and 56 dpo (4.43 x 10-4 ± 9.09 x 10-5, 
2.71 x 10-4 ± 1.04 x 10-4, respectively; p < 0.05). In the RAG-2-/- group, Tnfα expression 
was never significantly elevated relative to baseline at 7, 14, 28, or 56 dpo. There was a 
statistically significant difference between the WT and RAG-2-/- groups at 7 dpo (p < 
0.001). This finding suggests that immunodeficiency impairs early expression of Tnfα.  
With adoptive transfer of WT CD4+ T cells, Tnfα expression differed 
significantly from baseline at 7, 14, and 28 dpo, then levels returned to baseline at 56 dpo 
(3.30 x 10-4 ± 4.95 x 10-5, 5.64 x 10-4 ± 9.63 x 10-5, 3.18 x 10-4 ± 7.39 x 10-5, respectively; 
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p < 0.05). There were statistically significant differences between WT and RAG-2-/- + 
WT CD4+ groups at 14 dpo (p = 0.01). Comparing RAG-2-/- and RAG-2-/- + WT CD4+ 
groups revealed significant differences in Tnfα expression at 7, 14, and 28 dpo (p = 0.005, 
<0.001, 0.037, respectively). These data suggest that CD4+ T cells regulate inflammatory 
cytokine production after axotomy.  
 
4.2.3.2. Ifn-γ 
Ifn-γ expression has been described in previous studies done by our lab in the 
axotomized FMNuc (Mesnard et al., 2010; Mesnard et al., 2011) using SYBR green 
reagents and custom primers. With TaqMan assays, Ifn-γ expression could not be 
detected in the C or Ax FMNuc in either WT or RAG-2-/- animals at 0, 7, 14, 28, and 56 
dpo (n = 6 per group, per timepoint).  
 
4.2.3.3. Il-10 
Il-10 expression has been previously measured in our laboratory in 7 dpo WT and 
RAG-2-/- mice using SABiosciences primers (Xin et al., 2011). The TaqMan Il-10 assay 
was tested on WT animals at all the experimental timepoints (n = 1 per timepoint), and Il-
10 was not detectable in either the C or Ax FMNuc at any of the timepoints (data not 
shown).  
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4.2.4. Cell death receptor expression  
4.2.4.1. Tnfr1 
TNFR1 is a receptor that trimerizes after binding to TNFα, and via two cell 
signaling cascades, can either induce apoptosis via caspase 8 or trigger inflammatory 
gene expression via AP-1 and NF-κB (Baud & Karin, 2001; Wajant & Scheurich, 2011). 
Because of its association with cell death pathways, Tnfr1 expression was analyzed as a 
possible contributor to the increased MN death observed in RAG-2-/- mice.  
Analysis of Tnfr1 expression after FNA comparing WT and RAG-2-/- groups 
revealed a significant effect of postoperative time (Figure 10, F4,46 = 5.643, p < 0.001) 
and a significant interaction between group × postoperative time (F4,46 = 4.806, p = 
0.003). In the WT group, axotomy significantly increased Tnfr1 relative to the uninjured 
control only at 7 dpo (119 ± 31%; p < 0.05). In the RAG-2-/- group, Tnfr1 expression was 
significantly elevated relative to baseline after axotomy only at 14 dpo (139 ± 29%; p < 
0.05). There was a statistically significant difference between the WT and RAG-2-/- 
groups at both 7 and 14 dpo (p < 0.001, 0.029, respectively). These findings indicate a 
delayed Tnfr1 expression in immunodeficient animals relative to WT, correlating with the 
immunodeficient Tnfα expression response described previously.  
With adoptive transfer of WT CD4+ T cells, Tnfr1 expression is significantly 
different from baseline at 7, 14, 28, and 56 dpo (219 ± 13%, 220 ± 15%, 135 ± 12%, 73 ± 
6%, respectively; p < 0.05). There were statistically significant differences between WT 
and RAG-2-/- + WT CD4+ groups at 7, 14, and 28 dpo (p < 0.001, < 0.001, 0.005, 
respectively). Comparing RAG-2-/- and RAG-2-/- + WT CD4+ groups also revealed 
significant differences in Tnfr1 expression at 7, 14, and 28 dpo (p < 0.001, 0.002, 0.001, 
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respectively). These data indicate that when CD4+ T cells are isolated from the other 
cells of the adaptive arm of the immune system, they significantly increase Tnfr1 
expression. This result suggests that other lymphocytes, such as CD8+ T cells or B cells, 
modulate CD4+ T cell induction of Tnfr1. Regardless, this Tnfr1 expression is likely not 
associated with increased FMN death because FMN rescue is observed in RAG-2-/- + WT 
CD4+ T cell mice. Altogether, these data suggest that Tnfr1 expression after FNA is not 
correlated with apoptosis, instead, it is more likely associated with NF-κB activation.  
 
4.2.4.2. Tnfr1 transducers: Tradd, Fadd, Traf2 
TNFR1 activation can result in induction of cell death or NF-κB activation. 
TRADD (Tumor necrosis factor receptor type 1-associated death domain) is a protein 
associated with both signaling pathways. FADD (Fas-associated protein with death 
domain) is associated with transduction of apoptosis signaling, whereas TRAF2 (TNF 
receptor-associated factor 2) is associated with NF-κB activation (Baud & Karin, 2001). 
To determine if these two signaling pathways were differentially regulated by WT CD4+ 
T cells, mRNA levels of Tradd, Traf2, and Fadd were measured at 7, 14, and 28 dpo. For 
the genes examined, no significant induction of expression was observed in either WT or 
RAG-2-/- + WT CD4+ T cell groups after axotomy (data not shown). When tested by 
two-way ANOVA, there were no statistically significant differences between WT and 
RAG-2-/- + WT CD4+ T cell group expression profiles. To better understand the 
differential regulation of Tnfr1 expression after FNA, it is necessary to perform protein 
analysis of TNFR1 and its downstream mediators to quantify protein expression and 
assess protein activation status.  
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4.2.4.3. Fas 
Fas is a cell death receptor with special relevance to MN death observed in 
mSOD1 MND. Upon FasL binding, cell death can be induced by two downstream 
signaling cascades: the death-induced signaling complex (DISC) involving caspases 8 
and 3, or the Daxx/Ask1 (death-associated protein 6, apoptosis signal-regulating kinase 1, 
respectively) signaling cascade resulting in activation of neuronal nitric oxide synthase 
(nNos) (Raoul et al., 2002; Wajant, 2002). All CNS major cell types can produce FasL, 
with higher production in neurons and astrocytes (Flugel et al., 2000; Becher et al., 2006; 
Hovden et al., 2013; Zhang et al., 2014). Neuroimmunology studies reveal that this FasL 
expression by the brain protects the CNS from peripheral immune cells by utilizing Fas-
mediated apoptosis (Flugel et al., 2000; Becher et al., 2006). Examination of cell death 
pathways in mSOD1 mice reveals that MN, especially from mSOD1 mice, are highly 
sensitive to Fas and NO mediated death (Raoul et al., 2002). Further work describes that 
exogenous NO triggers FasL expression in MN (Raoul et al., 2006). Additionally, 
blocking the Fas signaling cascade by knocking out Daxx results in greater MN survival 
and decreased FasL expression in mSOD1 mice (Raoul et al., 2006). A study of cell death 
receptor expression after FNA on mSOD1 mice after FNA revealed that Fas/nNos 
signaling was highly expressed relative to WT, suggesting that the mSOD1 mutation 
leads to prominent expression of this cell death pathway (Haulcomb et al., 2014). 
Because Fas/nNos is related to MN death after target disconnection in mSOD1 MND, we 
wanted to explore if it played a role in the increased FMN death observed in 
immunodeficient animals.  
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Analysis of Fas expression after FNA comparing WT and RAG-2-/- groups 
revealed a significant effect of group (Figure 11, F1,52 = 10.566, p = 0.002) and 
postoperative time (F4,52 = 3.473, p = 0.014). In the WT group, axotomy significantly 
increased Fas expression relative to the uninjured control at 7, 14, 28, and 56 dpo (70 ± 
12%, 62 ± 16%, 62 ± 17%, 63 ± 21%, respectively; p < 0.05). In the RAG-2-/- group, Fas 
expression was not significantly elevated relative to baseline after axotomy at any of the 
examined timepoints. There was a statistically significant difference between the WT and 
RAG-2-/- groups at both 7 and 14 dpo (p = 0.002, 0.043, respectively). These findings 
suggest that Fas expression is not correlated with the increased neuronal loss observed in 
immunodeficient mice.  
With adoptive transfer of WT CD4+ T cells, Fas expression differed significantly 
from baseline at 28 and 56 dpo (76 ± 14%, 84 ± 29%, respectively; p < 0.05). There were 
statistically significant differences between WT and RAG-2-/- + WT CD4+ groups at 7 
dpo (p = 0.004). Comparing RAG-2-/- and RAG-2-/- + WT CD4+ groups also revealed 
significant differences in Fas expression at 56 dpo (p = 0.006). These data suggest that 
CD4+ T cells do not affect the early expression of Fas, however late expression of Fas 
does appear to be regulated by the adaptive arm of the immune system.  
 
4.2.4.4. nNos  
As described in the Fas section, nNos is a terminal step of the Fas signaling 
cascade that leads to apoptosis. Additionally, in the CNS, nNos expression is specifically 
located within MN, allowing it to be utilized as an indicator of MN-specific cell death 
(Raoul et al., 2002; Raoul et al., 2006; Haulcomb et al., 2014).  
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Analysis of nNos expression after FNA comparing WT and RAG-2-/- groups 
revealed a significant effect of postoperative time (Figure 12, F4,44 = 4.036, p = 0.007). In 
the WT group, axotomy significantly increased nNos relative to the uninjured control 
only at 56 dpo (26 ± 16%, respectively; p < 0.05). In the RAG-2-/- group, nNos expression 
was not significantly elevated relative to baseline after axotomy at any of the examined 
timepoints. There was a statistically significant difference between the WT and RAG-2-/- 
groups at 28 dpo (p = 0.042). These findings suggest that nNos expression, at most, is 
minorly associated with the increased neuronal loss observed at 28 dpo in 
immunodeficient mice.  
With adoptive transfer of WT CD4+ T cells, nNos expression differs significantly 
from baseline at 56 dpo (4 ± 10%, 13 ± 8%, 23 ± 4%, 92 ± 23%, respectively; p < 0.05). 
There were statistically significant differences between WT and RAG-2-/- + WT CD4+ 
groups at 56 dpo (p < 0.001). Comparing RAG-2-/- and RAG-2-/- + WT CD4+ groups also 
revealed significant differences in nNos expression at 56 dpo (p < 0.001). These data 
suggest that CD4+ T cells do not significantly modify nNos expression except at the 
latest stage of the timecourse.  
 
4.3. Aim 3: Analyze gene expression profile changes after facial nerve axotomy in 
mice immunoreconstituted with mSOD1 whole splenocytes or mSOD1 CD4+ T cells 
4.3.1. Motoneuron regeneration response 
4.3.1.1. Gap-43 
Comparing RAG-2-/- + WT WS mice to WT revealed a significant effect of both 
group (Figure 13A, F1,38 = 24.023, p < 0.001) and postoperative time (F3,38 = 39.362, p < 
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0.001). In the RAG-2-/- + WT WS group, Gap-43 expression was significantly increased 
relative to uninjured control at 7, 14, and 28 dpo, then levels returned to baseline at 56 
dpo (1552 ± 129%, 2064 ± 258%, 1075 ± 305%, respectively; p < 0.05). Gap-43 
expression was significantly increased in RAG-2-/- + WT WS mice relative to WT at 7, 
14, and 28 dpo (p = 0.044, <0.001, 0.002, respectively). These results indicate that 
provision of WS results in a significant increase in the MN regeneration response relative 
to WT, however this increased gene expression does not seem to translate to increased 
FMN survival after FNA.  
When RAG-2-/- + mSOD1 WS mice were compared to WT, a significant effect of 
group (Figure 13B, F1,41 = 31.420, p < 0.001) and postoperative time (F3,41 = 17.889, p < 
0.001) was observed. Additionally, there was a significant interaction between group × 
postoperative time (F3,41 = 3.839, p = 0.016). In the RAG-2-/- + mSOD1 WS group, Gap-
43 expression was significantly increased relative to uninjured control at 7, 14, and 28 
dpo, then levels returned to baseline at 56 dpo (3412 ± 662%, 2845 ± 470%, 1370 ± 
373%, respectively; p < 0.05). Gap-43 expression was significantly increased in RAG-2-/- 
+ mSOD1 WS mice relative to WT at 7, 14, and 28 dpo (p < 0.001, <0.001, 0.030, 
respectively). These results indicate that mSOD1 WS are also capable of augmenting the 
MN regeneration response.  
When the RAG-2-/- + mSOD1 WS and RAG-2-/- + WT WS groups were 
compared, the mSOD1 WS treatment resulted in a significantly increased Gap-43 
expression response at 7 dpo (Figure 13C, p = 0.002), and the groups had similar 
responses for the remainder of the time course. This elevated Gap-43 expression in the 
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RAG-2-/- + mSOD1 WS group is an intriguing finding given the increased FMN death 
observed in these animals after FNA.  
When RAG-2-/- + mSOD1 CD4+ T cell mice were compared to WT, a significant 
effect of group (Figure 13D, F1,42 = 36.893, p < 0.001) and postoperative time (F3,42 = 
45.542, p < 0.001) was observed. Additionally, there was a significant interaction 
between group × postoperative time (F3,42 = 8.172, p < 0.001). In the RAG-2-/- + mSOD1 
CD4+ group, Gap-43 expression was significantly increased relative to uninjured control 
at 7, 14, and 28 dpo, then levels returned to baseline at 56 dpo (2122 ± 293%, 3064 ± 
395%, 820 ± 218%, respectively; p < 0.05). Gap-43 expression was significantly 
increased in RAG-2-/- + mSOD1 CD4+ mice relative to WT at 7 and 14 dpo (p = 0.001, 
<0.001, respectively). These results indicate that mSOD1 CD4+ T cells increase the MN 
regeneration response relative to normal baseline.  
When the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + WT CD4+ groups were 
compared, the mSOD1 CD4+ treatment resulted in a significantly increased Gap-43 
expression response at 7 and 14 dpo (Figure 13E, p = 0.003, <0.001). This elevated Gap-
43 expression in the early phase suggests that the SOD1 mutation within the T cell results 
in a differential induction of the MN regenerative response relative to WT CD4+ T cells. 
Comparing the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + mSOD1 WS groups 
revealed a significant difference in Gap-43 expression at 7 dpo (Figure 13F, p = 0.019). 
Despite the greater FMN loss observed in the RAG-2-/- + mSOD1 WS group, there is a 
significantly greater MN regeneration response observed in this group in the early phase 
post-injury relative to the mSOD1 CD4+ T cell recipient group.  
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4.3.1.2. βII-tubulin 
Comparing RAG-2-/- + WT WS mice to WT revealed a significant effect of both 
group (Figure 14A, F1,33 = 15.900, p < 0.001) and postoperative time (F3,33 = 67.591, p < 
0.001). In the RAG-2-/- + WT WS group, βII-tubulin expression was significantly 
increased relative to uninjured control at 7, 14, and 28 dpo, then levels returned to 
baseline at 56 dpo (198 ± 6%, 216 ± 9%, 127 ± 20%, respectively; p < 0.05). βII-tubulin 
expression was significantly increased in RAG-2-/- + WT WS mice relative to WT at 14 
and 28 dpo (p = 0.015, <0.001, respectively). These data indicate that provision of WS 
results in a significant increase in the MN regeneration response relative to WT.  
When RAG-2-/- + mSOD1 WS mice were compared to WT, a significant effect of 
group (Figure 14B, F1,37 = 4.829, p = 0.034) and postoperative time (F3,37 = 53.941, p < 
0.001) were observed. In the RAG-2-/- + mSOD1 WS group, βII-tubulin expression was 
significantly increased relative to uninjured control at 7, 14, and 28 dpo, then levels 
returned to baseline at 56 dpo (160 ± 12%, 206 ± 21%, 113 ± 13%, respectively; p < 
0.05). βII-tubulin expression was significantly increased in RAG-2-/- + mSOD1 WS mice 
relative to WT at 28 dpo (p = 0.006). These results indicate that mSOD1 WS can 
modestly augment the MN regeneration response.  
When the RAG-2-/- + mSOD1 WS and RAG-2-/- + WT WS groups were 
compared, there were no significant differences in the βII-tubulin expression response 
(Figure 14C). 
When RAG-2-/- + mSOD1 CD4+ T cell mice were compared to WT, a significant 
effect of group (Figure 14D, F1,38 = 6.392, p = 0.016) and postoperative time (F3,38 = 
69.531, p < 0.001) were observed. Additionally, there was a significant interaction 
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between group × postoperative time (F3,38 = 5.568, p = 0.003). In the RAG-2-/- + mSOD1 
CD4+ group, βII-tubulin expression was significantly increased relative to uninjured 
control at 7, 14, and 28 dpo, then levels returned to baseline at 56 dpo (162 ± 7%, 200 ± 
19%, 134 ± 9%, respectively; p < 0.05). βII-tubulin expression was significantly increased 
in RAG-2-/- + mSOD1 CD4+ mice relative to WT at 28 dpo (p < 0.001). These results 
indicate that mSOD1 CD4+ T cells modestly increase the MN regeneration response 
relative to normal baseline.  
When the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + WT CD4+ groups were 
compared, the mSOD1 CD4+ treatment resulted in a significantly increased βII-tubulin 
expression response at 28 dpo (Figure 14E, p = 0.040). This elevated βII-tubulin 
expression suggests that the mSOD1 mutation within the T cell results in a differential 
induction of the MN regenerative response relative to WT CD4+ T cells. 
Comparing the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + mSOD1 WS groups 
revealed no significant differences in βII-tubulin throughout the timecourse (Figure 14F). 
Despite the greater FMN loss observed in the RAG-2-/- + mSOD1 WS group, there is a 
significantly greater MN regeneration response observed in this group in the early phase 
post-injury relative to the mSOD1 CD4+ T cell recipient group.  
 
4.3.2. Glial activation response 
4.3.2.1. Gfap 
Comparing RAG-2-/- + WT WS mice to WT revealed a significant effect of both 
group (Figure 15A, F1,34 = 98.170, p < 0.001) and postoperative time (F3,34 = 4.847, p = 
0.006) on Gfap expression. In the RAG-2-/- + WT WS group, Gfap expression was 
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significantly increased relative to uninjured control at 7, 14, 28, and 56 dpo (2234 ± 
213%, 2313 ± 255%, 2175 ± 435%, 1492 ± 4%, respectively; p < 0.05). Gfap expression 
was significantly increased in RAG-2-/- + WT WS mice relative to WT at 7, 14, 28, and 
56 dpo (p < 0.001 for each). These results indicate that adoptive transfer of WS results in 
a significant increase in the astrocyte activation response relative to WT.  
When RAG-2-/- + mSOD1 WS mice were compared to WT, a significant effect of 
group (Figure 15B, F1,38 = 45.296, p < 0.001) and postoperative time (F3,38 = 5.103, p = 
0.005) was observed. In the RAG-2-/- + mSOD1 WS group, Gfap expression was 
significantly increased relative to uninjured control at 7, 14, 28, and 56 dpo (2205 ± 
178%, 2681 ± 572%, 2080 ± 446%, 1116 ± 254%, respectively; p < 0.05). Gfap 
expression was significantly increased in RAG-2-/- + mSOD1 WS mice relative to WT at 
7, 14, 28, and 56 dpo (p < 0.001 for each). These results indicate that mSOD1 WS are 
also capable of inducing a strong astrocyte activation response.  
When the RAG-2-/- + mSOD1 WS and RAG-2-/- + WT WS groups were 
compared, there were no significant differences in the Gfap expression response (Figure 
15C). 
When RAG-2-/- + mSOD1 CD4+ T cell mice were compared to WT, a significant 
effect of group (Figure 15D, F1,39 = 87.272, p < 0.001) and postoperative time (F3,39 = 
3.704, p = 0.019) was observed. In the RAG-2-/- + mSOD1 CD4+ group, Gfap expression 
was significantly increased relative to uninjured control at 7, 14, 28, and 56 dpo (2203 ± 
385%, 3138 ± 270%, 2969 ± 313%, 1859 ± 515%, respectively; p < 0.05). Gfap 
expression was significantly increased in RAG-2-/- + mSOD1 CD4+ mice relative to WT 
at 7, 14, 28, and 56 dpo (p = 0.002, <0.001, <0.001, <0.001, respectively) These results 
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indicate that mSOD1 CD4+ T cells also significantly increase the astrocyte activation 
response relative to normal baseline.  
When the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + WT CD4+ groups were 
compared, the mSOD1 CD4+ treatment resulted in a significantly increased Gfap 
expression response at all post-axotomy timepoints (Figure 15E, p < 0.001 for each). This 
elevated Gfap expression suggests that mSOD1 CD4+ T cell differentially affect the 
astrocyte activation response relative to WT CD4+ T cells. 
Comparing the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + mSOD1 WS groups 
revealed no significant differences in Gfap levels throughout the timecourse (Figure 15F). 
Despite the greater FMN loss observed in the RAG-2-/- + mSOD1 WS group, there is 
comparable astrocyte activation observed between the two mSOD1 immunoreconstituted 
groups.  
 
4.3.2.2. Cd68 
Comparing RAG-2-/- + WT WS mice to WT revealed a significant effect of 
postoperative time (Figure 16A, F1, 46 = 5.795, p = 0.002) on Cd68 expression. In the 
RAG-2-/- + WT WS group, Cd68 expression was significantly increased relative to 
uninjured control at 7, 14, 28, and 56 dpo (811 ± 55%, 606 ± 49%, 636 ± 92%, 402 ± 
106%, respectively; p < 0.05). There were no significant differences in Cd68 expression 
between RAG-2-/- + WT WS and WT groups. These results indicate that adoptive transfer 
of WS results in an equivalent microglia activation response relative to WT.  
When RAG-2-/- + mSOD1 WS mice were compared to WT, a significant effect of 
postoperative time (Figure 16B, F3,38 = 6.972, p < 0.001) was observed. In the RAG-2-/- + 
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mSOD1 WS group, Cd68 expression was significantly increased relative to uninjured 
control at 7, 14, 28, and 56 dpo (857 ± 155%, 925 ± 125%, 920 ± 207%, 361 ± 76%, 
respectively; p < 0.05). Cd68 expression was not significantly different in RAG-2-/- + 
mSOD1 WS mice relative to WT. These results indicate that mSOD1 WS are also 
capable of inducing a microglia activation response comparable to WT.  
When the RAG-2-/- + mSOD1 WS and RAG-2-/- + WT WS groups were 
compared, there were no significant differences in the Cd68 expression response (Figure 
16C). 
When RAG-2-/- + mSOD1 CD4+ T cell mice were compared to WT, a significant 
effect of postoperative time (Figure 16D, F1,50 = 9.169, p < 0.001) was observed. In the 
RAG-2-/- + mSOD1 CD4+ group, Cd68 expression was significantly increased relative to 
uninjured control at 7, 14, 28, and 56 dpo (772 ± 127%, 725 ± 37%, 1063 ± 99%, 335 ± 
63%, respectively; p < 0.05). Cd68 expression was significantly increased in RAG-2-/- + 
mSOD1 CD4+ mice relative to WT at 28 dpo (p = 0.022) These results indicate that 
mSOD1 CD4+ T cells can modestly augment the microglia response at the late stage 
post-axotomy, otherwise the response is largely equivalent to WT.  
When the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + WT CD4+ groups were 
compared, the mSOD1 CD4+ treatment results in a significantly increased Cd68 
expression response at 28 dpo (Figure 16E, p = 0.001). This elevated Cd68 expression 
suggests that the there are some differences in the regulatory effects of mSOD1 and WT 
CD4+ T cells. 
Comparing the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + mSOD1 WS groups 
revealed no significant differences in Cd68 levels throughout the timecourse (Figure 
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16F). Despite the decreased FMN survival in the RAG-2-/- + mSOD1 WS group, there is 
comparable microglia activation observed between the two mSOD1 
immunoreconstitution groups.  
 
4.3.3. Inflammatory gene expression 
4.3.3.1. Tnfα 
Comparing RAG-2-/- + WT WS mice to WT revealed a significant effect of 
postoperative time (Figure 17A, F3, 28 = 9.060, p < 0.001) on Tnfα expression. There was 
also a significant interaction between group × postoperative time (F3, 28 = 3.507, p = 
0.028). In the RAG-2-/- + WT WS group, Tnfα expression was significantly increased 
relative to uninjured control at 7 and 28 dpo (2.71 x 10-4 ± 6.65 x 10-5, 3.45 x 10-4 ± 1.20 
x 10-4, respectively; p < 0.05). There were no significant differences in Tnfα expression 
between RAG-2-/- + WT WS and WT groups. These results indicate that adoptive transfer 
of WS results in an equivalent inflammatory cytokine expression response relative to 
WT.  
When RAG-2-/- + mSOD1 WS mice were compared to WT, a significant effect of 
postoperative time (Figure 17B, F3,29 = 7.698, p < 0.001) was observed. There was also a 
significant interaction between group × postoperative time (F3, 29 = 4.187, p = 0.014). In 
the RAG-2-/- + mSOD1 WS group, Tnfα expression was significantly increased relative to 
uninjured control at 7, 14, and 28 dpo (2.16 x 10-4 ± 5.83 x 10-5, 2.70 x 10-4 ± 1.33 x 10-5, 
3.67 x 10-4 ± 4.19 x 10-5, respectively; p < 0.05). Tnfα expression was significantly 
different in RAG-2-/- + mSOD1 WS mice relative to WT at 7 and 28 dpo (p = 0.011, 
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0.040, respectively). These results indicate that mSOD1 WS elicit a differential Tnfα 
expression response at both early and late post-axotomy phases.  
When the RAG-2-/- + mSOD1 WS and RAG-2-/- + WT WS groups were 
compared, there were no significant differences in the Tnfα expression response (Figure 
17C). 
When RAG-2-/- + mSOD1 CD4+ T cell mice were compared to WT, a significant 
effect of postoperative time (Figure 17D, F1,29 = 8.417, p < 0.001) was observed. There 
was also a significant interaction between group × postoperative time (F3, 29 = 3.387, p = 
0.031). In the RAG-2-/- + mSOD1 CD4+ group, Tnfα expression was significantly 
increased relative to uninjured control at 28 dpo (3.10 x 10-4 ± 8.41 x 10-5; p < 0.05). 
There was a significant difference between WT and RAG-2-/- + mSOD1 CD4+ expression 
of Tnfα at 7 dpo (p = 0.027).  
When the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + WT CD4+ groups were 
compared, the mSOD1 CD4+ treatment results in a significantly decreased Tnfα 
expression response at 14 dpo (Figure 17E, p = 0.003). This elevated Tnfα expression 
suggests that the mSOD1 CD4+ T cells differentially induce Tnfα expression relative to 
WT CD4+ T cells. 
Comparing the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + mSOD1 WS groups 
revealed no significant differences in Tnfα levels throughout the timecourse (Figure 17F). 
Although greater FMN loss occurs in the RAG-2-/- + mSOD1 WS group after FNA, the 
Tnfα expression profiles between the two mSOD1 immunoreconstituted groups are 
similar.  
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4.3.4. Cell death receptor expression 
4.3.4.1. Tnfr1 
Comparing RAG-2-/- + WT WS mice to WT revealed a significant effect of 
postoperative time (Figure 18A, F3, 34 = 5.112, p = 0.005) on Tnfr1 expression. In the 
RAG-2-/- + WT WS group, Tnfr1 expression was significantly increased relative to 
uninjured control at 7, 14, and 28 dpo (84 ± 2%, 96 ± 4%, 86 ± 17%, respectively; p < 
0.05). There were no significant differences in Tnfr1 expression between RAG-2-/- + WT 
WS and WT groups. These results indicate that adoptive transfer of WS results in an 
equivalent Tnfr1 expression response relative to WT.  
When RAG-2-/- + mSOD1 WS mice were compared to WT, a significant effect of 
postoperative time (Figure 18B, F3,38 = 6.638, p = 0.001) was observed. In the RAG-2-/- + 
mSOD1 WS group, Tnfr1 expression was significantly increased relative to uninjured 
control at 7, 14, 28, and 56 dpo (108 ± 5%, 102 ± 13%, 95 ± 13%, 44 ± 9%, respectively; 
p < 0.05). Tnfr1 expression was not significantly different in RAG-2-/- + mSOD1 WS 
mice relative to WT. These results indicate that mSOD1 WS are also capable of inducing 
a Tnfr1 expression response comparable to WT.  
When the RAG-2-/- + mSOD1 WS and RAG-2-/- + WT WS groups were 
compared, there were no significant differences in the Tnfr1 expression response (Figure 
18C). 
When RAG-2-/- + mSOD1 CD4+ T cell mice were compared to WT, a significant 
effect of postoperative time (Figure 18D, F3,39 = 4.718, p = 0.007) was observed. In the 
RAG-2-/- + mSOD1 CD4+ group, Tnfr1 expression was significantly increased relative to 
uninjured control at 7, 14, 28, and 56 dpo (88 ± 7%, 102 ± 11%, 91 ± 16%, 52 ± 9%, 
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respectively; p < 0.05). There were no significant differences in Tnfr1 expression 
between RAG-2-/- + mSOD1 CD4+ mice and WT mice. These results indicate that 
mSOD1 CD4+ T cells elicit a Tnfr1 expression response equivalent to WT.  
When the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + WT CD4+ groups were 
compared, the WT CD4+ treatment results in a significantly increased Tnfr1 expression 
response at 7, 14, and 28 dpo (Figure 18E, p < 0.001, <0.001, and 0.015, respectively). 
These differential Tnfr1 expression responses suggest that mSOD1 mutation affects the 
activity of isolated CD4+ T cells. 
Comparing the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + mSOD1 WS groups 
revealed no significant differences in Tnfr1 levels throughout the timecourse (Figure 
18F).  
 
4.3.4.2. Fas 
Comparing RAG-2-/- + WT WS mice to WT revealed a significant effect of 
postoperative time (Figure 19A, F4, 47 = 3.420, p = 0.016) on Fas expression. In the RAG-
2-/- + WT WS group, Fas expression was significantly increased relative to uninjured 
control at 28 and 56 dpo (65 ± 7%, 65 ± 31%, respectively; p < 0.05). There was a 
significant difference in Fas expression between RAG-2-/- + WT WS and WT groups at 7 
dpo (p = 0.024). These results indicate that adoptive transfer of WS does not increase Fas 
expression to WT levels in the early post-axotomy phase.  
When RAG-2-/- + mSOD1 WS mice were compared to WT, a significant effect of 
postoperative time (Figure 19B, F4,50 = 6.602, p < 0.001) was observed. In the RAG-2-/- + 
mSOD1 WS group, Fas expression was significantly increased relative to uninjured 
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control at 7, 14, 28, and 56 dpo (72 ± 23%, 55 ± 9%, 133 ± 23%, 82 ± 9%, respectively; p 
< 0.05). Fas expression was significantly different in RAG-2-/- + mSOD1 WS mice 
relative to WT at 28 dpo (p = 0.006). These results indicate that mSOD1 WS restore Fas 
expression at the early post-axotomy phase relative to WT levels, and also increase Fas 
expression in the late post-axotomy phase.  
When the RAG-2-/- + mSOD1 WS and RAG-2-/- + WT WS groups were 
compared, there were significant differences in the Fas expression response at 7 and 28 
dpo (Figure 19C, p = 0.025, 0.013, respectively). These findings demonstrate that WT 
WS do not affect early Fas expression, but mSOD1 WS do. At 28 dpo, mSOD1 WS 
significantly increase Fas expression. 
When RAG-2-/- + mSOD1 CD4+ T cell mice were compared to WT, a significant 
effect of postoperative time (Figure 19D, F3,44 = 7.115, p < 0.001) was observed. Also, 
there was a significant interaction between group × postoperative time (F3,44 = 7.919, p < 
0.001). In the RAG-2-/- + mSOD1 CD4+ group, Fas expression was significantly 
increased relative to uninjured control at 28 and 56 dpo (191 ± 32%, 81 ± 15%, 
respectively; p < 0.05). There was a significant difference in Fas expression between 
RAG-2-/- + mSOD1 CD4+ mice and WT mice at 28 dpo (p < 0.001). These results 
indicate that mSOD1 CD4+ T cells also increase Fas expression in the late post-axotomy 
phase. 
When the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + WT CD4+ groups were 
compared, the mSOD1 CD4+ treatment resulted in a significantly increased Fas 
expression response at 28 dpo (Figure 19E, p < 0.001). These findings suggest that 
mSOD1 mutation affects T cell induction of Fas expression.  
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Comparing the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + mSOD1 WS groups 
revealed that the mSOD1 CD4+ T cells elicit a significantly greater Fas expression at 28 
dpo (Figure 19F, p = 0.038). These data show that both mSOD1 lymphocyte groups 
results in augmented Fas expression at both early and late post-axotomy stages, with 
mSOD1 CD4+ T cells eliciting increased Fas expression at the late post-axotomy stage.  
 
4.3.4.3. nNos 
Comparing RAG-2-/- + WT WS mice to WT revealed a significant effect of 
postoperative time (Figure 20A, F3, 34 = 3.333, p = 0.031) on nNos expression. In the 
RAG-2-/- + WT WS group, nNos expression was not significantly different from 
uninjured control at any of the examined timepoints. There were no significant 
differences in nNos expression between RAG-2-/- + WT WS and WT groups. These 
results indicate that adoptive transfer of WS does not result in a differential nNos 
expression response relative to WT.  
When RAG-2-/- + mSOD1 WS mice were compared to WT, a significant effect of 
group (Figure 20B, F1,39 = 9.997, p = 0.003) was observed. In the RAG-2-/- + mSOD1 WS 
group, nNos expression was significantly increased relative to uninjured control at 28 and 
56 dpo (50 ± 25%, 62 ± 20%, respectively; p < 0.05). nNos expression was significantly 
different in RAG-2-/- + mSOD1 WS mice relative to WT at 28 dpo (p = 0.032). These 
results indicate that mSOD1 WS significantly increase nNos expression at the late post-
axotomy phase relative to WT.  
When the RAG-2-/- + mSOD1 WS and RAG-2-/- + WT WS groups were 
compared, there were no significant differences in the nNos expression response profiles 
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(Figure 20C). These findings demonstrate that WT WS and mSOD1 WS elicit 
comparable nNos expression responses. 
When RAG-2-/- + mSOD1 CD4+ T cell mice were compared to WT, a significant 
effect of postoperative time (Figure 20D, F3,38 = 5.804, p = 0.002) was observed. Also, 
there was a significant interaction between group × postoperative time (F3,38 = 4.647, p = 
0.007). In the RAG-2-/- + mSOD1 CD4+ group, nNos expression remained at baseline 
levels for the duration of the timecourse. There was a significant difference in nNos 
expression between RAG-2-/- + mSOD1 CD4+ mice and WT mice at 14 dpo (p = 0.009). 
These results indicate that mSOD1 CD4+ T cells increase nNos expression in the early 
post-axotomy phase. 
When the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + WT CD4+ groups were 
compared, the WT CD4+ treatment resulted in a significantly increased nNos expression 
response at 56 dpo (Figure 20E, p < 0.001). These findings suggest that there is a modest 
differential effect of the mSOD1 mutation on isolated T cell regulation of nNos 
expression at the late post-axotomy phase.  
Comparing the RAG-2-/- + mSOD1 CD4+ and RAG-2-/- + mSOD1 WS groups 
revealed that the mSOD1 WS treatments elicits a significantly greater nNos expression at 
7 and 56 dpo (Figure 20F, p = 0.030, 0.020, respectively). These data show that adoptive 
transfer of mSOD1 WS results in a significantly greater expression of a MN-specific 
death mechanism relative to mSOD1 CD4+ T cells alone.  
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Figure 1: FMN survival in IL-10/GFP mice. 
Average percent FMN survival ± SEM after FNA at 28 dpo.  
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Figure 2: GFAP colocalization with IL-10/GFP. 
 
GFAP fluorescent immunohistochemistry images at 40× magnification for the Ax 
FMNuc throughout the time course with IL-10/GFP reporter (green), GFAP (red), and 
nucleus (DAPI, blue) labeling. Numbers in the left correspond to days post-operation 
(dpo). 
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Figure 3: NeuN colocalization with IL-10/GFP. 
 
Fluorescent immunohistochemistry images at 40× magnification of the Ax FMNuc 
throughout the time course with IL-10/GFP reporter (green), NeuN (red), and nucleus 
(DAPI, blue) labeling. Left column numbers are days post-operation (dpo).   
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Figure 4: FMN survival in CX3CR1-cre/IL-10fl/fl and GFAP-cre/IL-10fl/fl mice. 
Average percent FMN survival ± SEM after FNA at 28 dpo. 
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Figure 5: Gap-43 gene expression profile after FNA in WT, RAG-2-/-, and RAG-2-/- + 
WT CD4+ T cell groups.  
 
mRNA expression of Gap-43 in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05 comparing WT to RAG-2-/-; $: p < 0.05 comparing WT to 
RAG-2-/- + CD4+ T cells; and #: p < 0.05 comparing RAG-2-/- to RAG-2-/- + CD4+ T 
cells. 
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Figure 6: βII-tubulin gene expression profile after FNA in WT, RAG-2-/-, and RAG-2-/- + 
WT CD4+ T cell groups. 
 
mRNA expression of βII-tubulin in the facial motor nucleus following facial nerve 
axotomy (Ax), relative to the control (C) facial motor nucleus. Mean percent change ± 
SEM was plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) 
timepoints. Symbols used: *: p < 0.05 comparing WT to RAG-2-/-; $: p < 0.05 comparing 
WT to RAG-2-/- + CD4+ T cells; and #: p < 0.05 comparing RAG-2-/- to RAG-2-/- + 
CD4+ T cells. 
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Figure 7: Gfap gene expression profile after FNA in WT, RAG-2-/-, and RAG-2-/- + WT 
CD4+ T cell groups. 
 
mRNA expression of Gfap in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05 comparing WT to RAG-2-/-; $: p < 0.05 comparing WT to 
RAG-2-/- + CD4+ T cells; and #: p < 0.05 comparing RAG-2-/- to RAG-2-/- + CD4+ T 
cells. 
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Figure 8: Cd68 gene expression profile after FNA in WT, RAG-2-/-, and RAG-2-/- + WT 
CD4+ T cell groups. 
 
mRNA expression of Cd68 in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05 comparing WT to RAG-2-/-; $: p < 0.05 comparing WT to 
RAG-2-/- + CD4+ T cells; and #: p < 0.05 comparing RAG-2-/- to RAG-2-/- + CD4+ T 
cells. 
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Figure 9: Tnfα gene expression profile after FNA in WT, RAG-2-/-, and RAG-2-/- + WT 
CD4+ T cell groups. 
 
mRNA expression of Tnfα in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05 comparing WT to RAG-2-/-; $: p < 0.05 comparing WT to 
RAG-2-/- + CD4+ T cells; and #: p < 0.05 comparing RAG-2-/- to RAG-2-/- + CD4+ T 
cells. 
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Figure 10: Tnfr1 gene expression profile after FNA in WT, RAG-2-/-, and RAG-2-/- + WT 
CD4+ T cell groups. 
 
mRNA expression of Tnfr1 in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05 comparing WT to RAG-2-/-; $: p < 0.05 comparing WT to 
RAG-2-/- + CD4+ T cells; and #: p < 0.05 comparing RAG-2-/- to RAG-2-/- + CD4+ T 
cells. 
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Figure 11: Fas gene expression profile after FNA in WT, RAG-2-/-, and RAG-2-/- + WT 
CD4+ T cell groups. 
 
mRNA expression of Fas in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05 comparing WT to RAG-2-/-; $: p < 0.05 comparing WT to 
RAG-2-/- + CD4+ T cells; and #: p < 0.05 comparing RAG-2-/- to RAG-2-/- + CD4+ T 
cells. 
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Figure 12: nNos gene expression profile after FNA in WT, RAG-2-/-, and RAG-2-/- + WT 
CD4+ T cell groups. 
 
mRNA expression of nNos in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05 comparing WT to RAG-2-/-; $: p < 0.05 comparing WT to 
RAG-2-/- + CD4+ T cells; and #: p < 0.05 comparing RAG-2-/- to RAG-2-/- + CD4+ T 
cells. 
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Figure 13: Gap-43 gene expression profile after FNA in RAG-2-/- + WT WS, RAG-2-/- + 
mSOD1 WS and RAG-2-/- + mSOD1 CD4+ T cell groups. 
 
mRNA expression of Gap-43 in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05. 
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Figure 14: βII-tubulin gene expression profile after FNA in RAG-2-/- + WT WS, RAG-2-/- 
+ mSOD1 WS and RAG-2-/- + mSOD1 CD4+ T cell groups. 
mRNA expression of βII-tubulin in the facial motor nucleus following facial nerve 
axotomy (Ax), relative to the control (C) facial motor nucleus. Mean percent change ± 
SEM was plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) 
timepoints. Symbols used: *: p < 0.05. 
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Figure 15: Gfap gene expression profile after FNA in RAG-2-/- + WT WS, RAG-2-/- + 
mSOD1 WS and RAG-2-/- + mSOD1 CD4+ T cell groups. 
 
mRNA expression of Gfap in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05. 
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Figure 16: Cd68 gene expression profile after FNA in RAG-2-/- + WT WS, RAG-2-/- + 
mSOD1 WS and RAG-2-/- + mSOD1 CD4+ T cell groups. 
 
mRNA expression of Cd68 in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05. 
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Figure 17: Tnfα gene expression profile after FNA in RAG-2-/- + WT WS, RAG-2-/- + 
mSOD1 WS and RAG-2-/- + mSOD1 CD4+ T cell groups. 
 
mRNA expression of Tnfα in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05. 
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Figure 18: Tnfr1 gene expression profile after FNA in RAG-2-/- + WT WS, RAG-2-/- + 
mSOD1 WS and RAG-2-/- + mSOD1 CD4+ T cell groups. 
 
mRNA expression of Tnfr1 in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05. 
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Figure 19: Fas gene expression profile after FNA in RAG-2-/- + WT WS, RAG-2-/- + 
mSOD1 WS and RAG-2-/- + mSOD1 CD4+ T cell groups. 
 
mRNA expression of Fas in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05. 
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Figure 20: nNos gene expression profile after FNA in RAG-2-/- + WT WS, RAG-2-/- + 
mSOD1 WS and RAG-2-/- + mSOD1 CD4+ T cell groups. 
 
mRNA expression of nNos in the facial motor nucleus following facial nerve axotomy 
(Ax), relative to the control (C) facial motor nucleus. Mean percent change ± SEM was 
plotted across uninjured (0) and 7, 14, 28, and 56 days post-operation (dpo) timepoints. 
Symbols used: *: p < 0.05. 
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CHAPTER 5: DISCUSSION 
5.1. Aim 1 Discussion 
Facial nerve axotomy in immunodeficient mice causes significantly more 
motoneuron loss relative to WT mice, indicating that the immune system is 
neuroprotective. This immune-mediated neuroprotection has been subsequently shown to 
involve both CD4+ T cells and IL-10. IL-10 is an important immunoregulatory factor that 
reduces inflammatory cytokine production, promotes tissue repair, and exerts therapeutic 
benefits in many neurodegenerative diseases, including ALS (Kiyota et al., 2012; Joniec-
Maciejak et al., 2014; Gravel et al., 2016; Zhou et al., 2016). While IL-10 is necessary for 
CD4+ T cell-mediated neuroprotection after target disconnection, it appears that CD4+ T 
cells are not the source of IL-10 (Xin et al., 2011). Rather, evidence in the literature 
suggests that neuroprotective IL-10 must derive from a CNS source, in part, because it 
cannot cross the BBB (Kastin et al., 2003; Xin et al., 2011). To fully understand the 
mechanism of CD4+ T cell-mediated neuroprotection, it is necessary to identify the cell 
source of IL-10 and its functional significance relative to motoneuron survival after 
injury.  
There is evidence that microglia are the IL-10 source based on the M1/M2 
microglia paradigm characterizing neuroprotective M2 microglia as robust manufacturers 
of IL-10 (Tam & Ma, 2014). Axotomy-activated T cells require antigen presentation in 
the CNS for neuroprotective secondary re-activation to occur, and microglia are the 
primary APC in the CNS (Aloisi, 1999; Byram et al., 2004; Byram et al., 2006). 
Furthermore, T cell-derived IL-4 is required for immune-mediated neuroprotection, and 
IL-4 promotes the M2 microglia phenotype (Deboy et al., 2006b; Chhor et al., 2013; Tam 
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& Ma, 2014). Also, IL-10 receptors are expressed by astrocytes and neurons in the facial 
motor nucleus (Xin et al., 2011). Altogether, this evidence leads to the hypothesis that 
antigen presentation by microglia activates IL-4 production by CD4+ T cells, which, in 
turn, induces the M2 microglia phenotype. These M2 microglia produce IL-10 that binds 
to IL-10 receptors on astrocytes and neurons to regulate their post-axotomy response to 
promote neuronal survival.  
 
5.1.1. Microglia are an IL-10 source in the axotomized facial motor nucleus 
Microglia production of IL-10 before and after facial nerve axotomy was assessed 
using multiple approaches. IL-10 protein quantification from isolated microglia in the 
cre/lox mouse validation process proves that microglia are a source of IL-10. However, 
the kinetics of IL-10 production by microglia within the facial motor nucleus after facial 
nerve axotomy remain unknown. Technical difficulties arose when immunofluorescent 
colocalization analysis was performed on IL-10/GFP reporter mice with microglia-
specific markers. Specifically, the tissue fixation required to preserve microglia-specific 
antigens ablates the GFP signal. At this time, the conclusion can be made that microglia 
produce IL-10, but their production of IL-10 after facial nerve axotomy has yet to be 
determined.  
To address the issue of microglial IL-10 production after FNA, three approaches 
can be explored. First, alternative tissue fixation strategies could be tested to see if they 
can preserve both GFP signal and microglia antigenicity. 1% PFA or paraformaldehyde-
lysine-periodate (PLP) fixatives are used in other studies to preserve GFP fluorescence 
(Komis, 2012; Bond, 2013). If this protocol modification succeeds, the amount of 
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colocalization between the different cell markers and GFP can be quantified using 
ImageJ, adding a more objective measure of cell-specific IL-10 production. Second, use 
of a direct IL-10 antibody could be assessed (Park et al., 2007; Wada et al., 2013). This 
approach was initially avoided because an IL-10 antibody could label both IL-10 within 
producing cells and effector IL-10 bound to cell receptors, which would confuse which 
cell is the source of IL-10. A colocalization assessment of the IL-10 antibody against the 
GFP fluorescence from the IL-10/GFP reporter mouse would support or refute this 
concern. If the IL-10 antibody staining recapitulated the GFP distribution in the IL-
10/GFP reporter, it could be used in immunohistochemistry colocalization with microglia 
markers on perfused WT brain tissue. Third, flow cytometry could be performed on the 
FMNuc to characterize IL-10 expression in a cell-specific manner (Cardona et al., 2006; 
Sun et al., 2009). A potential pitfall of this approach is that the small cell population of 
the FMNuc (about 2,000 FMN and 4,000-20,000 glia) may lead to detection issues. To 
resolve this problem, FMNuc from multiple animals could be pooled to reach sufficient 
cell numbers for flow cytometry. An advantage of this method is that intracellular IL-10 
could be directly immunolabeled in WT animals, avoiding the expense associated with 
IL-10/GFP reporter mice (Xin et al., 2008). Also, mean fluorescence intensity could be 
measured, allowing for quantification of IL-10 expression by each cell type (Xin et al., 
2008). Measuring microglia production of IL-10 after FNA will help in determining the 
sequence of events involved in immune-mediated neuroprotection. 
Numerous studies describe IL-10 production by microglia. Transcriptomic 
analysis of IL-10 expression in the brain indicates that microglia express more IL-10 
transcript than any other CNS cell type (Zhang et al., 2014). Multiple in vitro 
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experiments describe microglial IL-10 mRNA and protein production in both homeostatic 
conditions and after LPS challenge (Ledeboer et al., 2002; Tam & Ma, 2014; Ooi et al., 
2015; Chu et al., 2016; Gravel et al., 2016). In vivo LPS challenge also induces IL-10 
production by microglia (Gravel et al., 2016). An analysis of cell-specific IL-10 
production after LPS injection into rat cerebral cortex using immunofluorescent 
colocalization determined that microglia are the predominant producers of IL-10 (Park et 
al., 2007). In normal human brain tissue, microglia are not shown to express IL-10, 
however in multiple sclerosis lesions and areas of cerebral infarction, microglial 
expression of IL-10 is observed (Hulshof et al., 2002). Altogether, our work supports the 
evidence in the literature that microglia produce IL-10, and future experiments will 
determine the kinetics of IL-10 expression by microglia after facial nerve injury.  
 
5.1.2. Astrocyte expression of IL-10 is induced by axotomy 
Astrocyte expression of IL-10 was examined using colocalization 
immunohistochemistry on IL-10/GFP reporter mice. Unexpectedly, an induction of IL-10 
expression in astrocytes following axotomy was observed. The increase in IL-10 
expression coincides with the developing astrocyte activation response after axotomy, 
with maximal astrocytic expression of IL-10 at the late post-axotomy phase. This finding 
was surprising given that most literature focuses on microglia as the primary IL-10 
source. Part of this microglia-centric focus derives from the Ledeboer et al. 2002 study 
which compared astrocyte and microglia IL-10 mRNA and protein production in vitro. 
This study concluded that microglia express significantly greater quantities of IL-10 at 
homeostasis and after LPS stimulation than astrocytes. A study of LPS injection into rat 
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cerebral cortex identified a few astrocytes as immunopositive for IL-10 at 1 dpo using 
IHC, however microglia colocalized much more strongly with IL-10 at this timepoint 
(Park et al., 2007). In human brain tissue, astrocytes are the predominant producer of IL-
10. Astrocytes constitutively express IL-10 in normal human brain tissue, and in multiple 
sclerosis lesions and infarcted areas, greater IL-10 expression was observed in astrocytes 
relative to microglia. Primary human astrocyte in vitro examination confirms these 
findings (Hulshof et al., 2002). Further evidence for IL-10 expression by astrocytes 
comes from identification of microRNA 181 (miR-181) as a key regulator of astrocyte 
cytokine expression. Knockdown of miR-181 leads to proinflammatory cytokine 
production, whereas overexpression of miR-181 significantly increases IL-10 production 
by astrocytes in vitro (Hutchison et al., 2013). Altogether, these findings support the 
literature describing astrocyte production of IL-10.  
One shortcoming of this experiment is that GFAP does not label astrocytes in the 
uninjured facial motor nucleus (Graeber et al., 1988; Hermanson et al., 1995; Laskawi & 
Wolff, 1996; Klein et al., 1997; Horvat et al., 2001). Because our results suggest that 
astrocytes may be a significant source of IL-10 after FNA, it is imperative to assess 
astrocyte production both pre- and post-injury. To resolve this problem, an ALDH1L1 
antibody could be employed, which labels a broader population of astrocytes (Zamanian 
et al., 2012; Tyzack et al., 2014). ALDH1L1, also known as FDH (10-
formyltetrahydrofolate dehydrogenase), is a protein that participates in the production of 
tetrahydrofolate for nucleotide synthesis and methionine recycling (Krupenko, 2009; 
Yang et al., 2011). Recent studies advocate the use of ALDH1L1 antibody as a superior 
pan-astrocyte marker in comparison to GFAP (Cahoy et al., 2008; Yang et al., 2011; 
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Tong et al., 2014). In addition, combining astrocyte labeling with quantitative 
measurement of colocalization with GFP will provide an objective characterization of the 
effect of axotomy on astrocytic IL-10 production. In summary, our findings define a role 
for astrocytes in anti-inflammatory cytokine production after FNA. 
 
5.1.3. Constitutive neuronal expression of IL-10 is not impacted by axotomy 
Neuronal expression of IL-10 was also assessed in this study. The colocalization 
analysis utilizing IL-10/GFP mice reveals that facial motoneurons constitutively express 
IL-10, and axotomy does not alter this expression. This finding was unexpected given 
that most other studies do not report neuronal expression of IL-10. Both transcriptomic 
and proteomic analysis of neurons do not indicate that neurons are significant producers 
of IL-10, however homeostatic IL-16 and IL-18 production is described (Yu et al., 2004; 
Yang et al., 2005; Liao et al., 2008; Dammer et al., 2013; Zhang et al., 2014; Sharma et 
al., 2015). An extensive human proteome characterization project used 
immunohistochemistry to determine that neurons highly express IL-10, and glial cells 
express comparatively low levels of IL-10 (Uhlen 2015). Neuronal expression of other 
cytokines, such as TNFα, CCL2, IL-6, and TGF-β have been reported both constitutively 
and after injury (Liu et al., 1994; Acarin et al., 2000; Banisadr et al., 2005; White et al., 
2005). A previous study from our laboratory determined that CCL11 expression shifts 
from neurons to astrocytes in the axotomized facial motor nucleus. As the post-axotomy 
response resolves, neurons regain CCL11 expression (Wainwright et al., 2009c). Given 
that IL-10 protein levels do not change in the facial motor nucleus after axotomy, a 
similar neuron-to-glia shift in IL-10 production could be predicted, however is not 
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evident in the histology in this study (Xin et al., 2011). A quantitative analysis of cell-
specific IL-10 production in the facial motor nucleus is necessary to objectively describe 
the immunofluorescent findings. 
Overall, further characterization of cytokine expression by neurons will help 
understand their importance in CNS health and disease. Our novel finding of IL-10 
production by neurons represents an understudied area of neuroscience and could be a 
significant contributor to neuroprotective mechanisms.  
 
5.1.4. Neither microglial nor astrocytic IL-10 are required for neuronal survival after 
axotomy  
The functional significance of cell-specific IL-10 production after nerve injury 
was assessed using conditional knockdown mice. Our hypothesis was that microglia-
specific IL-10 was imperative for immune-mediated neuroprotection. When IL-10 was 
knocked down in microglia, no negative effects on facial motoneuron survival after 
axotomy were observed, refuting this hypothesis. This finding makes sense in the context 
of the histology data indicating that microglia, astrocytes, and neurons all produce IL-10. 
With the discovery that IL-10 expression is induced in astrocytes after axotomy, the 
effect of IL-10 knockdown in astrocytes was examined, and no effect on motoneuron 
survival after axotomy was observed.  
Together, these data present two possibilities: either a compensatory mechanism 
exists between astrocytes and microglia for IL-10 production, or neuronal IL-10 is 
necessary for neuroprotection. Of these two scenarios, neuronal IL-10 is less likely to be 
the key for neuroprotection because its expression remains unchanged after axotomy. 
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Instead, compensatory mechanisms between astrocytes and microglia to supplement IL-
10 production should be explored. Co-culture studies demonstrate multiple bidirectional 
communication pathways between astrocytes and microglia. For example, when 
astrocytes are mechanically stimulated in co-culture, they release ATP that binds to the 
P2X7 purinergic receptors on microglia, inducing a calcium wave in microglia (Verderio 
& Matteoli, 2001). Conversely, LPS induces microglia to release ATP, which binds to the 
purinergic receptor P2Y1R on astrocytes to increase excitatory postsynaptic currents 
(Pascual et al., 2012). In vitro, astrocyte conditioned media regulates microglia 
production of reactive oxygen species (Min et al., 2006). Microglia conditioned media 
also regulates astrocyte production of tenascin, an extracellular matrix protein (Smith & 
Hale, 1997). Microglia express significantly greater quantities of cytokines after LPS 
challenge when co-cultured with astrocytes than in isolation (Barbierato et al., 2013). 
Transgenic astrocytes that overexpress either IL-6 or IL-10 in vivo induce significant 
morphological and phenotypic changes in microglia (Almolda et al., 2014; Almolda et 
al., 2015; Villacampa et al., 2015). This astrocyte-microglia cooperative effort has 
important implications for neuronal survival after insult. For example, LPS-mediated 
neurotoxicity is alleviated when both astrocytes and microglia are present because 
microglial TNFα induces astrocyte production of BDNF and GDNF, promoting neuronal 
survival (Chen et al., 2015b). Altogether, abundant evidence describes an interdependent 
relationship between astrocytes and microglia, suggesting that a glial compensatory 
mechanism likely supplements IL-10 production in the cre/lox knockdown mouse model. 
To test this hypothesis, a double knockout mouse model could be developed using gene 
editing technology, such as CRISPR/Cas9, to knock out IL-10 in both cell populations 
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simultaneously. This experiment would allow us to determine if neuroprotective IL-10 
derives specifically from glia. 
If glial IL-10 is not responsible for neuroprotection, then neuronal IL-10 
production should be examined. To test if neurons are the IL-10 source, the IL-10 flox 
gene could be crossed with a Thy1-cre or a neurofilament light chain-cre mouse 
(Pramatarova et al., 2001; Lino et al., 2002; Jaarsma et al., 2008). Given that the 
immunofluorescence experiment identified neurons as a constitutive source of IL-10, 
neuronal IL-10 may be neuroprotective after axotomy, or it could serve an important 
homeostatic function in the facial motor nucleus. Development of this mouse model may 
reveal a novel interaction between neurons and the microenvironment mediated by IL-10 
signaling. Identifying which cells are responsible for IL-10 production after axotomy is 
important to provide a detailed mechanistic understanding of the function of IL-10 within 
the CD4+ T cell-mediated neuroprotection paradigm.  
 
5.1.5. IL-10 in other neurological diseases 
The study of the cell source of IL-10 and its expression after injury has broad 
implications for a range of neurological diseases. In many CNS injury and disease 
models, IL-10 has a neuroprotective function (Kwilasz et al., 2015). IL-10 promotes 
dopaminergic neuron survival in rodent models of Parkinson’s disease (Schwenkgrub et 
al., 2013; Joniec-Maciejak et al., 2014). In experimental autoimmune encephalitis (EAE), 
a model of multiple sclerosis, IL-10 deficiency worsens disease progression. In contrast, 
IL-10 overexpression in T cells confers resistance to EAE, likely due to inhibition of 
autoimmune Th1 cell development by IL-10 (Bettelli et al., 1998). IL-10 is important for 
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neuroprotection after spinal cord injury, and administration of IL-10 after spinal cord 
injury improves motor function and decreases pain-related grooming behaviors (Plunkett 
et al., 2001; Zhou et al., 2009). IL-10 deficiency also leads to resistance to thermal 
allodynia in a hot plate test, suggesting IL-10 may play dual roles in pain modulation (Tu 
et al., 2003). In sciatic nerve crush, IL-10 reduces inflammation at the injury site and 
promotes functional recovery (Siqueira Mietto et al., 2015). Retinal damage via injection 
of a neurotoxin is ameliorated via PACAP/IL-10 mediated neuroprotection (Wada et al., 
2013). In excitotoxic models of neuronal injury, IL-10 is necessary for preventing 
neuronal death, likely through reduction of reactive oxygen species production (Grilli et 
al., 2000; Mesples et al., 2003; Koriauli et al., 2015). IL-10 is also an important 
modulator of the inflammatory status of the hypothalamus, and alterations in IL-10 level 
affects feeding behavior and weight gain in animals (Gotoh et al., 2012). In addition, IL-
10 is critical for preserving the health of neurons in the penumbra after middle cerebral 
artery occlusion (Grilli et al., 2000). Overall, there is abundant evidence that IL-10 has a 
neuroprotective function in the CNS.  
In contrast to other neurodegenerative diseases, IL-10 is not explicitly 
neuroprotective in Alzheimer’s disease. IL-10 deficiency in the APP/PS1 (amyloid 
precursor protein/presenilin 1) model of AD improves plaque clearance and synaptic 
retention, and modest cognitive benefits are also observed (Guillot-Sestier et al., 2015). 
This phenomenon is also evident in infectious disease studies, where knockout of IL-10 
results in superior resolution of infection because myeloid cell activation and 
phagocytosis is not suppressed (Jost et al., 2014; Buxbaum, 2015).  
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5.1.6. Aim 1 summary of findings 
The results from Aim 1 indicate that microglia, astrocytes, and neurons are all 
sources of IL-10; however, neuroprotective IL-10 does not derive exclusively from 
microglia or astrocytes. Future studies will continue to evaluate cell-specific IL-10 
production and its functional significance for neuronal survival after target disconnection. 
This work has broad implications because of the relevance of IL-10 mediated 
neuroprotection to multiple neurodegenerative diseases. 
 
5.1.7. Aim 1 revised hypothesis and future directions 
The goal of this aim was to understand how IL-10 fit into the sequence of events 
in CD4+ T cell-mediated neuroprotection. The original hypothesis for this aim was that 
after axotomy, microglial antigen presentation reactivates CD4+ T cells, resulting in IL-4 
production by T cells that, in turn, induces an IL-10-producing M2 microglia phenotype. 
This hypothesis was based on well-established immunology studies that describe this 
sequence of events in macrophage activation (Kigerl et al., 2009; Laskin, 2009). The 
rejection of this hypothesis based on our results implies that this linear sequence of events 
may not translate to immune-mediated neuroprotection. A closer examination of this 
hypothesis is warranted so it can be revised appropriately for future studies. 
The first potential flaw in this hypothesis is that it assumes that CD4+ T cells 
interact with microglia in the injured facial motor nucleus. Previous work from our 
laboratory identified that MHCII within the CNS is required for immune-mediated 
neuroprotection, which led us to focus on microglia because of their well-defined role in 
antigen presentation (Aloisi et al., 1998; Byram et al., 2004). However, multiple CNS 
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cells can express MHCII, including astrocytes, perivascular macrophages, dendritic cells, 
oligodendrocytes, and endothelial cells in the BBB (Male et al., 1987; Etienne et al., 
1999; Hurley, 2003; Liu et al., 2005; Becher et al., 2006; Ernst & Christie, 2006; 
Gottfried-Blackmore et al., 2009; Zhang et al., 2014). Additionally, quantitative analysis 
of T cell infiltration and MHCII+ cells reveals that they are a relatively rare presence in 
the injured facial motor nucleus. Data suggest that approximately 30 – 50 MHCII+ cells 
and 120 - 150 CD4+ T cells are present in the injured facial motor nucleus, which has a 
resident population of 4,000 – 20,000 cells (Raivich et al., 1998; Ha et al., 2006; Ha et 
al., 2007a; Ha et al., 2007b; Dauer et al., 2011; Kandel, 2013; Haulcomb et al., 2014).  
An alternative hypothesis is that T cells interact with antigen-MHCII complexes 
within the BBB. T cells can infiltrate and reside within the Virchow-Robin space between 
the endothelial cells and astrocytic endfeet (Ransohoff et al., 2003; Becher et al., 2006; 
Filipello et al., 2016). In this space, pericytes, perivascular macrophages, and 
perivascular dendritic cells can engage in antigen presentation with the T cell (Hickey & 
Kimura, 1988; Becher et al., 2006; McMahon et al., 2006). Evidence indicates that 
MHCII expression is upregulated in perivascular macrophages after FNA (Liu et al., 
2005). Also, astrocyte and T cell interactions at the BBB have been demonstrated 
histologically in experimental autoimmune encephalopathy (Filipello et al., 2016). This 
antigen presentation can result in bidirectional communication between the T cells and 
astrocytes (Bertin et al., 2014; Endo et al., 2015; Filipello et al., 2016). Astrocyte cell 
membranes are connected by gap junctions through which signals can propagate rapidly 
to the astrocytes in the facial motor nucleus (Almad et al., 2016). Through this 
interconnected astrocytic web, a small number of interactions between T cells and 
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astrocytes can translate to extensive regulation of the glial response to injury. This 
literature supports revising the hypothesis to include astrocytes and other CNS cells as 
responsible for antigen presentation to T cells.  
Advanced imaging modalities can be used to examine the physical location of 
antigen presentation in the CNS after FNA. Tools such as confocal and two-photon 
microscopy used on living or explanted tissue have been highly revelatory in EAE. For 
example, confocal time-lapse imaging of leptomeningeal (pial and subarachnoid 
meningeal layers) explants demonstrates that T cells migrate through these tissues, 
interacting and forming immunological synapses with antigen presenting cells along the 
way (Kivisakk et al., 2009). There is a precedence for rapid explantation of the facial 
motor nucleus for microglia electrophysiology measurements, providing groundwork for 
combining live tissue imaging with FNA (Boucsein et al., 2000). In EAE, intravital two-
photon imaging shows that T cells crawl along the vascular surface before exiting the 
vasculature and identifies scanning behavior of T cells in the leptomeninges 
(Bartholomaus et al., 2009). This imaging method also allowed for quantification of 
contact frequency and length of interaction time between T cells and APCs within the 
leptomeninges in vivo (Bartholomaus et al., 2009). One advantage of using the EAE 
model to study T cells in the CNS is that this disease induces a robust T cell response. 
Translating these methods to our FNA model may be more challenging because 
comparatively smaller numbers of T cells are activated by this injury. Also, the EAE 
intravital imaging was performed on the spinal cord, which is considerably easier to 
access relative to the pons. To circumvent this, alternative peripheral nerve injury 
models, such as sciatic nerve injury, could be used to gain a better understanding of T cell 
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interactions within the BBB and meningeal layers in response to axotomy. If these 
imaging studies demonstrate that CD4+ T cells infiltrate the post-axotomy CNS tissue, an 
in vitro model of the BBB can be employed to determine which factors specifically 
promote migration (Bertin et al., 2014). This information is important for determining if 
CD4+ T cell mediated neuroprotection occurs via direct interaction with glia in the CNS, 
such as in ischemic brain injury, or if CD4+ T cells regulate glial responses indirectly via 
communication across the BBB (Gill & Veltkamp, 2016).  
A second flaw in the original hypothesis is its reliance on the M1/M2 
classification of microglia responses. The M1/M2 paradigm evolved from in vitro 
immunological studies of macrophages that described these two major subtypes (Kigerl 
et al., 2009; Laskin, 2009). Secretion of IFNγ by Th1 cells promotes the M1 phenotype, 
and M1 cells secrete inflammatory cytokines and reactive oxygen species. Conversely, 
the M2 phenotype is induced by Th2 production of IL-4, and M2 cells secrete anti-
inflammatory and pro-tissue repair cytokines (Kigerl et al., 2009; Laskin, 2009). This 
paradigm has been adapted to describe microglial responses in the brain, given that 
microglia and macrophages share a common origin. However, recent in-depth 
examination of macrophages and microglia has largely disproven this reductionist view 
of their responses. First, transcriptomic analysis of resident macrophages in multiple 
tissue types revealed that there is significant diversity in cell phenotype depending on 
where they reside, thus microglia and macrophages should not be assumed to be similar 
(Gautier et al., 2012). Second, immunologists have been lobbying for an end to the 
M1/M2 macrophage labels because there are different interpretations of these phenotypes 
and this paradigm fails to accurately describe in vivo macrophage activation responses 
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(Martinez & Gordon, 2014; Murray et al., 2014). The publication most responsible for 
this attitude shift compared 299 human-derived macrophage transcriptomes after in vitro 
activation by 28 different stimuli. When IFNγ and IL-4 stimulation groups were 
analyzed, a two-dimensional M1/M2 spectrum could be visualized. However, stimulation 
by other cytokines, pattern recognition receptor ligands, and metabolites resulted in a 
multi-dimensional range of responses (Xue et al., 2014). In an analysis of microglia 
responses to traumatic brain injury, expression of prototypical M1 and M2 cytokines are 
observed simultaneously, further refuting the M1/M2 dichotomy (Morganti et al., 2016). 
Altogether, this evidence suggests that M1/M2 polarity is an inappropriate paradigm for 
microglia activation in the CNS. To accurately define the post-axotomy microglia 
response, transcriptomic analysis of microglia at multiple timepoints after FNA is 
necessary, with a special focus on cytokine expression. Furthermore, a comparable 
analysis of astrocytic and neuronal phenotypes after FNA would allow for the most 
complete understanding of the facial motor nucleus response to peripheral target 
disconnection. Findings from this transcriptomic analysis should then be validated 
histologically using in situ hybridization and immunohistochemistry. This information 
will be immensely valuable in gaining a broad, unbiased understanding of 
neuroinflammatory responses to nerve injury. 
The downstream effects of IL-10 were not addressed in this study, however, these 
effects are the most important information needed to understand immune-mediated 
neuroprotection. In addressing this question, the lens of immunology may again lead to 
bias. In the context of traditional immunology, IL-10 is secreted by immune cells to 
induce the anti-inflammatory response. This response is primarily mediated by IL-10 
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binding to IL-10R, leading to JAK1 phosphorylation, which then phosphorylates STAT3. 
Phospho-STAT3 migrates to the nucleus and targets expression of multiple genes, 
including Socs3 (blocks IL-6), Bcl3 (suppresses TNFα), and Ptpn1 (dephosphorylates 
phospho-STAT3). IL-10 also suppresses immune cell activation and division, further 
dampening the immune response (Hutchins et al., 2013). When thinking about the role of 
IL-10 in the injured facial motor nucleus, it could act on glia to generate an anti-
inflammatory microenvironment. However, there is insufficient evidence describing the 
downstream mechanisms of IL-10-mediated neuroprotection in the CNS (Lobo-Silva et 
al., 2016). This work is complicated by the fact that STAT3 has 1700 possible genomic 
targets (Hutchins et al., 2013). In fact, IL-10 neuroprotection in the CNS could occur by a 
mechanism entirely disparate from its anti-inflammation role. One example of this is Dr. 
Carla Shatz’s work that identified MHCI as a critical molecule for synaptic pruning in 
neurodevelopment (Boulanger et al., 2001). In the immune system, MHCI is an antigen 
presenting molecule that interacts with CD8 on T cells. In the CNS, a blind screen of 
molecules identified MHCI as a necessary component for synaptic formation in visual 
system development (Corriveau et al., 1998). Further studies demonstrated that MHCI in 
the CNS does not rely on CD8 for its effects in synaptic elimination. Instead, MHCI is a 
significant regulator of long-term depression and calcium-permeable AMPA receptors 
(Lee et al., 2014). These MHCI studies reveal that the nervous system can reappropriate 
immune system proteins for their own devices. This conclusion is especially thought-
provoking given that our data demonstrate that neurons produce IL-10 constitutively. A 
thorough examination of IL-10’s downstream effects on astrocytes, microglia, and 
neurons is warranted to understand its role in regulating CNS responses to injury. To 
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accomplish this, cell cultures could be exposed to IL-10 and subsequent effects on cell 
transcriptomes could be analyzed. These findings would then be verified in mouse 
models that receive intrathecal IL-10 infusion via an osmotic pump. Dose-dependent 
curve analysis would further confirm these findings and provide important mechanistic 
information of IL-10-mediated neuroprotection.  
Another potential problem in this experiment design is its foundation on the 
IL-10-/- mouse data. In the Xin et al. 2011 study, IL-10-/- mice experience significantly 
more FMN loss after FNA, suggesting that IL-10 is important for neuroprotection. The 
IL-10-/- mouse is commonly used as a model of inflammatory bowel disease because IL-
10 deficiency results in profound gut inflammation and intestinal disease (Kuhn et al., 
1993; Kiesler et al., 2015). This significant alteration in gut homeostasis has a significant 
impact on the animal’s microbiome, which, in turn, can lead to a dramatically different 
immune system profile (Round & Mazmanian, 2009). By this logic, the neuronal death 
after injury in these IL-10-/- animals could be due to immune system abnormalities 
resultant from a defective microbiome. Alternatively, IL-10 deficiency could indirectly 
lead to neuronal death because expression of other cytokines after axotomy could be 
dysregulated. Roles for IL-4, IL-6, PACAP, TNFα, and other cytokines have all been 
explored using the FNA model (Zhou et al., 1999; Streit et al., 2000; Terrado et al., 2000; 
Bohatschek et al., 2004a; Moran & Graeber, 2004; Deboy et al., 2006b; Armstrong et al., 
2008). As so many cytokines are important for neuron survival after injury, using global 
cytokine knockout mice could cause a “butterfly effect,” hindering interpretation of these 
studies. On a broader level, these cytokine knock-out/knock-in experiments are small 
steps to incrementally understand the mechanisms of immune-mediated neuroprotection. 
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These major disadvantage of this experimental approach is that it resembles the Indian 
parable of blind men examining an elephant. Each blind person touches a specific part of 
the elephant, either its belly, tusk, ear, or trunk, and each person comes to a different 
incorrect conclusion about what the creature is. This parable exemplifies the risk of bias 
in narrowly focused scientific approaches. To avoid bias and to make significant progress 
in this field, it is necessary to use big-data approaches to see the full picture of the 
neuroimmune response to peripheral nerve injury.  
The ultimate goal of this work is to understand the mechanism of immune-
mediated neuroprotection in the normal animal. To address this question, I propose this 
revised hypothesis: CD4+ T cells interact with antigen presenting cells in the CNS, which 
leads to cytokine expression changes in the facial motor nucleus that promotes 
motoneuron survival after axotomy. First, confocal microscopy and intravital two-photon 
microscopy should be used to determine where and when CD4+ T cells interact with 
CNS antigen presenting cells. After identifying the location of antigen presentation, 
whether it is the Virchow-Robin space, leptomeninges. or CNS parenchyma, flow 
cytometry can then be used to identify the antigen presenting cells in this area. Potential 
APCs could include perivascular macrophages, perivascular dendritic cells, or astrocytes. 
With that information, the phenotypic changes of resident cells in the facial motor 
nucleus after T cell reactivation occurs should next be examined. Single-cell RNA 
sequencing on a collection of facial motoneurons, astrocytes, and microglia would 
provide a complete profile of what cytokines are being expressed by each cell type after 
axotomy pre- and post-T cell interaction with CNS APCs. These findings should then be 
confirmed by in situ hybridization, immunofluorescence, flow cytometry, and/or 
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quantitative protein analysis. Extensive studies of how these CNS cell types respond to 
cytokines is also warranted to avoid making erroneous assumptions of these cytokine 
effects based on immunological studies. Altogether, by using a “big data” approach and 
avoiding biased thinking, the role of T cells and cytokines in immune-mediated 
neuroprotection can be more effectively determined.  
 
5.2. Aim 2 Discussion 
As previously discussed in Aim 1, immunodeficient mice lacking the adaptive 
arm of the immune system have increased motoneuron death relative to WT mice after 
facial nerve axotomy, indicating that the immune system is neuroprotective (Serpe et al., 
1999). Immunoreconstitution of these mice with whole splenocytes, which contain B and 
T cells, restores motoneuron survival after injury to normal levels (Serpe et al., 1999; 
Serpe et al., 2003). Subsequent experiments identified CD4+ T cells as the key cell 
required for immune-mediated neuroprotection (Serpe et al., 2003).  
This discovery of the role of the immune system in central neuroprotection has 
important implications for neurodegenerative diseases. For example, 
immunodysregulation is evident in patients with ALS, including decreased circulating 
CD4+ T cells and increased cytokine levels in the peripheral blood (Hovden et al., 2013; 
Chen et al., 2014; Lu et al., 2016). The mSOD1 mouse model of ALS also exhibits 
significant immune changes, including profound lymphopenia, loss of splenic mass, and 
failure of T cells to respond to immunization (Kuzmenok et al., 2006; Banerjee et al., 
2008). Immunologic manifestations associated with mSOD1 motoneuron disease are 
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evident in CNS tissue as early as 40 days of age, suggesting that the immune system may 
participate in the development of ALS disease pathology (Alexianu et al., 2001).  
When FNA is superimposed on mSOD1 mice at the presymptomatic stage, 
increased motoneuron death is observed, with survival levels comparable to 
immunodeficient mice (Mesnard et al., 2011). Examination of the central molecular 
response to injury reveals that the motoneuron regeneration response remains intact. 
Instead, there is significant dysregulation of the glial microenvironment response to 
injury, as well as increased expression of the Fas/nNos cell death mechanism (Mesnard et 
al., 2011; Haulcomb et al., 2014). This finding was initially surprising because it was 
predicted that mSOD1 motoneuron disease would have an intrinsic negative effect on 
motoneuron health and function. These results shifted the focus of our work towards the 
microenvironment surrounding the motoneuron as the possible causative agent for 
increased motoneuron death in injury and disease. Altogether, this evidence leads to the 
theory that the immune system may be responsible for regulating the post-injury glial 
microenvironment response to promote motoneuron survival.  
To test this theory, the effect of immunodeficiency on the central molecular 
response to facial nerve axotomy was characterized. Also, the neuroprotective effects of 
CD4+ T cells were examined to describe the mechanism of immune-mediated 
neuroprotection. This is the first study of its kind to examine the effects of the peripheral 
immune system on the central molecular response to nerve injury. The prediction for this 
aim was that the molecular expression pattern after axotomy in RAG-2-/- mice would 
parallel the mSOD1 pattern of intact motoneuron regeneration, dysregulated glial 
microenvironment activation, and increased death receptor expression. It was also 
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expected that CD4+ T cell recipients would exhibit a normal microenvironment and cell 
death response to injury. In summary, the hypothesis for this aim is that 
immunodeficiency will impair the glial microenvironment response to FNA, leading to 
greater motoneuron death, and administration of CD4+ T cells will regulate glial 
responses to normal levels to promote motoneuron survival.  
 
5.2.1. The motoneuron regeneration response to peripheral nerve injury is unaffected by 
the adaptive arm of the immune system 
The first question addressed was whether peripheral immune status affected the 
motoneuron regeneration response to axotomy. In agreement with the original hypothesis, 
there is no observed effect of immunodeficiency on motoneuron regeneration-associated 
gene expression after injury. In CD4+ T cell reconstituted mice, a small increase in 
cytoskeletal gene expression was noted and is likely the result of the increased number of 
surviving motoneurons or permissive effects of the presence of CD4+ T cells on 
neuroregeneration. 
An interesting finding is that there is equivalent motoneuron regeneration gene 
expression in the RAG-2-/- group relative to WT at 28 dpo, despite a 25% reduction in 
facial motoneurons in the RAG-2-/- group. These data suggest that motoneurons that 
survive axotomy may express a higher concentration of regeneration-associated genes. 
For the first two weeks after axotomy, motoneurons significantly upregulate expression 
of cytoskeletal genes to regrow the daughter axon (Bisby & Tetzlaff, 1992). If the axon 
fails to reconnect to target musculature within a period of time, cytoskeletal gene 
expression is deactivated, and the loss of trophic support from the peripheral muscle can 
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lead to motoneuron death (Lieberman, 1971; Grafstein, 1975). For unknown reasons, 
there are differential motoneuron survival responses to axotomy in the facial motor 
nucleus. Kinetic analysis of FMN loss after FNA reveals that approximately 15% of 
neurons die, 35% of neurons depend on the immune system for survival, and 50% of 
neurons survive the injury, even as far as 6 months post-axotomy (Serpe et al., 2000, 
unpublished data). A subnuclear distribution pattern of FMN death after FNA is evident, 
with the ventrolateral (VL) subnucleus exhibiting the most FMN death (70% survival) 
and the ventromedial (VM) subnucleus having the least FMN death (97% survival) (Canh 
et al., 2006). Molecular expression profiles comparing the axotomized VL and VM 
subnuclei determined that higher regenerative gene expression was measured in the VL 
subnucleus (Mesnard et al., 2010). One would predict that with the increased motoneuron 
death in the VL is due to a reduced regenerative capacity, however this is not the case. 
Collectively, these data suggest that neuroregenerative gene expression does not equate 
with increased neuronal survival after axotomy. However, this molecular approach only 
assesses surviving motoneurons, which may have a robust regenerative program that 
skews the gene expression analysis. To explain why some motoneurons are predisposed 
to die, it is important to identify the intrinsic determinants of both motoneuron death and 
survival after axotomy. To accomplish this, I propose performing single-cell RNA 
sequencing of 100 axotomized facial motoneurons at 1 dpo, before any motoneuron death 
occurs. Considering that there are three fates (forever die, forever survive, or survival 
depends on immune system), I predict that the phenotypes of these 100 FMN will cluster 
into 3 groups with a similar distribution as the FMN survival pattern (15/35/50%). 
Analyzing the differences between these phenotypic clusters would allow for 
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identification of genes associated with survival or death after axotomy. These 
associations could be verified using an in vitro axotomy model, where siRNAs could be 
used to test if the neuronal genes identified are pro- or anti-survival (Gomis-Ruth et al., 
2014). Drugs that regulate these genes could be screened for using this in vitro approach, 
then translated to peripheral nerve injury in rodent models, with the goal of achieving 
total and permanent motoneuron survival after injury. Ultimately, the goal of these 
experiments would be to find clinically relevant drugs that regulate pro-survival gene 
targets as a new therapy for promoting neuronal survival after nerve injury. 
Overall, the findings from Aim 2 demonstrate that the motoneuron regeneration 
response is resilient within the context of immunodeficiency. The same conclusion is 
drawn from the study of the motoneuron regeneration response to axotomy in the 
mSOD1 mouse (Mesnard et al., 2011; Haulcomb et al., 2014). Findings that complete 
functional recovery occurs in RAG-2-/- and mSOD1 mice after facial nerve crush further 
support this claim that motoneuron regeneration remains intact in models of 
immunodeficiency or motoneuron disease (Beahrs et al., 2010; Mesnard et al., 2013). 
Overall, these results signify that immunodeficiency only impacts neuronal survival, not 
the regeneration response.  
 
5.2.2. Central glial activation after peripheral nerve injury is regulated by CD4+ T cells 
The effect of immune status on activation of astrocytes and microglia after facial 
nerve injury was also assessed. In the immunodeficient group, initial astrocyte and 
microglia activation is intact, however there is a failure to sustain glial activation in the 
middle and late post-axotomy phases. This dysregulation is most prominent in astrocytes. 
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The CD4+ T cell recipient group did not exhibit this decreased glial activation, indicating 
that CD4+ T cells are responsible for maintaining glial responses. This claim is further 
supported by evidence that T cells infiltrate the axotomized facial motor nucleus at 14 
dpo, the timepoint at which astrocyte activation depends on the presence of CD4+ T cells 
(Raivich et al., 1998; Hurley, 2003; Ha et al., 2007b; Almolda et al., 2014). Collectively, 
the data from Aim 2 suggest that early, innate glial responses are retained in 
immunodeficient mice, and continued glial activation relies on CD4+ T cells.  
Additional studies have identified decreased astrocyte and microglia activation in 
immunodeficient mice. For example, decreased microglia activation is observed in a T 
cell receptor (TCR) knockout/mSOD1 transgenic mouse (Chiu et al., 2008). 
CD4-deficient mice have decreased astrocyte activation relative to WT in a spinal nerve 
injury model of neuropathic pain (Cao & DeLeo, 2008). Decreased astrogliosis is evident 
in a combined RAG-2-/-/APP/PS1 mouse model of Alzheimer’s disease (Spani et al., 
2015). A possible mechanism for T cell induction of astrocyte activation is during the T 
cell secondary reactivation process in the CNS. As described in the section 5.1.7, T cells 
may interact with astrocytes during antigen presentation or by transmitting signals 
through the BBB (Aloisi, 1999; Almad et al., 2016). This astrocyte activation can have 
downstream effects on microglia activation responses through IL-6 and MCSF 
production, possibly explaining the concurrent decrease in microglia activation in 
immunodeficient mice (Klein et al., 1997; Almolda et al., 2014).  
In the mSOD1 molecular response to FNA, decreased astrocyte and microglia 
activation is also evident. Contrary to the immunodeficient model, astrocyte and 
microglia activation is decreased at both early and late post-axotomy stages in the 
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mSOD1 model of motoneuron disease (Haulcomb et al., 2014). This lack of astrocyte 
activation could be due to an intrinsic dysregulation of the astrocytic phenotype in the 
mSOD1 group. Evidence suggests that isolated mSOD1 astrocytes are intrinsically 
neurotoxic, supporting this claim that the mSOD1 transgene significantly alters astrocyte 
behavior (Di Giorgio et al., 2007; Haidet-Phillips et al., 2011; Chen et al., 2015a). 
Alternatively, the effect of the mSOD1 mutation on the peripheral immune system’s 
ability to regulate astrocyte activation could contribute to astrocyte dysregulation after 
peripheral nerve injury. Section 5.3.2. in the Aim 3 discussion addresses this question.  
To summarize, these findings demonstrate that the peripheral immune system, 
specifically CD4+ T cells, is responsible for sustaining central glial activation after 
peripheral nerve injury. There is differential dysregulation of the glial activation response 
in RAG-2-/- animals relative to mSOD1 animals. In immunodeficiency, initial glial 
activation occurs normally, however glial activation is not sustained throughout the time 
course. In mSOD1 animals, deficient glial activation is evident in both early and late 
post-axotomy phases, suggesting a factor outside the peripheral immune system could be 
contributing to microenvironment dysregulation in axotomy-induced target 
disconnection.  
 
5.2.3. Central inflammatory cytokine expression after peripheral nerve injury is 
regulated by CD4+ T cells 
To measure the effect of immune status on inflammatory cytokine expression, 
Tnfα gene expression was analyzed. Immunodeficiency resulted in a loss of early Tnfα 
expression, followed by a return to normal levels for the remainder of the time course. 
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The CD4+ T cell recipient group had normal levels of early Tnfα, followed by an 
augmented response relative to WT. These data suggest that Tnfα expression, especially 
in the early phase, is regulated by CD4+ T cells. This early timepoint is concurrent with 
the timing of T cell reactivation in the injured facial motor nucleus (Byram et al., 2004). 
Additionally, TNFα is an important regulator of glial activation. For example, TNFα 
increases astrocyte connectivity and induces nitric oxide production by microglia 
(Hensley, 2003; Almad et al., 2016). The recovery of late Tnfα expression in 
immunodeficient mice may coincide with microglia phagocytosis of dead facial 
motoneurons (Raivich et al., 1998).  
In mSOD1 mice, both Tnfα and Ifnγ are expressed constitutively in the uninjured 
facial motor nucleus, indicating a proinflammatory CNS environment. Axotomy induces 
greater expression of these inflammatory cytokines (Mesnard et al., 2011; Haulcomb et 
al., 2014). This basal inflammatory phenotype may be the result of mSOD1 affecting NF-
κB regulation in microglia, leading to dysregulated overexpression of inflammatory 
cytokines (Frakes et al., 2014). On the other hand, the mSOD1 mutation could impact the 
peripheral immune system’s ability to regulate the glial microenvironment, thus resulting 
in uncontrolled neuroinflammation. Collectively, these findings suggest that there is a 
“Goldilocks zone” for the central TNFα response after peripheral nerve injury. Sufficient 
TNFα is needed for activation of immune-mediated neuroprotective mechanisms, but 
excessive TNFα may result in neurotoxicity. 
It is necessary to perform protein analysis to verify these gene expression 
findings. mRNA analysis of neurons compared to neuropil within the axotomized facial 
motor nucleus demonstrate that Tnfα transcript is only detectable in the neuropil 
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(Mesnard et al., 2010). Microglia are the most likely source of TNFα in the facial motor 
nucleus based on transcriptomic data, however there is also evidence for neuronal 
production of TNFα in other areas of the brain (Liu et al., 1994; Acarin et al., 2000; 
Zhang et al., 2014). Identifying the cell source of TNFα will provide further mechanistic 
information of how CD4+ T cells influence the central response to peripheral nerve 
injury. Discovering that immune status impacts central TNFα production also encourages 
studying expression of other relevant cytokines to obtain a more complete 
characterization of the post-axotomy microenvironment response in immunocompetent 
and immunodeficient groups (Alexianu et al., 2001; Chen et al., 2004).  
Altogether, this work suggests that CD4+ T cells are required for early TNFα 
expression, which may be a key regulatory molecule in initiating signaling cascades that 
promote glial activation and neuroprotection.  
 
5.2.4. No relationship is evident between increased neuronal death and gene expression 
of cell death mechanisms in immunodeficient animals after peripheral nerve injury 
Examination of the prevalence of either the TNFR1 or Fas/nNos death 
mechanisms was performed because there is increased neuronal death in the 
immunodeficient group. Unexpectedly, neither death mechanism was prominently 
expressed in RAG-2-/- mice. A delayed Tnfr1 response was evident in RAG-2-/- mice 
relative to WT, coinciding with the lack of early Tnfα expression. There was no 
significant increase in Fas or nNos expression in immunodeficient mice relative to 
control. In contrast, mSOD1 mice exhibit a prominent peak in Fas expression in the late 
post-axotomy phase, coinciding with the timing of motoneuron death in this group 
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(Haulcomb et al., 2014). A motoneuron-specific downstream mediator of Fas death, 
nNos, is also upregulated in the mSOD1 group. Fas/nNos mediated motoneuron death has 
been well-described in ALS disease pathology, and its role in motoneuron death after 
target disconnection represents a unique finding warranting further study (Raoul et al., 
2002; Raoul et al., 2006).  
Surprisingly, in RAG-2-/- mice that received adoptive transfer of CD4+ T cells, a 
heightened Tnfr1 response was detected throughout the post-axotomy timecourse, 
mirroring the increased Tnfα expression in this group. Because this experimental group 
does not experience significant motoneuron death after FNA, it is unlikely that this 
increased Tnfr1 is inducing apoptosis. TNFR1 could be utilized by CD4+ T cells to 
upregulate adhesion molecule expression in astrocytes to assist T cell migration into the 
CNS parenchyma (Archambault et al., 2005). Also, CD4+ T cell induction of Tnfr1 could 
be regulating cytokine expression by acting through its secondary signaling pathway that 
induces NF-κB (Baud & Karin, 2001; McCoy & Tansey, 2008; Wajant & Scheurich, 
2011). To determine if the apoptotic or immunoregulatory signaling pathway was being 
induced, gene expression of Fadd (apoptosis), Traf2 (immunoregulation), and Tradd 
(both), was measured (Hsu et al., 1996; Sohda et al., 2015). No significant differences in 
gene expression were found in any of these genes when the CD4+ T cell recipient group 
was compared to WT. Downstream signaling through TNFR1 may not be detectable on 
the gene expression level, therefore, protein analysis of these mediators would need to be 
conducted to address this question.  
To summarize, neither death mechanism examined in this study is clearly 
connected to the increased motoneuron death in immunodeficient mice. In CD4+ T cell 
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recipients, an increased Tnfr1 expression response is observed, indicating that isolated 
CD4+ T cells may act in a differential manner than in their in situ environment. The 
implications for this finding is further explored in Aim 3, when gene expression analysis 
is performed on immunodeficient mice reconstituted with whole splenocytes.  
 
5.2.5. Aim 2 summary of findings 
The results from Aim 2 indicate that CD4+ T cell-mediated neuroprotection 
following facial nerve axotomy occurs via regulation of the glial microenvironment 
response to injury, rather than a direct action on motoneuron regeneration or suppression 
of a cell death mechanism. The mechanism of this immune-mediated neuroprotection 
may rely on TNFα/TNFR1 signaling to permit T cell migration into the CNS or regulate 
the neuroinflammatory response to peripheral nerve injury. These findings define an 
important role for the peripheral immune system in affecting central responses to 
peripheral nerve injury.  
 
5.2.6. Future directions 
The primary goal of this aim was to broadly identify the mechanism of immune-
mediated neuroprotection in the facial motor nucleus after axotomy. With the recognition 
that glial regulation significantly depends on CD4+ T cells, an in-depth examination of 
glial phenotype is warranted. GFAP and CD68 are commonly used markers for astrocyte 
and microglia reactivity, however they only represent a small aspect of the glial response 
(Laskawi & Wolff, 1996; Brettschneider et al., 2012; Marshall et al., 2013). Acquisition 
of single cell RNA-seq information from a collection of astrocytes and microglia at 
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various post-axotomy timepoints will provide a more complete picture of the injury 
response. Comparing WT and immunodeficient RNA-seq information will further 
identify which genes are specifically regulated by the adaptive arm of the immune 
system. These findings can be compared to other glial transcriptomic analyses to identify 
similarities to other disease contexts, for example, mSOD1 motoneuron disease, 
ischemia, or neuroinflammation (Zamanian et al., 2012; Chiu et al., 2013; Liddelow et 
al., 2017). These transcriptomic analysis results should also be confirmed using protein 
quantification methods because there are can be differences between gene and protein 
expression (Hensley et al., 2002; Hensley, 2003). The findings can also be verified 
histologically using both in situ hybridization and immunohistochemistry.  
Also, a histological comparison of WT and immunodeficient mouse glial 
responses would be useful in determining the morphological manifestations of decreased 
glial activation. In vitro comparison of RAG-2-/- and WT microglia responses to LPS 
reveals no significant differences in cytokine expression or morphological changes (Beers 
et al., 2008). Examination of microglia histology after facial nerve axotomy in 
immunodeficient mice would reveal if they are capable of proliferation and synaptic 
stripping (Graeber et al., 1993; Graeber et al., 1998; Boucsein et al., 2000). Studying 
astrocyte reactions is important for assessing if their morphological shift from 
protoplasmic to fibrillary phenotypes is affected by immunodeficiency, or if they fail to 
replace microglia in synaptic stripping at later post-axotomy timepoints (Tetzlaff et al., 
1988b; Moran & Graeber, 2004).  
In addition to glial activation, differences in TNFα expression in the early post-
axotomy phase were observed in immunodeficient mice. This finding suggests that early 
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TNFα may be an important signaling component for CD4+ T cell regulation of the glial 
microenvironment after axotomy. To explore this further, a TNFα blockade could be 
imposed after FNA in WT mice to observe if it inhibits CD4+ T cell-mediated 
neuroprotection. For this experiment, either a soluble TNFR or a TNFR-blocking 
antibody could be used to inhibit TNFα signaling between 3-14 dpo (Terrado et al., 
2000). Quantification of FMN survival after FNA at 28 dpo could then be used to 
measure if TNFα blockade during this time frame resulted in decreased FMN survival. In 
this experiment, I hypothesize that blocking TNFα at timepoints during which T cells are 
being reactivated in the CNS environment would impede glial activation and result in 
increased motoneuron death. Examination of cell-specific sources of TNFα could then be 
conducted to identify which CNS cells are the key participants in this process.  
One criticism for this work is its reliance on the RAG-2-/- mouse, which may be 
an inappropriate model because the lifelong immunodeficiency causes significant 
physiological changes. For example, immunodeficient mice are reported to have 
decreased cognitive function and impaired hippocampal neurogenesis (Kipnis et al., 
2004; Brynskikh et al., 2008; Wolf et al., 2009; Spani et al., 2015). Also, 
immunodeficiency has significant impacts on the host microbiome, which can translate 
into neurological effects (Round & Mazmanian, 2009; Mulle et al., 2013; Zhang et al., 
2015). For example, gut bacteria production of tryptophan metabolites confers 
neuroprotection in EAE (Rothhammer et al., 2016). A recent publication identified 
microbiome alterations in mSOD1 mice, and treatment with bacterial products extended 
mSOD1 mouse survival by an average of 38 days (Zhang et al., 2017). In this study, it is 
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possible that a secondary abnormality resultant from immunodeficiency may be 
increasing motoneuron death after axotomy.  
To test this theory, anti-CD4 antibodies could be administered to a WT mouse to 
selectively eliminate CD4+ T cells (Ghobrial et al., 1989; Archambault et al., 2005). This 
approach allows the animal to grow and develop with an intact immune system, thereby 
avoiding the secondary effects associated with lifelong immunodeficiency. This 
alternative mouse model of CD4+ T cell deficiency should exhibit immunodeficient-like 
FMN death after FNA, if the original hypothesis for this work is correct. One drawback 
for these antibody-depletion models is that the T cell elimination may result in peripheral 
immune activation, and multiple treatments are needed to maintain continuous 
deprivation of CD4+ T cells. Also, CD4+ T cells sequestered in the CNS may escape the 
antibody depletion. Despite these potential pitfalls, this approach may be necessary to 
validate the CD4+ T cell-mediated neuroprotection paradigm. 
 
5.3. Aim 3 Discussion 
Disconnection from target musculature is the hallmark of early presymptomatic 
disease pathology in ALS (Fischer et al., 2004; Dadon-Nachum et al., 2011). Axotomy-
induced target disconnection results in a similar injury response profile as seen in 
mSOD1 motoneuron disease pathology (Mesnard et al., 2011). When facial nerve 
axotomy is superimposed on presymptomatic mSOD1 mice, increased motoneuron death 
is observed, similar to the immunodeficient response to nerve injury (Serpe et al., 1999; 
Mariotti et al., 2002; Mesnard et al., 2011). This finding is surprising because, in theory, 
mSOD1 mice have an intact immune system. To test the neuroprotective capacity of 
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mSOD1 lymphocytes, facial nerve axotomy was administered to RAG-2-/- mice 
immunoreconstituted with mSOD1 whole splenocytes, and the mSOD1 immune cells 
failed to protect motoneurons from death. In contrast, isolated mSOD1 CD4+ T cells are 
capable of rescuing motoneuron survival to normal levels, suggesting that a factor within 
the mSOD1 whole splenocyte environment inhibits mSOD1 CD4+ T cell-mediated 
neuroprotection (Mesnard-Hoaglin et al., 2014). 
The conclusion from Aim 2 is that WT CD4+ T cells promote neuronal survival 
after injury by regulating the glial microenvironment response to injury. This result leads 
us to hypothesize that the mSOD1 whole splenocyte environment suppresses CD4+ T 
cell regulation of glial responses to target disconnection. By comparing post-axotomy 
molecular responses, we predicted a dysregulated glial response would be evident in the 
RAG-2-/- + mSOD1 WS group, similar to what was observed in the immunodeficient 
group in Aim 2. We also predicted that the glial response in the mSOD1 CD4+ T cell 
recipient group would be comparable to the WT counterpart. As an additional control, a 
WT whole splenocyte reconstitution group was added to confirm that whole splenocyte 
treatment results in a WT-like molecular response after axotomy. 
 
5.3.1. WT whole splenocyte reconstitution of immunodeficient mice results in a 
differential gene expression response relative to WT 
When the molecular response of WT whole splenocyte recipient mice was 
compared to WT, many unexpected differences were found. First, whole splenocyte 
recipients had an increased motoneuron regenerative response to injury relative to WT. 
This finding could be the result of CD8+ T or B cells generating a permissive 
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environment that promotes motoneuron regenerative gene expression. Other studies have 
identified CD8+ T cell infiltration of the injured facial motor nucleus, supporting this 
hypothesis (Ha et al., 2007a).  
Additionally, a significant increase in astrocyte activation is observed in whole 
splenocyte recipients relative to both WT and isolated WT CD4+ T cell recipients. An 
interaction between CD8+ T or B cells and astrocytic endfeet at the BBB could result in 
this hyperactivated astrocyte response. Depending on immune status, there appears to be 
three levels of astrocyte activation: the reduced response with immunodeficiency, the 
normal response in WT and CD4+ T cell recipients, and an increased response with 
whole splenocyte recipients. This pattern suggests that astrocytes are highly sensitive to 
peripheral immune status. Their presence at the BBB uniquely situates them to be both 
sensors and transducers of communication signals between the periphery and the CNS. 
Astrocytes are commonly described as innate immune cells because of their functional 
role in the BBB, expression of pattern recognition receptors, and participation in antigen 
presentation (Carpentier et al., 2005; Farina et al., 2007; Ransohoff & Brown, 2012). The 
results from this study also suggest that astrocytes may also act as an extension of the 
adaptive arm of the immune system transducing immune-mediated neuroprotective 
signals from the peripheral blood to the CNS. Further work is needed to support this 
claim.  
Microglia activation and inflammatory cytokine expression response to axotomy 
in whole splenocyte recipient mice are equivalent to WT. This finding suggests that 
CD8+ T and B cells do not significantly affect these responses, supporting the conclusion 
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from Aim 2 that CD4+ T cells are specifically responsible for regulation of these 
responses.  
The Tnfr1 response in whole splenocyte recipients is also equivalent to the WT 
response. In contrast, isolated WT CD4+ T cell recipients exhibit a heightened Tnfr1 
response relative to both of these groups. These data suggest that whole splenocyte 
components regulate CD4+ T cell effects on the facial motor nucleus. The impact of the 
increased Tnfr1 with isolated CD4+ T cells is unknown, though hypothesized to be 
related to regulation of cytokine expression and T cell infiltration into the CNS. Overall, 
data from this experiment indicate that CD4+ T cell induction of Tnfr1 can be 
differentially regulated depending on the presence of CD8+ T or B cells.  
As expected, whole splenocyte recipients did not have increased Fas or nNos 
expression relative to WT after axotomy. The only significant difference in expression 
responses was decreased early Fas expression in all three RAG-2-/- animal groups, with or 
without immunoreconstitution. The implications for this difference are unknown, 
however do not seem to correspond with motoneuron survival after injury.  
To summarize, whole splenocyte adoptive transfer into immunodeficient mice 
results in a differential molecular response to injury relative to both WT and isolated WT 
CD4+ T cell recipient animals. Also, it was discovered that astrocytes are highly sensitive 
to peripheral immune status.  
These significant differences between WT and WT whole splenocyte 
reconstituted mice are unexpected and deserve further investigation. WT whole 
splenocyte transfer into immunodeficient mice restores both circulating lymphocytes and 
nodular architecture in the spleen (Serpe et al., 1999). One possible explanation for the 
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differences between these two groups is that the grafted immune cells may have different 
phenotypic behaviors relative to their host. These effects may be perpetuated by 
microbiome differences in RAG-2-/- mice relative to WT (Zhang et al., 2015). 
Furthermore, the post-mortem whole splenocyte collection protocol may cause 
significant, permanent changes to lymphocyte behavior. An extensive evaluation of 
whole splenocyte engraftment into RAG-2-/- mice may also explain the different observed 
molecular responses. The effectiveness of tail vein injection of whole splenocytes used in 
this study could be compared to bone marrow transplant immunoreconstitution, which 
would include more progenitor cells and may more closely approximation the WT 
immune status (Beers et al., 2008; Bottcher et al., 2013). A parabiosis procedure 
connecting a WT and RAG-2-/- mouse could also be an alternative immunoreconstitution 
strategy to provide in vivo WT lymphocytes to an immunodeficient animal with minimal 
cellular processing (Bottcher et al., 2013). These experimental approaches would help in 
identifying why WT whole splenocyte transfer into RAG-2-/- mice does not result in a 
similar molecular response to injury compared to WT.  
 
5.3.2. MN death in mSOD1 whole splenocyte recipients is not due to immunodeficient-
like microenvironment dysregulation 
Next, the molecular response to peripheral target disconnection of 
immunodeficient mice reconstituted with mSOD1 whole splenocytes was evaluated. 
These responses were compared to WT whole splenocyte recipients instead of WT 
because of the significant differences found in comparing the molecular response of these 
two groups.  
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First, motoneuron regeneration is not impaired in mSOD1 whole splenocyte 
recipients, in agreement with prior studies and the Aim 2 findings (Mesnard et al., 2011; 
Haulcomb et al., 2014). Surprisingly, there is no impairment in astrocyte or microglia 
activation in mSOD1 versus WT whole splenocyte recipients. This finding refutes the 
original hypothesis that mSOD1 whole splenocytes block CD4+ T cell regulation of the 
microenvironment to injury. In addition, the astrocyte hyperactivation in WT whole 
splenocyte recipients is also observed in mSOD1 whole splenocyte recipients, further 
supporting the claim that astrocytes are acutely sensitive to peripheral immune status.  
An area for future study is an in-depth examination of the astrocytic response to 
injury. It is possible that mSOD1 whole splenocytes induce an alternative activation 
status of astrocytes that is neurotoxic, whereas WT whole splenocytes promote a 
neuroprotective astrocytic phenotype. A study from Dr. Ben Barres’ laboratory 
characterizes two polar astrocytic phenotypes induced by neuroinflammatory or ischemic 
CNS injuries (Zamanian et al., 2012; Liddelow et al., 2017). A major discovery from 
their work is that C3, a complement protein, is prominently and exclusively expressed in 
neurotoxic astrocyte phenotypes, and astrocytic C3 is identified in multiple 
neurodegenerative diseases (Liddelow et al., 2017). Gene expression analysis of C3 could 
be employed to identify, on a broad level, if different astrocyte phenotypes are evident 
when comparing mSOD1 and WT whole splenocyte recipient groups. In addition, use of 
single cell RNA-seq on a collection of post-axotomy astrocytes is warranted to compare 
the astrocytic response of WT or mSOD1 whole splenocyte recipient groups. Overall, the 
current data suggest that glial activation is unimpaired in mSOD1 whole splenocyte 
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recipients, however, further characterization of astrocyte phenotype is necessary to rule 
out neurotoxic astrocytic phenotype activation.  
Another interesting finding is that Tnfα expression in mSOD1 versus WT whole 
splenocyte recipient groups are comparable. In contrast, significant dysregulation of Tnfα 
expression is observed in mSOD1 mice both at homeostasis and after injury (Mesnard et 
al., 2011; Haulcomb et al., 2014). In mSOD1 whole splenocyte recipients, there is no 
induction of Tnfα in the homeostatic facial motor nucleus, and axotomy-induced Tnfα 
expression is regulated to normal levels. The findings suggest that the peripheral immune 
system is likely not the cause of increased Tnfα in mSOD1 mice, and instead, the mSOD1 
transgene is inducing effects in the facial motor nucleus. To confirm this, the immune 
system could be depleted in mSOD1 animals using irradiation or chemotherapeutic drugs 
and TNFα expression in the CNS could be measured. No change in TNFα expression in 
the CNS would confirm that neuroinflammation with mSOD1 motoneuron disease is the 
result of intrinsic processes independent from the peripheral immune system. 
Alternatively, an increase in TNFα expression would suggest that the immune system 
dampens neuroinflammation, whereas a decrease in expression would indicate that the 
immune system exacerbates neuroinflammation. Also, the timing of this aberrant 
cytokine production in the mSOD1 mouse model is unknown. Evidence suggests that 
neuroinflammation occurs presymptomatically, even as early as 50 days of age, however 
the exact age of onset is not known (Hensley et al., 2002; Chen et al., 2004). The most 
thorough examination of temporal gene expression in mSOD1 animals utilized only 
female littermate controls for the male experimental animals, which may confound the 
detection of early TNFα changes (Chen et al., 2004). Analyzing the expression of 
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neuroinflammatory-associated genes at regular intervals from 1 – 90 doa in the CNS, 
nerve, and muscle tissue will provide important information about the onset and 
progression of axonal die-back disease pathology in mSOD1 mice (Dadon-Nachum et al., 
2011).  
When cell death mechanism pathways were compared, no significant differences 
in Tnfr1 expression after injury were observed in mSOD1 whole splenocyte recipients 
relative to control. Overall, this evidence suggests that Tnfr1 is not prominently 
associated with the facial motoneuron death after axotomy observed in mSOD1, 
RAG-2-/-, or RAG-2-/- + mSOD1 whole splenocyte groups (Mesnard-Hoaglin et al., 
2014).  
In contrast, a prominent induction of Fas expression was observed in mSOD1 
versus WT whole splenocyte recipients. This induction profile matches the Fas gene 
expression profile in mSOD1 mice, suggesting that mSOD1 peripheral immune cells may 
induce central motoneuron death mechanisms (Haulcomb et al., 2014). This finding was 
surprising because the original study describing Fas expression in ALS characterizes it as 
a cell autonomous death mechanism. This study revealed that mSOD1 motoneurons are 
highly susceptible to Fas and nitric oxide triggered death, however, they have normal 
responses to trophic deprivation and excitoxicity (Raoul et al., 2002). Furthermore, this 
increased sensitivity to Fas-mediated death is only detectable in mSOD1 motoneurons, 
not sensory, cortical, or cerebellar neurons (Raoul et al., 2002). Follow-up work 
discovered a Fas/FasL feedback loop within mSOD1 neurons that fit with the cell 
autonomous ALS theory. In this loop, FasL expression by neurons results in Daxx 
induction of nNos, resulting in neuron-specific nitric oxide production that perpetuates 
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FasL expression in neurons. Knocking out the Daxx gene significantly increases 
motoneuron survival in mSOD1 animals and reduces neuronal FasL expression. 
Altogether, the Fas death pathway in motoneuron disease seemed to result from intrinsic 
dysregulation within the motoneuron, however this study suggests that the peripheral 
immune system may significantly contribute to the induction of Fas-mediated cell death.  
To summarize, mSOD1 whole splenocyte transfer into immunodeficient mice 
does not result in an immunodeficient-like central molecular response to peripheral nerve 
injury. Instead, these data suggest that motoneuron death could occur by two 
mechanisms. First, induction of a neurotoxic glial phenotype by mSOD1 whole 
splenocytes may promote neuronal death. Second, mSOD1 whole splenocytes could 
cause increased motoneuron death by aberrant induction of Fas/nNos expression in the 
post-axotomy facial motor nucleus.  
 
5.3.3. Pro-survival molecular responses induced by mSOD1 CD4+ T cells significantly 
differ from WT CD4+ T cells 
The central molecular response to axotomy was measured in mSOD1 CD4+ T cell 
recipients, and unexpected differences in comparison with WT CD4+ T cell recipients 
were discovered. Motoneuron regeneration responses are significantly elevated in 
mSOD1 versus WT CD4+ T cell recipients, especially axon growth-cone associated 
proteins. Additionally, a three-fold increase in astrocyte activation was detected in 
mSOD1 versus WT CD4+ T cell recipients. This increased astrocyte response may 
translate into enhanced motoneuron regeneration gene expression because astrocyte and 
neuronal interactions are tightly linked (Acarin et al., 2000; Tian et al., 2012). One 
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explanation for the increased astrocyte response is that an instigating factor within the 
mSOD1 mouse environment induces a CD4+ T cell phenotype that is a potent astrocyte 
activator. If this phenotype is maintained in the adoptive transfer process, it could be 
responsible for increased astrocyte induction. This astrocyte response is axotomy-
dependent, as no induction of astrocyte activity is observed in the uninjured facial motor 
nucleus of mSOD1 CD4+ T cell recipients (data not shown). 
Another distinction between WT and mSOD1 CD4+ T cells is the differential 
induction of Tnfr1 expression after axotomy. Increased Tnfr1 expression in WT CD4+ T 
cell recipients in Aim 2 led to the conclusion that isolated CD4+ T cells behave in a 
differential manner than in the immunocompetent environment. Unexpectedly, this 
behavior does not hold true in the mSOD1 CD4+ T cell group because the Tnfr1 response 
in mSOD1 CD4+ T cell recipients approximates normal levels. These findings provide 
support for the claim that there are significant phenotypic differences between WT and 
mSOD1 CD4+ T cells.  
Additionally, an increased Fas induction in the late post-axotomy phase is 
observed in mSOD1 CD4+ T cell, not WT CD4+ T cell, recipients. This Fas expression 
is likely linked to the mSOD1 transgene’s effects on peripheral immune cells, and these 
data suggest that CD4+ T cells alone are capable of inducing this Fas expression.  
Altogether, mSOD1 and WT CD4+ T cells differentially regulate the molecular 
response within the injured facial motor nucleus to promote neuronal survival. The 
distinct motoneuron, astrocyte, and cell death pathway expression patterns suggest that 
significant phenotypic differences exist between mSOD1 and WT CD4+ T cells, refuting 
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the original hypothesis that they act in an identical manners to protect injured 
motoneurons.  
 
5.3.4. Differential induction of motoneuron-specific death mechanisms in mSOD1 whole 
splenocyte versus mSOD1 CD4+ T cell reconstituted immunodeficient mice 
The ultimate goal for Aim 3 was to identify significant differences in regulation 
of the central molecular response to facial nerve injury in immunodeficient mice 
reconstituted with either mSOD1 whole splenocytes or isolated mSOD1 CD4+ T cells. 
Because mSOD1 whole splenocytes fail to rescue neuronal survival after axotomy, it was 
hypothesized that CD4+ T cell-mediated regulation of the glial microenvironment was 
inhibited in the whole splenocyte environment. To our surprise, there was equivalent 
regulation of microenvironment responses by both mSOD1 whole splenocytes and CD4+ 
T cells. This study only used two markers to assess the glial response to injury, and 
studying additional markers of glial activation status will allow for characterization of 
neuroprotective or neurotoxic glial phenotypes. Additionally, mSOD1 whole splenocytes 
did not negatively impact the motoneuron regeneration response or the TNFα/TNFR1 
axis.  
In this study, the only observed gene expression change between mSOD1 whole 
splenocytes and CD4+ T cells that could potentially explain the increased neuronal death 
is increased nNos expression at both early and late timepoints in mSOD1 whole 
splenocyte recipients. Fas, an upstream inducer of nNos expression, is increased in the 
late post-axotomy phase in both mSOD1 whole splenocyte and CD4+ T cell recipients, 
mimicking the expression response seen in the mSOD1 mouse (Haulcomb et al., 2014). 
 141 
This finding indicates that the mSOD1 immune system, specifically CD4+ T cells, could 
be responsible for mediating Fas expression induction. However, only the mSOD1 whole 
splenocyte recipients exhibit a significant increase in nNos, suggesting that motoneuron 
death due to Fas/nNos signaling is restricted to mSOD1 whole splenocyte recipients, not 
isolated mSOD1 CD4+ T cell recipients. These results suggest that either CD8+ T or B 
cells are responsible for promoting motoneuron death by induction of nNos.  
To summarize, these gene expression data suggest that the increased motoneuron 
death observed in mSOD1 whole splenocytes could be due to peripheral immune 
induction of a motoneuron-specific death pathway prevalent in ALS. Isolated mSOD1 
CD4+ T cells are able to protect motoneuron survival because the cell inducing nNos 
neurotoxicity is not present. An alternative hypothesis is that mSOD1 whole splenocytes 
may promote a neurotoxic glial phenotype relative to mSOD1 CD4+ T cells.  
 
5.3.5. Aim 3 summary of findings and revised hypothesis 
The results from Aim 3 lead to the conclusion that WT whole splenocytes and 
CD4+ T cells can both be neuroprotective via differential regulation of the central 
response to axotomy, with astrocytic activation playing a prominent role. Importantly, 
target genes thought to be necessary for neuronal survival are upregulated in mSOD1 
whole splenocyte recipients. Furthermore, motoneuron regeneration gene expression after 
axotomy does not correlate with motoneuron survival after injury, as a regenerative 
phenotype occurred in the facial motor nucleus regardless of immunodeficiency or 
disease status. However, astrocyte activation was found to be highly dependent on 
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peripheral immune status, suggesting that astrocytes play a major role in transducing 
peripheral immune signals into the CNS.  
The hypothesis that the mSOD1 whole splenocyte environment inhibits CD4+ T 
cell-mediated microenvironment regulation, as well as facial motoneuron rescue, after 
axotomy is not supported by these data. Instead, there are several other possible 
explanations. For example, generation of a neurotoxic astrocyte phenotype could be 
induced by mSOD1 whole splenocytes. Additionally, mSOD1 whole splenocytes may 
promote the Fas/nNos motoneuron-specific death mechanism after axotomy.  
 
5.3.6. Future directions 
Glial phenotype characterization, especially the astrocyte response to facial nerve 
injury, should be performed in mSOD1 whole splenocyte and mSOD1 CD4+ T cell 
reconstituted animals. As described in section 5.3.2., C3 can be used as a broad marker 
for neurotoxic astrocytes, and this may be a good starting point for identifying differential 
astrocyte activation by mSOD1 whole splenocytes or mSOD1 CD4+ T cells. The 
different astrocyte activation responses can be further examined by performing 
transcriptomic analysis of their post-axotomy response (Zamanian et al., 2012; Liddelow 
et al., 2017).  
Additionally, the results in Aims 1, 2, and 3 suggest the astrocyte may be an 
especially important component of immune-mediated neuroprotection. These findings 
have been largely unexpected because the original hypothesis suggested that microglia 
were the cells responsible for transducing neuroprotective CD4+ T cell signaling into the 
CNS. Instead, this work indicates that astrocytes are the CNS mediators of T cell 
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neuroprotection. Alternatively, neuroprotection could require a cooperative effort of both 
microglia and astrocytes to promote neuronal survival. A novel way to test these theories 
is to employ PLX3997, a drug that eliminates >99% of microglia in the brain (Elmore et 
al., 2014; Elmore et al., 2015). Administration of this drug for two months to 
continuously eliminate microglia has no significant effects on motor function, cognition, 
or learning in mice (Elmore et al., 2014). Superimposing FNA on microglia-depleted 
mice would reveal if astrocytes alone are capable of mediating neuroprotective 
mechanisms to promote motoneuron survival the facial motor nucleus.  
The Fas/nNos induction by mSOD1 whole splenocytes and mSOD1 CD4+ T cells 
requires further analysis. To test if Fas-mediated motoneuron death is induced by 
mSOD1 whole splenocytes, the downstream signaling cascade of Fas could be disrupted 
to see if facial motoneuron survival is rescued after FNA. A RAG-2-/-/Daxx-/- mouse 
could be generated and receive an adoptive transfer of mSOD1 whole splenocytes, and 
facial motoneuron survival at 28 dpo FNA could be quantified. This experiment would 
support or refute the claim that increased neuronal death in mSOD1 whole splenocyte 
recipient mice is due to peripheral immune system induction of Fas-mediated cell death. 
Confocal microscopy of CD8+ T or B cells could be used to identify if these cells directly 
infiltrate the CNS parenchyma or communicate across the BBB to induce Fas/nNos 
expression. Also, mSOD1 whole splenocytes could be depleted of CD8+ T cells or B 
cells using negative selection magnetic cell sorting before adoptive transfer into RAG-2-/- 
animals. FMN survival at 28 dpo FNA could then be quantified in these two groups to 
identify which cell type is responsible for promoting motoneuron death after peripheral 
nerve injury.  
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5.4. Significance of findings 
The work presented in this dissertation advances our understanding of the 
mechanisms underlying immune-mediated neuroprotection after neuronal injury or 
disease. Regarding the role of IL-10 in facial motoneuron survival after axotomy, we 
have determined that multiple sources of IL-10, both neuronal and glial, could contribute 
to peripheral immune cell-mediated neuroprotection. These experiments used an in vivo 
approach for assessing cell-specific cytokine production, an important innovation 
considering the failure of in vitro findings to translate meaningfully to whole-organism 
studies. Future studies characterizing central cytokine expression after peripheral nerve 
injury will be crucial for developing a broader picture of the immune response within the 
injured facial motor nucleus. Characterization of the central molecular response to 
peripheral nerve injury in immunodeficient versus immunocompetent mice also provides 
novels insights. The discovery that CD4+ T cells are responsible for molecular regulation 
of the CNS microenvironment after peripheral target disconnection is important in view 
of the role of CD4+ T cells in many neurodegeneration diseases. Finally, this work 
provides support for the non-cell autonomous theory of motoneuron death in ALS 
through use of the axotomy model of target disconnection. Restriction of the mSOD1 
mutation to the peripheral immune system compartment results in significant alterations 
in the central response to peripheral nerve injury, suggesting that the ALS immune 
system may contribute to disease pathology. These contributions may involve promotion 
of neurotoxic glial phenotypes or induction of motoneuron-specific death mechanisms, 
and studying these effects further will elucidate new therapeutic strategies utilizing 
immunotherapy as a treatment for ALS.   
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